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SUMMARY
Bullous pemphigoid is a chronic autoimmune blistering 
disease of the elderly. The disorder is associated with 
linear deposition of IgG and complement along the epider­
mal basement membrane. Circulating IgG autoantibodies are 
present in the majority of patients and bind to a normal 
component of the basement membrane zone, the bullous 
pemphigoid antigen.
In the present study, certain immunological aspects 
of bullous pemphigoid were investigated and compared with 
pemphigus vulgaris and other immunologically mediated bul­
lous diseases that may clinically resemble bullous pem­
phigoid, such as dermatitis herpetiformis and acquired 
epidermolysis bullosa.
The concentration of bullous pemphigoid and pemphigus 
vulgaris antigens in normal skin on different sites of the 
body was determined by indirect immunofluorescence using 
specimens from the face, trunk and limb and thirty serum 
samples. The end point titre of antibody reactivity in 
different areas was assessed. The greatest amount of bul­
lous pemphigoid antigen was found in facial and limb skin 
whereas the pemphigus vulgaris antigen was more uniformly 
expressed over human skin from the various body sites.
X
Indirect immunofluorescence was also used to compare the 
sensitivity of normal human skin and two animal sub­
strates, guinea pig lip and primate oesophagus, for the 
detection and titration of basement membrane zone and in­
tercellular antibodies. All bullous pemphigoid and pem­
phigus sera produced a positive reaction on the three 
substrates but the highest antibody titres were observed 
when oesophagus sections were used in the immunofluores­
cence assays.
The distribution of tissue-bound and circulating IgG 
subclasses in patients with active pemphigoid and pem­
phigus was investigated by direct and indirect im­
munofluorescence using monoclonal antibodies specific for 
the four human IgG subclasses. In bullous pemphigoid IgG4 
was the most frequently detected subclass whereas IgG3 was 
the rarest. Similarly, IgG4 was the predominant antibody 
in the skin and serum from pemphigus vulgaris patients.
Indirect complement immunofluorescence was used to 
determine the complement fixing abilities of bullous pem­
phigoid and pemphigus antibodies. Complement fixing an­
tibodies were observed in 60% and 41% in pemphigoid and 
pemphigus sera respectively. Analysis of the IgG sub­
classes in complement fixing bullous pemphigoid antibodies 
showed no compatibility with the complement activation 
characteristics of individual IgG subclasses whereas all 
complement fixing sera contained a complement activating 
IgG subclass.
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The localisation of various basement membrane zone 
antigens including bullous pemphigoid, epidermolysis bul­
losa acquisita, type IV collagen and type VII collagen was 
studied using the sodium chloride split skin technique. 
Indirect immunofluorescence using cryostat sections of 1M 
sodium chloride-separated skin showed that type IV and 
type VII collagen which are associated with the lamina 
densa and sublamina densa stain the dermal edge of 
separated skin. Bullous pemphigoid antibodies produced an 
epidermal staining pattern whereas epidermolysis bullosa 
acquisita antibodies were associated with fluorescence of 
the dermal side of the split.
A distinct staining pattern of tissue-bound an­
tibodies was also seen when bullous pemphigoid biopsies 
were separated by the same technique.
The bullous pemphigoid antigen was further charac­
t e r i s e d  by p e r f o r m i n g  sodium dodecyl sulfate 
polyacrylamide gel electrophoresis and Western immunoblot­
ting studies. The findings confirmed the presence of more 
than one bullous pemphigoid antigen and that the major an­
tigen is the 220-240 KDprotein.
Circulating IgA class anti-endomysial antibodies are 
directed against the connective tissue surrounding in­
dividual smooth muscle fibrils. The sensitivity and 
specificity of these antibodies for the diagnosis of der­
matitis herpetiformis were investigated by determining 
their incidence in the sera of twenty dermatitis her­
X II
petiformis patients and forty patients with other bullous 
disorders. The endomysial antibody test was positive in 
73% of dermatitis herpetiformis patients on normal diet 
and in 20% of patients maintained on a gluten-free diet. 
The antibodies were not detected in any of the control 
subjects.
X II I
1. INTRODUCTION
1.1 GENERAL INTRODUCTION
The identification of bullous pemphigoid as a dis­
tinct subepidermal bullous disease was preceded by much 
confusion regarding its nosologic position in the clas­
sification of chronic bullous eruptions. Until its recog­
nition as a well-defined entity, it had been confused with 
a variety of bullous diseases such as pemphigus, der­
matitis herpetiformis and erythema multiforme. Bullous 
pemphigoid was first described as a separate disease by 
Lever in 19531. The designation pemphigoid was given by 
Lever because the disease was clinically similar to pem­
phigus but with the histologic lack of acantholysis which 
is the essential feature of pemphigus. The term 'bullous' 
was added to distinguish it from another type of pem­
phigoid, benign mucosal pemphigoid (cicatricial 
pemphigoid).
Prior to Lever's classical description of bullous 
pemphigoid, it was grouped by some authors with pemphigus 
vulgaris and had various names including pemphigus vul­
garis chronicus and pemphigus vulgaris benignus2.
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Bullous pemphigoid is now regarded as one of the pem­
phigoid spectrum of diseases which includes cicatricial 
pemphigoid, localized scarring pemphigoid and pemphigoid 
gestationis. The disease predominantly affects the el­
derly but occasionally occurs in young adults and 
children2. Unlike pemphigus vulgaris, there is no racial 
prevalence and males and females are equally affected1-2.
1.1.1 Clinical Features
The characteristic clinical feature of bullous pem­
phigoid is the presence of large tense bullous lesions 
(Figure 1) which may measure several centimetres in size 
and have an irregular border. They usually contain a 
clear exudate but some blisters may be haemorrhagic. The 
tense bullae may remain intact for days. After rupture or 
reabsorption of blister fluid the bullous lesions become 
flaccid. The lesions do not rupture easily as in pem­
phigus (Figure 2). The blisters which do rupture leave 
denuded areas which tend not to increase in size as may 
occur in pemphigus vulgaris but show a tendency for heal­
ing without scarring1-2. The blisters of bullous pem­
phigoid may arise on normal appearing skin or on an 
erythematous base. The presence of clusters of bullae is 
not regularly seen but may be present in cases of exten­
sive involvement. Although bullae predominate the clini­
cal picture, patients may have a variety of other lesions 
such as erythematous patches which may have a serpiginous
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Figure  1. Bullous pemphigoid.  Tense  b li s ters  on normal- 
appearing  and erythematous  skin.
Figure 2. Pemphigus vu lgar is .  Trunk of a patient s h o w ­
ing eros ions  and dif fuse erythema.
configuration with central clearing. Irritation and 
cutaneous lesions suggestive of erythema multiforme or 
dermatitis herpetiformis may also precede the formation of 
bullous pemphigoid blisters1*3. The distribution of 
blisters in bullous pemphigoid is often generalized and 
may involve the entire skin surface; however, the most 
commonly affected areas are the lower abdomen, the inner 
aspects of the thighs, the groins, the axillae and the 
flexural surfaces of the arms and legs1.
In contrast to pemphigus, the Nikolsky sign is nega­
tive in bullous pemphigoid5. The mucous membranes may oc­
casionally be involved in bullous pemphigoid but mucosal 
lesions are rarely a presenting feature1. The incidence 
of mucous membrane involvement varies from 10% - 40% of 
cases5-7. The lesions are less severe than those of pem­
phigus vulgaris and are usually restricted to the mouth. 
When oral lesions are present they mostly affect the buc­
cal mucosa and consist of small blisters that often remain 
intact and tend to heal rapidly if they rupture. Involve­
ment of the vermilion border of the lips is rare. Other 
mucous membranes which may rarely be involved include con­
junct ivae, larynx, pharynx, oesophagus, vulva and anal 
mucosa1. The degree of pruritus in bullous pemphigoid is 
variable. It may be absent in some patients but in others 
it may be intense enough to require systemic treatment. 
Generalized pruritus may be a manifestation of bullous
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pemphigoid. Cases have been reported with unexplained 
prolonged pruritus preceding the onset of classical bul­
lous pemphigoid eruption8*9.
There are many reports of bullous pemphigoid co­
existing with autoimmune as well as with other disorders. 
In many of these reports the presence of two diseases in 
one patient may merely represent a coincidental associa­
tion. However, the co-existence of bullous pemphigoid 
with diseases such as diabetes mellitus and psoriasis may 
be of clinical significance. Chaung et al.10 studied the 
incidence of diabetes mellitus in patients with bullous 
pemphigoid in comparison with a selected control group of 
a similar age. The result of their retrospective assess­
ment showed that 20% of bullous pemphigoid patients had 
diabetes mellitus prior to steroid therapy in contrast to 
only 2.5% of the control group.
The association of psoriasis and bullous pemphigoid 
has been suggested in several studies. In the majority of 
cases bullous pemphigoid was induced by psoralen plus 
ultraviolet A light (PUVA), ultraviolet B light and tar, 
and ultraviolet light and anthralin11 >12. Others13 have 
demonstrated a statistically significant increased in­
cidence of psoriasis in bullous pemphigoid patients that 
was unconnected to therapy. In a retrospective case con­
trolled study Grattan et al.13 found psoriasis in 11% of 
62 bullous pemphigoid patients but in none of the control 
group. The co-existence of bullous pemphigoid and
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rheumatoid arthritis has been reported many times in the 
literature. One study suggested that the relationship be­
tween these two disorders represents more than a chance 
association14
Many cases of bullous pemphigoid have been described 
in the literature in which there was an association with 
malignancies of the lymphoreticular system, skin, lung, 
breast, genitalia, pancreas, kidney, gastrointestinal and 
urinary tracts15. However, Rook16 has indicated that bul­
lous pemphigoid and malignancy are diseases of elderly in­
dividuals and their coincidental association would not be 
surprising. Large series of bullous pemphigoid patients 
have been studied to determine the incidence of malignancy 
in bullous pemphigoid and to analyse the significance of 
this association. Most series comparing bullous pem­
phigoid with matched control groups showed no increased 
incidence of malignancy in bullous pemphigoid patients. 
Ahmed et al.17 reviewed 33 cases of bullous pemphigoid and 
found only one patient (3%) to have an associated car­
cinoma. The incidence in an age-matched group was 4.2%. 
Stone and Schroeter15 reviewed 73 patients with bullous 
pemphigoid and compared them with two age- and sex-matched 
control groups. Their results showed no increase in the 
incidence of malignancy in bullous pemphigoid than in the 
control groups. Some reports5*7 have suggested that bul­
lous pemphigoid patients with negative indirect im­
munofluorescence have a higher frequency of internal
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malignancy in comparison with seropositive patients. 
However, controlled studies have not been performed to 
evaluate the significance of this association.
Bullous pemphigoid is a chronic but a much more 
benign disease than pemphigus vulgaris. The disease lasts 
a few months to several years and is characterized by 
periods of remission and exacerbation. Recurrences occur­
ring after months or years of remission are usually less 
severe than the initial attack1*5.
Bullous pemphigoid is a self-limiting disease and the 
patient's general health usually remains good. Unlike 
pemphigus vulgaris, the mortality rate is relatively low, 
even prior to the introduction of steroid therapy. 
However, the disease may be fatal in elderly debilitated 
patients1*2. Some authors have suggested that a prolonged 
clinical remission can be achieved in bullous pemphigoid 
patients treated with adequate doses of corticosteroids 
and/or immunosuppressive agents18*19.
1.1.2 Clinical Variants
Localized bullous pemphigoid. It has been recognized 
for many years that bullous pemphigoid may start and 
remain a localized disease. This variant occurs in up to 
30% of bullous pemphigoid patients6*20*21. In the series 
of Ahmed et al.6, six of the seven patients reported had 
lesions confined to one extremity while in one patient the 
disease was localized to the scalp. Person et al.21
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reported five patients with localized pemphigoid. The le­
sions were either restricted to one extremity or symmetri­
cally involving two extremities. Localized bullous pem­
phigoid can be successfully treated with topical 
corticosteroids22.
Childhood pemphigoid. Bullous pemphigoid rarely oc­
curs in children. The clinical manifestations are similar 
to those of bullous pemphigoid in adults23 . The disease 
must be distinguished from other bullous disorders of 
childhood including chronic bullous dermatosis of 
childhood and dermatitis herpetiformis. The diagnosis can 
only be confirmed by immunofluorescence studies.
Vesicular pemphigoid. In this variant the blisters 
are usually small, tense and grouped24. Although the 
clinical picture may be suggestive of dermatitis her­
petiformis, direct immunofluorescence studies reveal IgG 
deposits along the basement membrane zone.
Polymorphic pemphigoid. Honeymann et al.25 suggested 
this term for cases showing some clinical features of der­
matitis herpetiformis without evidence of jejeunal 
atrophy. Direct immunofluorescence shows deposits of IgG 
or IgA at the basement membrane zone. Cases associated 
with IgG may represent a variant of bullous pemphigoid 
whereas those associated with IgA probably represent 
patients with linear IgA bullous dermatosis.
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Vegetating pemphigoid is a rare variant of bullous 
pemphigoid. The disease is characterized by purulent 
vegetating lesions in the flexural areas which are similar 
to the lesions encountered in pemphigus vegetans. 
However, the direct immunofluorescent features are consis­
tent with bullous pemphigoid26.
Hyperkeratotic scarring pemphigoid is an unusual 
variant which is histologically characterized by sub- 
epidermal blister, hyperkeratosis, papillomatosis and 
acanthosis22. This variant closely resembles another type 
of bullous pemphigoid, pemphigoid nodularis, which is 
characterized by lesions which clinically and histologi­
cally mimic prurigo nodularis27.
These variants have direct immunofluorescent features 
compatible with bullous pemphigoid.
1.1.3 Differential Diagnosis
Epidermolysis bullosa acquisita. This term was first 
introduced to describe patients with clinical manifesta­
tions of epidermolysis bullosa developing in adulthood 
with absent family history of epidermolysis bullosa28. 
Epidermolysis bullosa acquisita is clinically associated 
with trauma-induced blisters, skin fragility and erosions 
which mostly occur on the extensor surfaces and heal with 
milia and scars. Histologically, the disease is charac­
terized by a subepidermal blister and a moderate inflam­
matory cell infiltrate composed primarily of neutrophils.
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Routine immunofluorescent studies show features identical 
to those of bullous pemphigoid. An inflammatory variant 
of epidermolysis bullosa acquisita has been described29. 
It is associated with clinical features which may mimic 
bullous pemphigoid and thus result in diagnostic dif­
ficulties .
Dermatitis herpetiformis is a disease of young 
adults. It is characterized by intensely pruritic 
papules, vesicles or bullae. The lesions develop in a 
symmetrical distribution over the extensor surfaces, scalp 
and buttocks30. The histologic picture is characteristic 
but can occasionally be difficult to distinguish from bul­
lous pemphigoid31. However, the two diseases can be dif­
ferentiated by direct immunofluorescence which in der­
matitis herpetiformis demonstrates granular IgA deposits 
in the dermal papillae. In addition, circulating anti­
basement membrane zone antibodies cannot be detected in 
dermatitis herpetiformis32. Almost all patients have an 
associated gluten sensitive enteropathy and an increased 
prevalence of the HLA-B8,DR3 and DQw2 HLA types32-33 .
Linear IgA bullous dermatosis represents a 
heterogeneous group of patients with a characteristic pat­
tern of Ig deposition. Immunofluorescent studies in these 
patients demonstrate tissue-bound IgA in a linear fashion 
along the basement membrane zone, in contrast to the 
g r a n u l a r  IgA p a t t e r n  o b s e r v e d  in d e r m a t i t i s  
herpetiformis32. Linear IgA bullous dermatosis is also
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characterized by a much lower incidence of jejeunal en­
teropathy and of HLA Be histocompatibility antigen32. 
Although linear IgA bullous dermatosis may present with 
clinical features suggestive of bullous pemphigoid, it af­
fects a younger age group and shows tissue-bound IgA 
rather than IgG. Furthermore, circulating anti-basement 
membrane zone antibodies in linear IgA bullous dermatosis 
are of the IgA rather than the Ip class32.
Cicatricial pemphigoid is a rare, chronic, subepider- 
mal bullous disorder which mainly affects the mucous 
membranes. The oral and ocular mucosal surfaces are the 
most commonly involved sites. However, lesions may also 
occur in the larynx, oesophagus, genitalia and anal 
mucosa5*34. The major feature of cicatricial pemphigoid 
lesions is their tendency towards healing with scarring. 
Clinically, lesions appear as intact blisters or erosions. 
Involvement of the gingiva occurs commonly in the initial 
stages and may lead to the diagnosis of desquamative 
gingivitis34. The ocular mucous membranes are affected in 
approximately two-thirds of patients2*5*34. Involvement 
of the conjunctiva can result in ectropion, trichiasis, 
symblepharon formation and corneal ulcerations2. 
Cutaneous eruption occurs in 10%-30% of patients2*34. 
The lesions consist of tense blisters which are usually 
localized to the face and scalp. Occasionally, patients 
may have a generalized bullous eruption35. Localized 
scarring pemphigoid (Brunsting-Perry) is a variant of
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cicatricial pemphigoid. It is characterized by a bullous 
eruption that remains limited to one area but in contrast 
to classical bullous pemphigoid it tends to heal with 
scarring36.
1.1.4 Pathology
Light microscopy. The major histologic finding in 
bullous pemphigoid is a subepidermal blister1. Early 
blisters are found completely beneath the epidermis. 
However, in older lesions regeneration in the floor begins 
at the periphery and extends over the whole floor. This 
regeneration results in an apparent intraepidermal posi­
tion of the blister31. The epidermis forming the roof of 
the blister is intact in early lesions, however necrosis 
may occur in older lesions31. The dermal changes are 
variable and depend on whether a biopsy was obtained from 
bullae arising on normal appearing or on erythematous, in­
flamed skin. It is recommended that biopsies be selected 
from an early blister which shows specific diagnostic fea­
tures. Non-erythematous lesions show a sparse perivas­
cular inflammatory infiltrate of monocytes and eosinophils 
not sufficient to establish a diagnosis5. Biopsies taken 
from erythematous lesions which may be urticarial are also 
unhelpful because the only pathological findings they show 
are dermal oedema and a perivascular accumulation of in­
flammatory cells that are rich in eosinophils. Con­
versely, inflammatory blisters show dense dermal in­
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filtrate composed of numerous eosinophils with monocytes 
and neutrophils. The infiltrate is around the blood ves­
sels, in the papillary dermis and in the blister cavity. 
As in dermatitis herpetiformis, the inflammatory in­
filtrate may extend to the tips of dermal papillae and 
form microabscesses. These consist predominantly of 
eosinophils rather than neutrophils31.
Electron microscopy. Ultrastructural studies per­
formed on specimens obtained from non-inflamed lesions 
show thinning of the basement membrane, disruption of 
anchoring filaments and blister formation within the 
lamina lucida which is localized between the plasma 
membrane of basal cells and the lamina densa37. The 
dermo-epidermal separation occurs as a result of the dis­
ruption and disappearance of anchoring filaments37-38. In 
inflamed bullous pemphigoid lesions the earliest 
ultrastructural finding consists of a marked dermal in­
filtrate of eosinophils and histiocytes. Subsequently, 
the basement membrane shows discontinuities with fragmen­
tation and disappearance of anchoring fibrils, anchoring 
filaments and hemidesmosomes and degeneration of the basal 
cells39.
1.1.5 Immunologic Assessment
Immunologic abnormalities of the skin and serum 
detected by the techniques of immunofluorescence proved to 
be of considerable value in the evaluation of acquired
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bullous disorders. Prior to the use of immunofluorescence 
methods in the investigation of these disorders, im­
munologic studies were performed with agglutination 
tests40. However, the reactions obtained with these tests 
tended to be non specific. A major development in the un­
derstanding of the pathogenesis of blistering diseases oc­
curred when it was demonstrated that bullous pemphigoid 
and pemphigus patients have tissue bound and circulating 
IgG antibodies41*42. Studies showed that serum antibodies 
are specific for the corresponding diseases and that they 
yield distinct responses demonstrable by the indirect im­
munofluorescence test. The characteristic reaction ob­
tained with sera from bullous pemphigoid patients consists 
of staining the area of the basement membrane of 
stratified squamous epithelium whereas the antibodies in 
the sera of pemphigus patients react with the intercel­
lular areas.
The existence of circulating anti-basement membrane 
zone antibodies in patients with bullous pemphigoid was 
first recognized by Beutner et al. in 196542. Studies 
using the indirect immunofluorescence technique had 
revealed that sera of three patients, then diagnosed as 
having either bullous pemphigoid or dermatitis herpetifor­
mis, contained antibodies directed against the basement 
membrane zone. In one patient who demonstrated positive 
basement membrane antibodies^direct immunofluorescent ex­
amination of a skin specimen showed in vivo binding of an­
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tibodies along the basement membrane zone. The presence 
of bullous pemphigoid antibodies reactive with an antigen 
in the basement membrane was also reported by Chorzelski 
et al. in 196643. These observations were of great sig­
nificance in providing a more precise definition of the 
immunopathology of bullous pemphigoid and in confirming 
Lever's classification of bullous pemphigoid as a distinct 
bullous disorder. Further immunofluorescent studies of 
bullous pemphigoid extended the initial observations and 
confirmed the presence of anti-basement membrane zone an­
tibodies in the majority of cases with active 
lesions44*45. In 1967 Jordon et al.44 demonstrated that 
fourteen of sixteen bullous pemphigoid patients with ac­
tive disease had circulating antibodies whereas the an­
tibodies could not be detected in the sera of six patients 
who were in clinical remission. Thus, the presence of an­
tibodies appeared to be related to the severity of the 
disease. The authors suggested that, like pemphigus vul­
garis in which the titre of circulating intercellular an­
tibodies decline or become undetectable in patients who 
are in remission, a similar correlation may exist in bul­
lous pemphigoid.
In some patients the indirect immunofluorescence test 
may be negative in the initial stages whereas tissue bound 
antibodies are detectable by the direct technique. Jordon
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et al.44 suggested that initially the antibodies may be 
bound in vivo and thus are not available in detectable 
serum concentration.
Although most of the indirect immunofluorescence 
studies for the demonstration of anti-basement membrane 
zone antibodies were performed using primate skin and 
mucosa as a substrate, species specificity studies have 
shown that autoantibodies in the sera of bullous pem­
phigoid patients are not species specific and react, in 
addition to primate tissue, with human skin, rabbit and 
guinea pig epithelial tissue46.
In addition to serum studies in bullous pemphigoid, 
Jordon et al.44 investigated the presence of in vivo bound 
IgG using direct immunofluorescence. Positive staining 
was found within skin lesions in four of five patients and 
in three of them also within normal skin.
Studies by Chorzelski et al.47 presented additional 
evidence confirming findings of tissue bound as well as 
circulating antibodies in the majority of bullous pem­
phigoid patients with active disease. Furthermore, sera 
obtained from typical cases of dermatitis herpetiformis 
were tested and showed no antibodies against the basement 
membrane zone, which underlined the specificity of these 
antibodies.
The immunological findings obtained by various inves­
tigators have focused - attention on the possibility 
that bullous pemphigoid may be an immunologically mediated
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disorder, and on the diagnostic and prognostic value of im­
munofluorescence studies in differentiating bullous pem­
phigoid from dermatitis herpetiformis and pemphigus.
1.2 THE IMMUNOFLUORESCENCE FEATURES OF BULLOUS 
PEMPHIGOID AND PEMPHIGUS
Considerable knowledge about the immunopathology of 
bullous pemphigoid and pemphigus has accumulated since the 
early studies of Beutner and Jordon41 and Jordon et al.42 
which demonstrated both tissue bound and circulating 
autoantibodies in the skin and serum of patients with 
these conditions. Our understanding of the immunological 
mechanisms involved in these bullous disorders has in­
creased substantially by studies using various techniques 
including direct and indirect immunofluorescence, comple­
ment indirect immunofluorescence, immunoelectron micros­
copy and immunochemical methods. These studies have been 
of utmost importance in establishing bullous pemphigoid 
and pemphigus as distinct immunologically mediated en­
tities and in providing immunologic diagnostic criteria. 
This section will focus on the most widely used im­
munologic tests for the evaluation of bullous pemphigoid 
and pemphigus, the direct and indirect immunofluorescence 
assays.
16
1.2.1 Bullous Pemphigoid
Direct immunofluorescence. Since the discovery of 
immune deposits in bullous pemphigoid skin, direct im­
munofluorescence has been regarded as a basic and crucial 
method for the accurate diagnosis of this condition. Im- 
munoreactants deposited in perilesional skin appear as a 
continuous fine linear pattern of fluorescence at the 
basement membrane zone. Granular or interrupted patterns 
may be seen in some areas. In biopsy specimens where 
there is epidermal/dermal separation the direct im­
munofluorescence test may be negative or the immune 
deposits may be present on the blister roof or on both 
sides of the blister48. The immunoreactants, IgG and the 
third component of complement C3 can be detected in the 
majority of patients with bullous pemphigoid. In some 
cases IgG is absent and only C3 is detectable6. The IgG 
deposits are present in up to 90% of cases and the linear 
deposits of C3 can be detected in almost all patients with 
bullous pemphigoid 5»6. Although C3 is the most fre­
quently encountered complement at the basement membrane 
zone, other components of the classical and alternate 
pathways have been observed including Clq, C4, C5, proper­
din, and BjH globulin49*50 . IgA, IgM, IgD and IgE 
deposits have been reported50. Deposits of the im­
munoglobulins IgA and IgM are each detected in ap­
proximately 25% of patients6*50. IgD and IgE deposits 
have only been reported in association with IgG6*48. Ab­
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sence of IgG may occur, especially in early disease, but 
IgG may be found a few weeks later or during recurrences6. 
Current evidence suggests that IgG and C3 deposits disap­
pear with remission6. The presence of IgA deposits in 
atypical cases of bullous pemphigoid may cause diagnostic 
difficulties, especially if IgG and IgA produce staining 
reactions which are of comparable intensity. The problem 
in such cases arises from the difficulty in differentiat­
ing bullous pemphigoid from linear IgA bullous dermatosis. 
A positive indirect immunofluorescence test for IgG anti­
basement membrane zone antibodies suggests the diagnosis 
of bullous pemphigoid. Because of the importance of 
direct immunofluorescence in the diagnosis of bullous pem­
phigoid, the site from which a biopsy is obtained must be 
carefully selected. Linear deposits of IgG and C3 may be 
absent in clinically blistered areas or from skin too dis­
tant from lesions. Therefore, the skin biopsy specimen is 
best obtained from an area approximately 2cm from a 
lesion46. Skin adjacent to a fresh bulla is preferred be­
cause in older lesions the basement membrane may be com­
pletely destroyed, resulting in a negative immunofluores­
cence finding. It has been suggested that the optimal 
site for a biopsy may be perilesional skin from a flexural 
area on the basis of the results obtained by Goldberg et 
al.4 who demonstrated regional variations in the expres­
sion of bullous pemphigoid antigen with the highest con­
centrations apparently being in the intertriginous areas.
18
In another study, Weigand51 studied the effect of anatomic 
region on the direct immunofluorescence test for bullous 
pemphigoid and found that immunofluorescence biopsies from 
the lower extremities are frequently negative. This ob­
servation, therefore, suggests that, whenever possible, 
the lower extremities are best avoided as a biopsy site 
for immunofluorescence studies in bullous pemphigoid. Al­
though linear deposits of IgG and C3, revealed by direct 
immunofluorescence, are considered characteristic of bul­
lous pemphigoid, they have also been regularly 
demonstrated in a similar immunofluorescent pattern in 
other blistering eruptions including cicatricial pem­
phigoid, herpes gestationis, epidermolysis bullosa ac- 
quisita and bullous systemic lupus erythematosus5*52-54 . 
Available techniques cannot reliably differentiate the 
deposits in bullous pemphigoid from those in cicatricial 
pemphigoid or herpes gestationis. However, differentia­
tion from those in epidermolysis bullosa acquisita and 
bullous systemic lupus erythematosus is possible by direct 
immunoelectron microscopy55*56 .
Indirect immunofluorescence. This serologic tech­
nique is used in bullous pemphigoid for detecting anti­
basement membrane zone antibodies in patients' sera. In 
this technique normal tissue is used as a substrate. 
Frozen tissue sections are overlaid with appropriate dilu­
tions of serum. Fluorescein-labelled antihuman IgG is 
subsequently overlaid on the sections which labels the IgG
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that previously bound to the basement membrane zone. The 
diagnostic value of immunofluorescence has been confirmed 
in many studies. They demonstrated that circulating 
anti-basement membrane zone antibodies can be detected in 
approximately 70% of patients with bullous pemphigoid. 
The incidence of a positive indirect immunofluorescence 
examination was 72% in Tuffan&lli1s study57 of 81 patients 
and 67% among the 84 patients of Person and Rogers5. The 
anti-basement membrane zone antibodies were detected in 
the sera of 69% of 36 patients studied by Ahmad et al.6 
and in 72% of 124 cases reviewed by Hodge et al.7. Al­
though a proportion of bullous pemphigoid patients, par­
ticularly at the early stages of the disease, have no 
demonstrable serum antibodies, follow-up examination of 
these patients' sera often yields a positive indirect im­
munofluorescence test6. The failure to demonstrate serum 
basement membrane zone antibodies in such patients has 
been attributed to the presence of unoccupied binding 
sites in the basement membrane zone and, therefore, cir­
culating antibodies become detectable only after the 
saturation of these binding sites by basement membrane 
zone antibodies6. The serum antibodies produce a linear 
pattern of fluorescence at the basement membrane zone 
which mimics the pattern observed on direct immunofluores­
cence. Several authors have reported the presence of cir­
culating antibodies that were not detected by routine in­
direct immunofluorescence. Kumar et al.58 suggested that
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"occult" anti-basement membrane zone antibodies can be 
detected by standard indirect immunofluorescence following 
prolonged incubation of bullous pemphigoid serum with 
whole skin. Hermann59 detected circulating anti-basement 
membrane zone antibodies in the sera of four bullous pem­
phigoid patients only after treating serum with urea to 
dissociate circulating immune complexes. IgG antibodies 
bound to antigen can generate many molecules of C3. The 
complement indirect immunofluorescence technique makes use 
of this amplification principle to increase the sen­
sitivity of the assay system. In some patients antibodies 
capable of binding complement can be demonstrated in sera 
that are negative by routine indirect immunofluorescence. 
Millns et al.60 reported complement fixing antibodies in 
seven bullous pemphigoid sera that were negative by stan­
dard indirect immunofluorescence. It appears that in such 
cases the anti-basement membrane zone antibodies are 
present in serum in concentrations too low to be detected 
by classical indirect immunofluorescence but may be 
detected by the more sensitive complement indirect im­
munofluorescence .
The variability in the incidence of seropositive bul­
lous pemphigoid patients and the failure to detect the 
circulating antibodies in some cases may also be ascribed 
to the type of epithelial substrate used in the indirect 
immunofluorescence technique. Some authors have suggested 
that the type of epithelial tissue used has a major impact
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on the result of serum testing for bullous pemphigoid 
antibodies61. In some cases the use of inappropriate 
epithelial substrate may lead to a false negative indirect 
immunofluorescence test62. There has been considerable 
controversy regarding the optimal choice of substrate for 
use in the indirect immunofluorescence assay. Some 
authors advocated the use of normal human skin, whereas 
others suggested that primate tissue is the ideal sub­
strate for detecting bullous pemphigoid antibodies6*61.
A correlation between bullous pemphigoid circulating 
antibodies and disease activity was suggested in the early 
reports of Jordon et al.44 and Peck et al.63. In a subse­
quent study, Katz et al.64 found correlation between titre 
of circulating anti-basement membrane zone antibodies and 
the severity of disease in eight bullous pemphigoid 
patients. Although some authors suggested that there is 
no direct correlation between antibody titres in bullous 
pemphigoid and disease activity5»47•65, studies of large 
series of patients demonstrated that a general correlation 
exists. Successful control of the disease was associated 
with low or undetectable serum antibodies and relapses 
followed by the reappearance of basement membrane zone 
antibodies6*66. Maize & Provost66 found monitoring serum 
and tissue bound antibodies to be useful in the management 
of bullous pemphigoid patients.
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1.2.2 Pemphigus
Pemphigus is one of the most serious acquired bullous 
disorders. The disease is characterized by flaccid bullae 
which rupture easily and leave denuded areas that tend to 
materially increase in size, causing discomfort and 
serious complications2. The fragility of skin in pem­
phigus is due to loss of adhesion between epidermal cells 
as a result of antibodies binding to the cells67. Clini­
cally, pemphigus may be divided into two groups depending 
on the location of the blister within the epidermis. In 
pemphigus foliaceus and pemphigus erythematosus the le­
sions form in a superficial, often subcorneal, location 
whereas in pemphigus vulgaris and pemphigus vegetans the 
blisters arise in a predominantly suprabasal location2. 
Both groups are associated with tissue bound and circulat­
ing autoantibodies directed against intercellular antigens 
67.
Direct immunofluorescence. The deposition of IgG an­
tibodies in the skin of patients with pemphigus was first 
reported by Beutner et al. in 196542. The deposits were 
observed within skin lesions of five patients and in four 
of the five patients also within normal skin. In addition 
to their value in understanding the nature of immunologi­
cal mechanisms involved in pemphigus, IgG intercellular 
deposits constitute a sensitive and reliable diagnostic 
test since they can be demonstrated in almost all cases 
with active disease67. The demonstration of these an­
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tibodies is particularly useful in cases of suspected pem­
phigus with only a few lesions and negative indirect 
immunofluorescence68. Complement C3 is often deposited in 
the intercellular areas of lesional skin whereas in normal 
skin complement deposits are uncommon. Judd and Lever69 
found C3 deposits in normal skin in only 50% of their 
patients. In addition to IgG, other immunoglobulins may 
be detected in some patients. IgA and IgM are present in 
up to 50% of cases in mucosa and perilesional skin69. 
Studies have shown that the direct immunofluorescence 
remains positive for a long time after the disease has 
regressed. Judd and Lever69 found a positive direct im­
munofluorescence test in 58 of 63 patients with pemphigus 
vulgaris and pemphigus foliaceus. Eleven of the 58 were 
in remission for more than a year and four of them for 
over five years. Most of the patients with a negative 
direct immunofluorescence test were free of lesions for 
several years.
Indirect immunofluorescence. Circulating antibodies 
in the sera of patients with pemphigus were originally 
reported by Beutner and Jordon in 196441. Using indirect 
immunofluorescence, they demonstrated that sera from these 
patients contain antibodies against an antigen in the in­
tercellular areas of stratified squamous epithelium. In a 
subsequent report Beutner et al.42 confirmed their earlier 
observations and showed that the antibodies were detected 
in nine out of 16 patients. Three cases showed doubtful
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staining and four were negative. It is now well recog­
nized that these antibodies are of the IgG class and can 
be detected in the majority of patients with active 
disease70. Thus, the detection of these antibodies is 
useful for confirming the diagnosis and differentiating 
pemphigus from other bullous disorders. However, it must 
be noted that circulating intercellular antibodies have 
been occasionally described in diseases other than pem­
phigus, including various autoimmune diseases such as sys­
temic lupus erythematosus71, myasthenia gravis71 and bul­
lous pemphigoid5. The antibodies are also frequently 
detected in patients with burns72.
Some authors have questioned the reliability of in­
direct immunofluorescence as a diagnostic technique in 
pemphigus. In an extensive study Judd and Lever69 per­
formed direct and indirect immunofluorescence on 63 
patients to determine the reliability of these tests as 
diagnostic procedures. Of the 63 cases, 92% showed a 
positive direct immunofluorescence test whereas circulat­
ing intercellular antibodies were demonstrated in less 
than half the sera tested. They also described four 
patients with moderate or extensive disease who showed no 
evidence of serum antibodies but had a positive direct im­
munofluorescence test. On the basis of these results the 
authors considered the demonstration of tissue bound an­
tibodies a more sensitive diagnostic method in pemphigus. 
However, since the type of substrate used in the indirect
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immunofluorescence assay has a major influence on the out­
come of the test, some authors attributed the results ob­
tained by Judd and Lever to the inappropriate choice of 
antigenic substrate73. In another investigation, a 
retrospective analysis of 106 cases of pemphigus showed 
that 69 cases (65%) were positive by both direct and in­
direct immunofluorescence. A significant finding was the 
detection of circulating intercellular antibodies in 
another 28 patients in whom immunofluorescence examination 
of biopsies was negative. Only 9 patients were seronega­
tive but were positive by direct immunofluorescence for in 
vivo-bound immune deposits74. The results, therefore, em­
phasize the reliability of indirect immunofluorescence as 
a laboratory method for the diagnosis of pemphigus. In 
addition to its diagnostic value, intercellular antibody 
titre determination has also been suggested to have a 
prognostic significance because of the tendency of serum 
antibodies to parallel disease activity. This association 
between the patient's clinical condition and serum an­
tibody titre was first suggested by Beutner et al.42. 
This was confirmed in a subsequent report by Chorzelski et 
al.75. Sams and Jordon65 performed serial antibody titre 
determinations on three pemphigus patients and showed a 
direct correlation with disease activity. Weismann76 
studied 24 patients and confirmed that relapses were as­
sociated with elevation of antibody levels and that clini­
cal improvement was followed by a decline in antibody
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titre. O'Loughlin77 investigated 17 patients over a six 
year period and found that successful control of the dis­
ease was accompanied by a fall of serum antibodies to un­
detectable levels. In such cases treatment was reduced 
and eventually discontinued. Conversely, some inves­
tigators have questioned the use of serial antibody titres 
to gauge treatment or as a prognostic indicator although 
they acknowledged the existence of a general correlation 
between titres of intercellular antibodies and disease 
severity70*79. Others have disputed the existence of any 
such correlation. Anderson et al.00 noted high antibody 
titres in clinically free patients whereas some patients 
with extensive disease had low or undetectable antibody 
titres. Similarly, Judd and Lever69 found a negative 
titre in 41% of patients with lesions while 45% of 
patients free of lesions showed a positive titre. They 
concluded that antibody titre determinations were not 
reliable for evaluating disease severity.
1.3 IMMUNOGLOBULIN G SUBCLASSES
The division of gammaglobulins into subclasses was 
first reported in 1960 by Drey01. His study showed that 
human IgG is composed of a mixture of three subclasses. 
Subsequent investigations by Grey and Kunkle02 and Terry
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and Fahey03 using antisera to isolated myeloma proteins 
showed that there were four subclasses of IgG. This sub­
division of gammaglobulins was based on differences in the 
structure of the heavy chain of each of the subclasses. 
Although the original reports defined the IgG subclasses 
on the basis of antigenic differences between myeloma 
proteins, they also demonstrated that the antisera to 
myeloma proteins also reacted with the same epitopes in 
normal sera. The development of specific monoclonal an­
tibodies has led to the accurate identification and 
measurement of the four subclasses. Many investigators 
have studied the IgG subclasses extensively and showed 
that each is characterized by specific structural, 
biological and physiochemical features.
1.3.1 Physiochemical Features
Studies of the physiochemical properties of IgG sub­
classes showed distinctive differences between them. 
Structurally, the molecular weight of IgG, IgG2 and IgG4 
is about 51 daltons^whereas the molecular weight of 
IgG3 is larger by approximately 5'I<D - 84. The
larger molecular weight of IgG3 is the result of an un­
usually large middle part of the heavy chain, hinge 
region, which covalently links the two G3 chains to each 
other. Another unique feature of IgG3 is the presence of 
five interheavy chain disulfide bonds. IgG! and IgG4 have 
two bonds while the heavy chains in IgG2 are joined by
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four bonds85. In addition, there is a high incidence of 
IgG3 in monoclonal cryoglobulins. Grey86 detected an­
ti gammaglobulin activity in five of seven myeloma proteins 
in patients with cryoglobulins. Four of these proteins 
were of the IgG3 subclass. These observations indicate 
that cryoprecipitation of G3 subclass occurs in a higher 
frequency than anticipated because this subclass repre­
sents only 7% of the total IgG.
The peptic cleavage pattern of the IgG subclasses was 
investigated and showed differences in their suscep­
tibility to enzymic degradation. It was demonstrated that 
IgGx and IgG3 are the fractions sensitive to papain di­
gestion, separating into Fab and Fc fragments. On the 
other hand, IgG2 and IgG4 are resistant to papain87. Dif­
ferences in the sensitivity to pepsin have also been 
noted. IgGj and IgG2 show resistance peptic degradation. 
Conversely, IgG3 and IgG4 are sensitive to pepsin digest­
ion with formation of F(ab)2 fragments88. These observa­
tions indicate that IgG3 is the subclass particularly sus­
ceptible to enzymic degradation. The relative resistance 
of IgG2 to enzymic digestion may be attributed to the 
presence of four interheavy chain disulfide bonds85. Al­
though the complete amino acid sequence of the various IgG 
subclasses has not been determined, studies of the amino 
acid composition of the heavy chains of the four sub­
classes showed a high degree of homology89.
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1.3.2 Biologic Properties
The introduction of specific monoclonal antibodies 
against human IgG subclasses had made it possible to ef­
fectively study and define their biological characteris­
tics. Studies to determine the metabolic properties of 
the various IgG subclasses have been based on investiga­
tions using myeloma proteins due to the lack of purified 
normal proteins. The properties of IgGi are similar to 
IgG3, whereas many of the IgG2 characteristics are shared 
by IgG4. The different IgG subclasses demonstrate vari­
able ability to fix complement. IgG2 and IgG3 are potent 
complement activators while IgG2 binds less well to 
complement. IgG4 is unique in being a non complement 
fixing antibody90. It has been shown that myeloma IgG 
proteins of all subclasses bind to the Clq subunit of the 
first component of complement and the affinity decreases 
in the order IgG3>IgG1>IgG2>IgG491. Hautanen et al.92 
demonstrated that the complement components C3c and C3d 
bind strongly to IgGx and IgG3/ whereas no significant 
binding could be detected to IgG2 or IgG4.
Morrell93 investigated the turnover of IgG subclasses
(t&1
and reported that the average biologic halflife of IgGX/ 
G2 and G4 was 21 days. Spiegelberg et al.94 also reported 
a similar ^i/% _ for these subclasses, however they 
found Tl/2 to be 11-12 days. In both studies G3 was shown 
to have a shorter Tl/2: 7-8 days. The shorter half life 
of G3 is associated with a higher fractional catabolic
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rate than other subclasses93. The reactivity of protein 
A, a staphylococcal wall antigen, with the various IgG 
subclasses is confined to IgG1# G2 and G489 . This selec­
tive binding of IgG subclasses has been used for the pur­
pose of isolating IgG3. Interestingly, IgG3 also fails to 
react with rheumatoid factors. IgGi shows the strongest 
reaction whereas lesser activity is seen with IgG2 and 
IgG*95. Active transfer across the placenta is a unique 
feature of gammaglobulins and it has been demonstrated 
that all four subclasses are transferable through the 
placenta89. In common with other biological functions of 
human IgG subclasses, there appear to be distinctive dif­
ferences between the four subclasses with regard to their 
ability to bind to different white blood cells. Simmons96 
studied the distribution of surface and cytoplasmic IgG 
subclasses in peripheral lymphocytes and found IgG2 and 
IgG4 to be the predominant surface immunoglobulins, while 
IgGx and IgG3 were more frequently expressed in the 
cytoplasm.
It has been<suggested that IgG2 and IgG4 are "antigen 
recognizing units" and that their deficiency may be as­
sociated with severe recurrent pyogenic infections 97. 
Endresen98 demonstrated IgG receptors on the surface of 
human platelets which were specific for IgGx and IgG3. A 
study of thrombocytopenic purpura showed that in 33 of 38 
cases anti-platelet maternal antibodies belong to IgGx and 
IgG2 subclasses99. Similarly, it has been shown that
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receptors for IgG on human monocytes100 and neutrophils101 
interact effectively with IgGx and IgG3. Thus, these par­
ticular subclasses of IgG can act as effective opsonizing 
antibodies due to the presence of receptors for their Fc 
portions on phagocytic cells and their ability to activate 
complement.
Antibodies which have the ability to bind to mast 
cells and basophils have been termed homocytotropic an­
tibodies. A definite type of homocytotropic antibodies 
are IgE class antibodies which remain in the skin for long 
periods and have been recognized as the predominant im­
munoglobulin class mediating hypersensitivity reactions89. 
It has been postulated that the IgG4 subclass also has 
homocytotropic properties and contributes to allergic 
reactions102. Vijay and Perelmutter103 showed that IgG4 
does bind to human basophils and leads to the release of 
histamine on challenge with appropriate antigens. There­
fore it may participate in allergic reactions as IgE does. 
However, IgG4 sensitizes the skin for a shorter period of 
time compared to IgE, and it is characterized by weaker
binding to mast cells and resistance to heat at 56°C89.
re
Conversely, van Toohenbergen and Aalbers@104 could not 
confirm the results of Vi jay et al.103 and concluded that 
IgG4 was incapable of sensitizing basophil leucocytes in 
vitro.
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Some have regarded IgG4 as a marker of allergy since 
elevated levels of this subclass are consistently higher 
in allergic patients compared to non allergic individuals. 
Increased levels of IgG4 are only rarely found in healthy 
non allergic subjects97. In contrast, some studies sug­
gested that these antibodies contribute to the beneficial 
effects of immunotherapy. Devey et al.105 demonstrated 
that IgG4 was the major antibody in the serum of hyposen- 
sitized patients and proposed that it may play a role in 
inhibiting hypersensitivity. Van der Giessen et al.106 
showed that IgG antibodies found in allergic individuals 
in response to immunization with grass pollen extract were 
predominantly of the IgG4 subclass. They suggested that 
they act as allergen neutralizing antibodies.
1.3.3. Antibodies
Although antibody activities may be found in all sub­
classes, certain IgG subclasses may be produced in 
response to specific antigens. Recent studies have shown 
a restricted IgG response in patients with acquired bul­
lous disorders such as pemphigus107, bullous pemphigoid108 
and herpes (pemphigoid) gestationis109. A response 
restricted to specific subclasses has also been observed 
in other autoimmune disorders. Eisenberg et al.110 
studied patients with systemic lupus erythematosus and 
reported predominant restriction of anti sm antibody to 
IgGj. They also found antiribonucleoprotein antibodies to
33
be predominantly IgG!. Schur et al.111 reported that an- 
tinuclear antibodies were of the IgGx and IgG3 subclasses. 
Studies have also shown that anti DNA antibodies in the 
serum of systemic lupus erythematosus patients are 
predominantly of the IgGi and IgG3 subclasses n o , m . 
These findings are of particular interest in view of the 
complement activating potential of IgGj and IgG3 fractions 
with subsequent complement mediated inflammation.
Antibodies to polysaccharides are primarily IgG2112. 
This subclass also dominates immune reactions involving 
carbohydrate antigens113. Specific antibodies to both 
tetanus and diphtheria toxoids were found in IgG1 and 
IgG2113. When screening for IgG subclass restriction of 
hepatitis B surface antigen antibodies, IgG3 was the most 
frequently found subclass besides the dominating IgG!112. 
Although it is evident from these studies that some an­
tigens stimulate the production of specific IgG sub­
classes, the cause for a restricted response to one or two 
subclasses is not known.
1.3.4 Serum Level Abnormalities
The levels of IgG subclasses in normal human serum 
have mostly been determined using the radial immunodiffu­
sion technique. IgGi is the major subclass; it com­
prises 64-70% of the total gammaglobulins. IgG2 and IgG3 
constitute 23-38% and 4-7% respectively. IgG4 forms only 
3-4% of the total human IgG114.
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Disturbances of the serum levels of the IgG sub­
classes have been reported by various investigators and 
consist of elevation, depression or complete lack of one 
or more of the subclasses. Many of the cases reported 
were associated with d i f f e r e n t  types of i m ­
munodeficiencies. However, serum concentration abnor­
malities have also been described in a variety of other 
disorders. The deficiency patterns of IgG subclasses vary 
and total IgG may be depressed or normal.
Oxelius et al.115 studied a group of immunodeficient 
patients and detected low levels of one or more IgG sub­
classes. The authors observed that the deficiency of one 
subclass may be associated with elevated levels of other 
IgG subclasses which indicates a possible compensatory 
mechanism. In such cases total IgG is normal or even 
elevated. The deficiency of specific IgG subclasses has 
been associated with severe chronic infections par­
ticularly affecting the upper respiratory tract. Van 
Loghera116 reported that IgGj was undetectable in a family 
with three children. Two of the children were in good 
health while the third suffered from a chronic purulent 
ear infection. Furthermore, the author reported a healthy 
individual who had a selective IgG2 deficiency, thus sup­
porting the suggestion that a deficiency of one subclass 
is compensated for by other subclasses. A hereditary lack 
of IgG2 and IgG4 has been associated with frequent infec­
tions, particularly caused by Haemophilus influenzae117.
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A high susceptibility of IgG2-deficient patients to recur­
rent infections by polysaccharide encapsulated bacteria 
such as pneumococci and Haemophilus influenzae has been 
reported by others118. Normal individuals without recur­
rent infections and complete absence of IgG3 were 
described by Lefranc et al.119. It has been speculated 
that the absence of clinical disease in IgG3 deficiency 
could be the result of IgG3 having similar biologic 
properties to IgG1# which represents 70% of total IgG. On 
the other hand, complete lack or marked deficiency of IgG4 
was found to be incompatible with good health. In a study 
by Heiner et al.97 severe recurrent pyogenic infections, 
mostly of the respiratory tract, have been observed in 
children and adults with selective IgG4 deficiency. The 
authors also reported very low levels of IgG4 in five of 
35 patients with bronchiectasis and suggested a causal 
relationship. Rarely, low but detectable levels of IgG4 
have been observed in healthy subjects. Disturbances of 
serum IgG subclasses have been noted in various systemic 
diseases. IgG2 and/or IgG3 may be depressed in patients 
with juvenile diabetes mellitus117. Mothers of infants 
infected with group B streptococcus have been shown to 
have low levels of IgGi and IgG3117. Some investigators 
have reported high levels of I g G 4 in atopic 
disorders120*121. These findings are of importance in 
view of the evidence suggesting that IgG anaphylactic an­
tibodies are implicated in some forms of human immediate
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type hypersensitivity122. IgGi and IgG3 were markedly 
elevated in a group of 12 adults and 14 children with sys­
temic lupus erythematosus while IgG2 and IgG4 were 
undetectable117. Serum IgG subclasses have also been 
studied in some blistering disorders of the skin. In­
creased levels of serum IgG4 have been reported in 
patients with pemphigus vulgaris107 and bullous 
pemphigoid108 whereas total serum IgG subclasses were not 
raised above normal in patients with endemic pemphigus 
foliaceus123.
1.4 IMMUNOLOGICAL CHARACTERISTICS OF BULLOUS PEMPHI­
GOID AND EPIDERMOLYSIS BULLOUS ACQUISITA ANTIGENS
Like bullous pemphigoid, epidermolysis bullosa ac- 
quisita is a chronic subepidermal blistering disease 
characterized by circulating and in vivo bound antibodies 
to the basement membrane zone. In both disorders anti­
basement membrane zone antibodies produce a morphologi­
cally indistinguishable linear pattern of staining by con­
ventional direct and indirect immunofluorescence methods. 
This immunofluorescence feature is also shared by another 
subepidermal bullous disease, cicatricial pemphigoid10.
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This limitation of routine immunofluorescence technique 
has contributed to diagnostic difficulties and confusion 
regarding the nosology of these disorders.
Ultrastructural immunocytochemistry has played an im­
portant role in classifying bullous disorders that may 
have identical immunofluorescence findings by demonstrat­
ing that immune deposits may be localized in a specific 
area of the basement membrane zone55-124 .
Other techniques that have become useful in classify­
ing subepidermal bullous diseases are immunoprecipitation 
and immunoblotting. These methods require that patients' 
sera contain circulating antibodies in order to detect the 
relevant antigen. Using these methods, some of the 
biochemical characteristics of different antigens can be 
established. Furthermore, it can be determined whether 
circulating antibodies from one patient recognize the same 
antigen as antibodies from another patient.
Because of the limited use of these techniques, the 
differential diagnosis is usually made on the differences 
in the clinical and histologic features of the disease. 
However, the reliance on these features may lead to incor­
rect diagnoses because patients with epidermolysis bullosa 
acquisita may have clinical and histologic features that 
are similar to those associated with bullous pemphigoid29.
38
1.4.1 The Basement Membrane Zone
Knowledge of the structure of the basement membrane 
of human skin is essential for understanding the 
ultrastructural location of antigens in the different bul­
lous disorders and the use of the newly developed 
monoclonal antibodies in the investigation and diagnosis 
of these diseases.
The basement membrane zone is the area where the 
epidermis is connected to the dermis (Figure 3). 
Ultrastructural studies have shown that it is composed of 
four structures125. The first of these structures is the 
plasma membrane of the basal cells. From the plasma 
membrane of keratinocytes extend electron dense structures 
called hemidesmosomes from which tonofilaments radiate. 
The second structure of the basement membrane zone is lo­
cated beneath the plasma membrane and is referred to as 
the lamina lucida. It is an electron lucent, homogenous 
area approximately 20-40nm in width. Anchoring filaments 
are collagen fibrils which extend perpendicularly across 
the lamina lucida and insert into the lamina densa. 
Laminin is a high molecular weight non collagenous 
glycoprotein that has been localized to the lamina 
lucida126. Beneath the lamina lucida is the lamina densa 
which is the third major component of the basement 
membrane zone. In contrast to the lamina lucida, the 
lamina densa is wider (30-60nm) and has an electron dense 
amorphous appearance. Type IV collagen is a distinct an-
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Figure 3. Schematic s tru ctu re  of the dermal-  
epidermal junction (adapted from referen ce  125) .  
TF = tonofilam ents , H = hemidesmosomes, PM = 
plasma membrane, A = anchoring filaments, LL = 
lamina lucida, LD = lamina d en sa , AF = anchoring  
f ib r i ls .
tigenic component which is located within the lamina 
densa127. The fourth structure of the basement membrane 
zone is the sublamina densa area which is located just 
beneath the lamina densa and includes different types of 
fibrillar structures. Anchoring fibrils are electron
dense structures that radiate from the lower aspect of the 
lamina densa and extend into the upper papillary 
dermis125. Recent studies have shown that the major 
structural component of anchoring fibrils is type VII
collagen128'129.
1.4.2 Bullous Pemphigoid
The bullous pemphigoid antigen is a normal con­
stituent of the basement membrane zone. It is mostly 
detected in tissues containing stratified squamous
epithelium but is also found in epithelial basement
membranes of urethra, bladder, bronchi and gall bladder46. 
The antigen is defined immunologically by antibodies 
present in the sera of patients with bullous pemphigoid 
which bind to the basement membrane of normal stratified 
squamous epithelial substrates.
Studies have shown that epidermal cells in culture 
could synthesize the bullous pemphigoid antigen130. Stan­
ley et al.131 confirmed this finding and demonstrated that 
sera from different patients with bullous pemphigoid react 
with the same antigen.
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The localization of bullous pemphigoid antigen has 
been studied by immunoelectron microscopy techniques. It 
was shown that in vivo bound immunoglobulins were mainly 
confined to the lamina lucida55-132. Similarly, indirect 
immunoelectron microscopy demonstrated that circulating 
bullous pemphigoid antibodies bind the lamina lucida133. 
However, more recent investigations suggested that bullous 
pemphigoid antigen is also associated with the 
hemidesmosomes134-135 . When epidermal cells in suspension 
are air dried and treated with bullous pemphigoid serum 
and FITC conjugated antihuman IgG a polar rim of fluores­
cence is observed136-137 . It has been proposed that this 
indicates that the bullous pemphigoid antigen is localized 
to the dermal pole of basal cells134. Subsequent studies 
suggested that the antigen is a molecule with an intracel­
lular component associated with an extracellular portion 
localized within the lamina lucida. The actual localiza­
tion of the antigen in the basement membrane zone and 
within normal keratinocytes has been determined by several 
investigators. In a study by Mutasim et al.134 viable 
murine epidermal sheets, separated below the lamina densa 
using dithiothreitol, incubated with bullous pemphigoid 
serum, and sectioned and treated with antihuman IgG, did 
not show staining at the basement membrane zone. Con­
versely, typical linear fluorescence was seen when the 
sheets were processed by standard indirect immunofluores­
cence. The authors also studied the effects of per-
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meabilization of cell membrane on the detection of an­
tigen. The epidermal sheets were treated with a per- 
meabilizing agent and then incubated with bullous pem­
phigoid serum prior to sectioning and processing. Linear 
staining was observed along the basement membrane zone.
Because the plasma membrane of viable cells is im­
permeable to antibody molecules, the results of these ex­
periments were regarded as evidence that an intracellular 
bullous pemphigoid antigen exists in epidermal sheets. 
Similar results were obtained using basal cell suspen­
sions. It was demonstrated that basal cells with perme­
able membranes bind bullous pemphigoid antibodies. 
Similar observations were reported by Regnier et al.138. 
Furthermore, they extracted the bullous pemphigoid antigen 
from non-viable basal cell populations that stain ex- 
tracellularly with bullous pemphigoid serum and from 
another pool of non-permeabilized keratinocytes. When the 
two were compared by immunoblotting, it was shown that the 
bullous pemphigoid antigen from both extracts was 220kd. 
Immunoelectron microscopy studies using permeabilized 
epidermal sheets and bullous pemphigoid serum show im- 
munoreactants almost exclusively intracellularly as clumps 
along the dermal pole of the basal cell plasma membrane. 
The sites of deposition corresponded to the location of 
hemidesmosomes. Only faint and focal staining was noted 
in the lamina lucida134. When trypsin dissociated per-
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meabilized basal cells were examined by immunoelectron 
microscopy IgG deposits were observed on intracytoplasmic 
vacuoles which represent "internalized hemidesmosomes"134.
The association of bullous pemphigoid antigen with 
the intracellular part of hemidesmosomes has been con­
firmed by others138. Other indirect immunoelectron 
microscopy studies using both peroxidase and colloidal 
gold techniques revealed that bullous pemphigoid antigen 
is localized inside the basal cell and preferentially as­
sociated with the hemidesmosomal plaques and tonofibrils
135 .
The various studies which demonstrate an intracel­
lular location for bullous pemphigoid antigen are in con­
trast with the earlier reports132*133 which suggested that 
the antigen is localized within the lamina lucida. 
Mutasim et al.139 have recently investigated the dis­
crepancy between reported ultrastructural binding sites of 
bullous pemphigoid antibodies. Antibody binding was ex­
amined by placing viable skin and bullous pemphigoid serum 
in organ culture. Under these conditions direct im­
munoelectron microscopy showed immune deposits located ex­
clusively in the upper lamina lucida, predominantly 
beneath the hemidesmosomes. Conversely, indirect im­
munoelectron microscopy using skin cryosections 
demonstrated intracellular binding of anti-basement 
membrane zone antibodies in association with the hemides­
mosomes. The detection of an extracellular bullous pem­
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phigoid antigen in the direct technique was attributed to 
the intact plasma membrane of viable cells; consequently, 
bullous pemphigoid antibodies had access only to the ex­
tracellular antigen. It was concluded that the bullous 
pemphigoid antigen is a transmembrane protein with bullous 
pemphigoid antibodies capable of binding both an extra- 
and an intracellular antigen.
Studies using immunochemical techniques have recently 
been used to determine the biochemical characteristics of 
bullous pemphigoid antigen. Initial studies by Diaz et 
al.140 in 1977 demonstrated a 20kQ protein extracted from 
normal human epidermis separated from the dermis by sodium 
thiocyanate. Using immunoprecipitation from buffer saline 
extracts of cultured epidermal cells, the bullous pem­
phigoid antigen was identified as a high molecular weight 
protein with disulfide chains of approximate molecular 
weight of 220kb. The same antigen was precipitated by 
sera from different bullous pemphigoid patients which sug­
gested the existence of a single bullous pemphigoid 
antigen131. The same group also demonstrated that the 
bullous pemphigoid antigen is distinct from laminin and 
fibronectin which are also high molecular weight com­
ponents of the basement membrane131-141. In a subsequent 
study Stanley et al.142 showed that bullous pemphigoid an­
tigen can be directly extracted from human skin. Using 
sodium dodecyl sulfate extracts of suction derived 
epidermis and Western immunoblotting, the bullous pem­
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phigoid antigen was demonstrated to consist of two non­
disulfide linked polypeptide chains with molecular weights 
of approximately 220-240kD.
1.4.3 Epidermolysis Bullosa Acquisita
In 1971 Roen*3k et al.28 reviewed the literature on 
epidermolysis bullosa acquisita and reported three cases. 
They suggested that this acquired blistering disease is a 
distinctive condition and established four criteria for 
the diagnosis which included (a) trauma-induced bullae 
over the joints of the hands, feet, elbows and knees, 
atrophic scars, milia and nail dystrophy; (b) adult onset 
of the disease; (c) negative family history of epider­
molysis bullosa; (d) exclusion of other bullous diseases 
including porphyria cutanea tarda, pemphigus, bullous pem­
phigoid, dermatitis herpetiformis and bullous drug erup­
tion. Histologically, epidermolysis bullosa acquisita is 
characterized by a subepidermal blister. Biopsies from 
areas of scarring show homogenization of the upper dermis 
with or without a mild mononuclear perivascular cell 
infiltrate28. Inflammatory lesions may be difficult to 
differentiate from bullous pemphigoid. They are as­
sociated with dermal oedema and a moderate to intense in­
flammatory infiltrate composed of neutrophils, eosinophils 
and monocytes. Occasionally, the infiltrate consists 
mainly of neutrophils143. Immunofluorescence studies
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showed that patients with epidermolysis bullosa acquisita 
had immunofluorescence features that resemble those of 
bullous pemphigoid and cicatricial pemphigoid53.
The clinical features of epidermolysis bullosa ac­
quisita are markedly variable and may simulate those 
characteristic of other bullous disorders. This variation 
in clinical presentation and the similarity between 
routine histologic and immunofluorescence features in 
epidermolysis bullosa acquisita and other subepidermal 
blistering diseases led to the suggestion that epider­
molysis bullosa acquisita was not a distinct entity and 
that its clinical features are manifestations of other 
specific diseases such as bullous pemphigoid and cicatri­
cial pemphigoid 144,1 4 5. However, subsequent im­
munoelectron microscopy studies demonstrated features dif­
ferent from those in bullous pemphigoid and cicatricial 
pemphigoid. Nieboer et al.56 showed that immune deposits 
were found in the upper dermis beneath the lamina densa. 
This is in contrast to pemphigoid, where the immune reac­
tants are deposited above the lamina dense132-133 . 
Studies by Yaoita et al.124 confirmed the immunoelectron 
microscopy findings in epidermolysis bullosa acquisita and 
showed that circulating anti-basement membrane zone an­
tibodies in epidermolysis bullosa acquisita patients also 
bind to the sublamina densa area. The authors proposed a 
modification to the diagnostic criteria originally out­
lined by Roenigk et al.28: (a) mechano-bullous lesions
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with scarring and milia; (b) negative family history of 
epidermolysis bullosa; (c) subepidermal blister histologi­
cally; (d) deposition of IgG at the basement membrane 
zone; (e) IgG deposits in the sublamina densa zone.
In addition to the immunoelectron microscopy dif­
ferences between bullous pemphigoid and epidermolysis bul­
losa acquisita, immunoblotting and immunoprecipitation 
studies have shown that the two disorders are biochemi­
cally distinct. The antigen reactive with epidermolysis 
bullosa acquisita autoantibodies is a normal constituent 
of the skin basement membrane. This antigenic component 
has recently been partially characterized by Woodly et 
al.146. Crude basement membrane zone extracts prepared 
from normal human skin were separated by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis and reacted in 
a Western blot assay with epidermolysis bullosa acquisita 
sera. Antibodies in epidermolysis bullosa acquisita serum 
samples detected a 290kD and 145k£? protein. Monoclonal 
antibodies that specifically bind to the epidermolysis 
bullosa acquisita antigen have been reported. The an­
tibodies demonstrate an immunofluorescence and im­
munoelectron microscopy binding pattern which is identical 
to that produced by polyclonal antibodies. Moreover, 
these antibodies identify the 290kO and 145kb proteins in 
the basement membrane extracts of human skin147-149.
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Stanley et al.150 showed that epidermolysis bullosa 
acquisita antigen is synthesized in culture by human 
keratinocytes and fibroblasts. They identified the 290kd 
chain of the antigen by immunoprecipitation studies using 
monoclonal and polyclonal epidermolysis bullosa acquisita 
sera. Further studies indicated that the target antigen 
for epidermolysis bullosa acquisita antibodies is the car­
boxyl terminal region of type VII collagen147*151. Using 
Western blotting, type VII procollagen and basement 
membrane extracts of skin, Woodly et al.151 studied the 
labelling patterns produced by polyclonal sera from 
epidermolysis bullosa acquisita patients, the monoclonal 
antibodies to epidermolysis bullosa acquisita antigen, 
and monoclonal antibodies to the carboxyl terminal of type 
VII collagen. They showed that all antibodies detect an 
antigen at 290kD. Furthermore, all epidermolysis bullosa 
acquisita sera and monoclonal antibodies failed to react 
with pepsinized type VII collagen which consists of a 
triple helical molecule but lacks the carboxyl terminal 
domain. .
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1.5 DERMATITIS HERPETIFORMIS
Dermatitis herpetiformis was first described by Duhr- 
ing in 1884152. Under this category he described a 
pruritic disorder with polymorphous eruption of 
erythematous papular, urticarial and vesicular lesion of­
ten in a characteristic herpetiform pattern. Duhring, 
however, included in his original publication not only 
what is now considered as dermatitis herpetiformis but 
also bullous pemphigoid which was termed bullous der­
matitis herpetiformis. The confusion between dermatitis 
herpetiformis and bullous pemphigoid continued until they 
were separated by Lever in 1953. In addition to the 
clinical and histological153 differences between the two 
diseases, it was demonstrated that sulfapyridine was ef­
fective in controlling dermatitis herpetiformis but had 
minimal or no effect on bullous pemphigoid154. The detec­
tion of granular immunoglobulin deposits in the skin of 
dermatitis herpetiformis patients was the first indication 
that the disease may be immunologically mediated155.
1.5.1 Clinical Features30
Unlike bullous pemphigoid, dermatitis herpetiformis 
tends to predominantly affect males. Although the disease 
has been reported in various age groups, it mostly occurs 
in the second to fourth decades. The lesions of der­
matitis herpetiformis usually develop in a symmetrical
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fashion and regularly involve the extensor surfaces. The 
sites of predilection include the elbows, extensor 
forearms, knees, buttocks and scalp. The primary lesion 
of dermatitis herpetiformis is an erythematous papule or a 
papulovesicle (Figure 4). Large bullae are not usually 
present. Bullous lesions may occur in some patients after 
the withdrawal of long-term therapy156. The "herpetiform" 
grouped arrangement of lesions is highly characteristic of 
the disease. However, scattered, non-grouped lesions are 
often present. The Koebner phenomenon has been reported 
in dermatitis herpetiformis157 with lesions occurring in 
areas of trauma or prolonged pressure. The demonstration 
of this phenomenon may account for the distribution of le­
sions on the scalp, elbows, knees and buttocks. The 
majority of dermatitis herpetiformis patients experience 
an intense degree of pruritus and burning. In many 
patients these symptoms precede the eruption of lesions 
which leads to excoriation and crusting. Occasionally, 
excoriated lesions are the only presenting manifestation, 
and the clinical diagnosis is reached on the basis of the 
characteristic distribution of lesions. Hyperpigmentation 
and hypopigmentation commonly occur following the involu­
tion of lesions30*156 .
It is now well recognized that the majority of der­
matitis herpetiformis patients have some degree of gluten 
sensitivity which causes intestinal abnormalities of the 
coeliac disease type158. This strong association between
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Figure 4. Dermatitis herpetiform is. Grouped  
p ap u lo -v es ic le s  in vo lv in g  the ex ten so r  forearm.
gluten ingestion and skin disease indicates that the in­
testinal defect may have an essential role in the 
pathogenesis of dermatitis herpetiformis. A gluten-free 
diet is associated with control of the rash and reversal 
of the pathological changes in the gut159.
1.5.2 Histopathology
The histologic features of clinical non-vesicular le­
sions consist of accumulations of neutrophils and some 
eosinophils at the tips of dermal papillae153. With 
progressive infiltration of neutrophils in papillae 
microabscesses form. The development and progressive in­
crease of microabscesses eventually leads to bulla forma­
tion. The cellular infiltrate of the underlying dermis is 
composed of neutrophils and some eosinophils. Many 
neutrophils show fragmentation of their nuclei, "nuclear 
dust"31*160. The dermal blood vessels are usually sur­
rounded by lymphohistiocytic infiltrate as well as 
neutrophils and eosinophils160.
The neutrophilic papillary microabscesses are diag­
nostic of dermatitis herpetiformis. A study of Kint et 
al.161 showed that these lesions were observed in all 14 
patients tested. However, in a study of 105 biopsy 
specimens by Connor et a l . 160, the papillary 
microabscesses were present in only 52% whereas 
leukocytoclasia was noted in 77% of specimens. Lever31 
concluded that the biopsies were not obtained from clini­
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cally non-vesicular areas which regularly show the 
neutrophil microabscesses. Occasionally, the differentia­
tion between dermatitis herpetiformis and bullous pem­
phigoid may be difficult. Some lesions may show a sub­
epidermal blister with a cellular infiltrate that contains 
a significant number of eosinophils, thus resembling the 
h i s t ologic picture of bullous p e m p h i g o i d 162. 
Microabscesses may also be seen in bullous pemphigoid. 
They usually contain eosinophils, but at times may be com­
posed largely of neutrophils5.
1.5.3 Immunopathology
The presence of immunoreactants in the skin of 
patients with dermatitis herpetiformis was first reported 
by Cormane155 in 1967, who found immunoglobulins in both 
involved and uninvolved skin. In a subsequent study, Van 
der Meer163 reported immunoglobulins in the uninvolved 
skin in 10 of 12 patients. The immunoglobulin class was 
IgA. IgG was also detected in some patients. These find­
ings confirmed that dermatitis herpetiformis is distinct 
from other blistering eruptions and that it may be im- 
munologically mediated. The demonstration of IgA an­
tibodies in the skin of suspected cases of dermatitis her­
petiformis is regarded as an essential criterion for the 
diagnosis164-165. IgA deposits are found with or without 
other immunoreactants in more than 95% of cases when unin­
volved skin is tested164. Different patterns of IgA
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deposition are seen in the skin of dermatitis herpetifor­
mis patients. Chorzelski et al.166 were the first to 
describe the localization of IgA deposits at different 
sites. The majority of patients show IgA almost ex­
clusively located in the dermal papillae. The appearance 
of deposits is usually granular. However, some patients 
may have a fibrillar component to the IgA deposits which 
appear as string of fluorescence. Infrequently, IgA 
deposits may be present in a homogenous linear pattern 
along the basement membrane zone. Cases associated with 
this pattern were initially considered as variants of der­
matitis herpetiformis164. However, linear IgA deposition 
is now considered a separate disease termed linear IgA 
bullous dermatosis32. A small proportion of patients show 
a granular linear pattern which appears as a fine granular 
line restricted to the basement membrane zone32.
Occasionally, some biopsy specimens from suspected 
cases of dermatitis herpetiformis yield a negative direct 
immunofluorescence test for IgA. It has been suggested 
that patients who lack IgA deposits do not have dermatitis 
herpetiformis167. It must be noted, however, that the 
selection of the biopsy site in patients with dermatitis 
herpetiformis is important. Specimens of inflamed skin or 
a blister usually yield a false negative immunofluores­
cence result166. It must also be emphasized that in some 
patients repeated biopsies and studies of serial sections 
may be required before a positive result is obtained167.
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Zone et al.168 suggested that uninvolved, distant skin 
tends to yield decreased amounts of IgA. Deposits of IgA 
could not be detected in such locations in four of 14 der­
matitis herpetiformis patients who were in active disease, 
However, granular IgA deposits were observed in all cases 
in biopsies obtained from normal-appearing skin that was 
approximately 5mm from an active lesion169. Marks158 
questioned the reliability of direct immunofluorescence 
for IgA as a diagnostic test in dermatitis herpetiformis 
and indicated that there are patients who met all other 
diagnostic criteria, except IgA, and respond to sul- 
fapyridine or dapsone therapy. Fry et al.167 studied
similar cases and found that an alternative diagnosis can 
be reached in the majority of cases.
Complement, most commonly the third component, is 
present in a distribution similar to IgA163. Im­
munoglobulins other than IgG are occasionally found in the 
skin in dermatitis herpetiformis. These are also seen in 
a distribution identical to IgA. In a study of 19 
patients, Chorzelski et al.166 found IgG in six patients 
and IgM in five patients. In another study of 78 
patients, IgG and IgM were detected in two and seven 
patients respectively164.
A variety of circulating antibodies have been iden­
tified in dermatitis herpetiformis. Gastric parietal cell 
antibodies, thyroid antibodies and antinuclear antibodies 
have been detected in variable frequencies170. Serum from
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patients with dermatitis herpetiformis may also contain 
antibodies against reticulin and gliadin and the more 
recently described antiendomysial antibodies170-172.
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2. MATERIALS AND METHODS
2.1 THE DEMONSTRATION OF BULLOUS PEMPHIGOID AND 
PEMPHIGUS ANTIBODIES BY INDIRECT IMMUNOFLUORESCENCE
2.1.1 The Expression of Bullous Pemphigoid and 
Pemphigus Vulgaris Antigens in Normal Skin
The expression of bullous pemphigoid and pemphigus 
vulgaris antigens was assayed by indirect immunofluores­
cence using specimens of normal human skin from different 
body regions as a substrate.
Skin specimens. The specimens were obtained from the 
edges of surgically excised benign skin lesions. No skin 
was taken from patients with blistering or autoimmune dis­
ease. Antigen expression studies were performed on normal 
skin specimens obtained from different individuals. 
Tissue was specifically selected from the face, trunk and 
flexural aspect of lower limb.
To examine the expression of pemphigus vulgaris an­
tigen, normal skin specimens from the same areas were also 
used.
All skin specimens were immediately frozen in liquid 
nitrogen and stored at -70°C until use.
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Serum samples. Bullous pemphigoid studies were per­
formed using two panels of sera from eighteen patients. 
Nine sera had anti-basement membrane zone antibodies in 
titres of 1:80 whereas the remaining nine samples had cir­
culating bullous pemphigoid antibody titres equal to or 
greater than 1:160 when tested against sections of monkey 
oesophagus or guinea pig lip. All patients had linear 
deposits of IgG and/or C3 at the basement membrane zone 
demonstrated by direct immunofluorescence.
Studies were also performed on twelve selected sera 
submitted for routine immunofluorescence tests for cir­
culating intercellular antibodies. All serum samples were 
from patients diagnosed both clinically and im- 
munopathologically as having pemphigus vulgaris. The 
titre of circulating pemphigus antibodies was equal to or 
higher than 1:80 when tested against monkey oesophagus or 
guinea pig lip by indirect immunofluorescence in an ini­
tial routine assay. In addition, sera from two normal in­
dividuals were used as negative controls. Samples were 
aliquoted and stored at -70°C.
Indirect immunofluorescence. Five micromete ryos- 
tat sections of normal skin specimens were mounted on 
gelatine coated slides, air dried and washed briefly in 
phosphate buffer saline (0.120M NaCl, 0.008M Na2HP04 and 
0.002M KH2P04, pH7 . 4)
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In order to avoid false positive reactions caused by 
blood group antibodies which can react with intercellular 
areas of epithelial tissues, pemphigus sera were absorbed 
with erythrocytes of groups A and B (1:1 vol/vol) for 30 
minutes at 37°C.
Immunofluorescence testing of both bullous pemphigoid 
and pemphigus sera was performed according to the standard 
technique173.
The cryostat sections were treated with serial dilu­
tions of bullous pemphigoid and pemphigus vulgaris sera 
starting at 1:10. Phosphate buffered saline was used to 
dilute serum. All samples were assayed simultaneously.
The slides were placed in a moist chamber and in­
cubated at 37°C for 30 minutes. The sections were then 
washed in three changes of phosphate buffered saline for 
15 minutes. Rinsing in phosphate buffered saline was 
aimed at removing excess antibodies that are not specifi­
cally bound. The final stage of the indirect im­
munofluorescence assay consisted of overlying the tissue 
sections with fluorescein isothiocyanate (FITC) conjugated 
goat antihuman IgG (Dako). The protein concentration of 
the used conjugate was 3.7mg/ml and the Molar fluorescein 
to protein ratio was 2.3. The working dilution of the 
conjugate was 1:20. The dilution was made in phosphate 
buffered saline. The slides were incubated at 37°C for 30 
minutes and then washed in three changes of phosphate buf-
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fered saline for 30 minutes to remove unbound 
fluorescein-labelled antihuman IgG. The slides were
drained and carefully dried around the sections.
A drop of mounting medium (glycerine/phosphate buf­
fered saline) was placed onto each section and covered 
with a clean coverslip.
The slides were examined under a Leitz fluorescence 
microscope.
Statistical analysis. The highest dilutions of serum 
samples were grouped according to body site and the 
geometric mean was determined. A comparison between the 
three locations was performed using Fisher's exact test. 
Differences were considered significant if P value was 
less than 0.05.
2.1.2 Comparison of Different Epithelial Substrates
Used for the Titration of Bullous Pemphigoid and 
Pemphigus Antibodies
Studies were performed on 36 selected sera submitted 
for routine immunofluorescence tests for antibodies to 
epithelial antigens. All serum samples included were from 
patients diagnosed clinically as having either bullous 
pemphigoid or pemphigus vulgaris. Prior to testing pem­
phigus sera, they were absorbed with red blood cells of 
groups A and B. The absorption differentiates between the
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intercellular staining of the epithelium caused by pem­
phigus antibodies and by antibodies to blood group A 
and/or B antigens.
Substrates. Each serum sample was assayed on three 
different substrates - monkey oesophagus, guinea pig lip 
and human skin. These epithelial substrates are commonly 
used as sources of pemphigoid and pemphigus antigens in 
indirect immunofluorescence examination.
Experiments were performed simultaneously on all sub­
strates .
Oesophagus and lip sections were obtained from newly 
sacrificed animals. Sections of normal human skin were 
obtained from fresh normal surgical biopsy specimens from 
the face. Tissue from the face was selected for its 
strong expression of both bullous pemphigoid and pemphigus 
antigens.
All tissues were immediately frozen and stored at 
-70°C until use.
Indirect immunofluorescence. Indirect immunofluores­
cence to determine antibody titres was performed by the 
standard technique described in section 2.1.1. All sera 
were tested in serial dilutions starting from 1:10. Posi­
tive and negative control sera were included with each ex­
periment .
60
The positive control sera for pemphigoid and pem­
phigus studies were selected on the basis of reaction with 
comparable antibody titres on all three substrates, thus 
ensuring that negative or low titre reactions were not due 
to the poor quality of a particular substrate.
2.2 COMPARISON OF IgG SUBCLASSES AND COMPLEMENT BINDING 
ACTIVITY IN PATIENTS WITH BULLOUS PEMPHIGOID AND 
PEMPHIGUS VULGARIS
The distribution of IgG subclasses in the skin and 
serum of patients with pemphigoid and pemphigus was inves­
tigated. The diagnosis of bullous pemphigoid was con­
firmed by direct immunofluorescence of perilesional skin 
demonstrating anti-basement membrane zone antibodies and 
complement. The diagnosis of pemphigus was established by 
the detection of IgG antibodies in the intercellular areas 
of the epidermis by direct immunofluorescence.
Tissue. Perilesional skin from 17 patients with bul­
lous pemphigoid and 10 patients with pemphigus vulgaris 
were included in the study. All skin specimens were ob­
tained during active disease.
Serum. Samples from 25 bullous pemphigoid patients 
and 17 pemphigus vulgaris patients were included in this 
investigation.
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Normal human skin and serum from healthy individuals 
served as controls.
Substrate. Monkey oesophagus was used as a substrate 
for indirect immunofluorescence studies. Fresh specimens 
were stored at -70°C until used. Prior to testing, a 
block of the substrate was mounted and 5um sections were 
cut on a cryostat.
2.2.1 Direct Immunofluorescence173
"fWc. cryostat sections of perilesional
pemphigoid and pemphigus skin were first tested for IgG 
and C3 deposits. The third component of complement was 
detected by FITC-conjugated rabbit antihuman C3 complement 
(Dako). The protein concentration of the conjugate was 
4.4mg/ml and the Molar fluorescein to protein ratio was 
2.3. The working dilution of the conjugate was 1:20. The 
reagent was diluted in phosphate buffered saline.
The slides were placed in a moist chamber and in­
cubated for 30 minutes at 37°C. The slides were then 
washed in several changes of phosphate buffered saline for 
30 minutes. This immunofluorescence technique was also 
used to determine the distribution of IgG subclasses in 
pemphigoid and pemphigus skin.
The frozen tissue sections were overlaid with mouse 
monoclonal antibodies against the human IgG subclasses Glt 
G2, G3 and G4 (Sigma). The antibodies were produced by 
the fusion of mouse myeloma cells and spleen cells from an
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immunized mouse. All the IgG subclasses antibodies used 
were conjugated to FITC. A working dilution of 1:50 in 
phosphate buffered saline was used.
Antihuman IgGi - Clone No. 8C/6-39. The specific im­
munoglobulin concentration = 4.5mg/ml. The Molar fluores­
cein to protein ratio was 6.0.
Antihuman IgG2 - Clone No. HP-6014. The Molar
fluorescein to protein ratio was 4.0.
Antihuman IgG3 - Clone No. HP-6050. The Molar
fluorescein to protein ratio was 3.6.
Antihuman IgG4 - Clone No. HP-6025. The Molar
fluorescein to protein ratio was 4.1.
The protein concentration of the monoclonal an­
tibodies IgG2, IgG3 and IgG4 is not available.
There is no cross reactivity between the different 
IgG subclasses. The specificity of each clone has been 
determined by several immunological methods174.
2.2.2 Indirect Immunofluorescence
Pemphigoid and pemphigus sera, diluted 1:10, were 
first screened for the presence of IgG against the base­
ment membrane zone and intercellular areas using 
polyclonal goat antihuman IgG. Subsequently, indirect im­
munofluorescence studies to assay the IgG subclasses of 
anti-basement membrane zone and intercellular antibodies 
were performed. Direct and indirect immunofluorescence
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results were graded according to the intensity of fluores­
cence: (++) = strong positive; ( + ) = positive; (-) =
negative staining.
Preliminary testing of pemphigoid and pemphigus skin 
and sera showed no demonstrable IgG2. Therefore, this 
particular subclass was not sought in subsequent experi­
ments .
2.2.3 Indirect Complement Immunofluorescence
To examine the relationship between IgG subclasses^ 
distribution in pemphigoid and pemphigus antibodies^ and 
their capability to fix complement, an indirect complement 
immunofluorescence technique was used. The investigation 
included all pemphigoid and pemphigus serum samples for 
which the distribution of IgG subclasses has been deter­
mined .
The indirect complement immunofluorescence method 
used, which measures the avidity with which antibodies fix 
complement, was based on a modification of the method 
described by Beutner et al.173.
The procedure consists of three stages. The first 
stage is similar to the initial step of classical indirect 
immunofluorescence. Normal human skin was used as a sub­
strate. Cryostat sections were overlaid with patients' 
sera at a dilution of 1:10. In the second stage the sec­
tions were incubated with a source of complement. Serum
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collected from healthy individuals was used as a source of 
complement. Normal serum was stored at -70°C and used 
within two weeks.
Complement fixing IgG antibodies that reacted with 
antigen in the first stage activate complement in the 
second stage to generate numerous C3 molecules which are 
deposited at the antigen antibody binding sites. The 
final stage consisted of incubating the sections with FITC 
conjugated rabbit antihuman C3 antibody.
All incubations were for 30 minutes at 37°C. The 
slides were washed in phosphate buffered saline for 15 
minutes between incubations. Appropriate controls were 
included with each experiment.
2.1 IMMUNOFLUORESCENCE - SPLIT SKIN AND WESTERN IMMUNO- 
BLOTTING STUDIES
2.3.1 Indirect Immunofluorescence Using Sodium Chloride- 
Split Skin
Sera. Serum samples were obtained from 27 patients 
with bullous pemphigoid. Sera were collected during ac­
tive disease. Immunopathologic studies showed deposition 
of IgG and/or C3 along the basement membrane zone of the 
skin by direct immunofluorescence. Circulating anti­
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basement membrane zone antibodies were detected by stan­
dard indirect immunofluorescence technique on cryostat 
sections of monkey oesophagus or guinea pig lip. Antibody 
titres ranged between 1:40 and 1:320. A serum sample from 
a patient with the diagnosis of epidermolysis bullosa ac- 
quisita was also included. Direct immunofluorescence of 
perilesional skin from this patient showed intense linear 
deposits of IgG and C3 at the basement membrane zone. 
Electron microscopy of a skin biopsy showed a cleavage 
beneath the lamina densa. Circulating IgG anti-basement 
membrane zone antibodies were positive at a titre of 1:160 
when tested on cryostat sections of normal human skin. 
Normal sera from 7 healthy individuals were used as nega­
tive controls.
Skin. Several pieces of normal human skin were ob­
tained from the flexor aspect of the forearm and leg from 
different individuals with no evidence of blistering or 
autoimmune disease. Half of one specimen was quickly 
frozen in liquid nitrogen and stored at -70°C. It was 
used to compare the sensitivity of intact and separated 
skin for the detection of anti-basement membrane zone an­
tibodies. Excess fat was removed from all specimens, 
after which they were washed in phosphate buffered saline 
and treated with 1M sodium chloride according to the 
method of Scaletta et al.175 as follows: the samples were
incubated for 48-96 hours in freshly prepared 1M sodium 
chloride at 4°C or at room temperature with constant
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agitation. The sodium chloride solution was .changed 
every 24 hours. At the end of the incubation period the 
specimens were placed with the dermis side down. The 
epidermis was then gently separated from the dermis using 
forceps. Alternatively, the epidermis may be carefully 
dislodged from the dermis by gentle traction to the skin. 
Specimens were frozen and stored at -70°C until use.
Immunoreagents.
Mouse anti-type IV collagen (Dako). The protein con­
centration of this antibody was 4.05mg/ml. It was used at 
a dilution of 1:50.
Mouse anti-type VII collagen. This monoclonal an­
tibody was obtained from Serotec. The antibody specifi­
cally reacts with the carboxyl terminus of type VII col­
lagen. It was used at a dilution of 1:10.
FITC-conjugated rabbit anti-mouse immunoglobulins 
(Dako). The protein concentration of this reagent was 
3.1mg/ml and the Molar fluorescein/protein ratio was 2.3. 
The conjugate was used at a dilution of 1:20 in phosphate 
buffered saline.
Indirect immunofluorescence. The procedure was per­
formed using 5um cryostat sections of intact and separated 
skin. Testing was carried out on intact skin and sections 
from two different specimens of separated skin to localize 
type IV collagen and type VII collagen and to confirm the 
ultrastructural level of separation. Bullous pemphigoid, 
epidermolysis bullosa acquisita and control sera were ex­
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amined at a dilution of 1:10 on intact and split skin. 
The epidermolysis bullosa acquisita serum and 12 bullous 
pemphigoid sera were also reacted against two other 
specimens of separated skin. In addition, the epider­
molysis bullosa acquisita sample and 8 pemphigoid sera 
were simultaneously tested in serial dilutions on intact 
and split skin.
So <A v uv*. cl' tfT —
2.3.2 Direct Immunofluorescence of ,.fSeparated
Biopsy Specimens 
Perilesional skin biopsy specimens from seven 
patients with bullous pemphigoid and a patient: with 
epidermolysis bullosa acquisita were separated at the der­
mal epidermal junction by sodium chloride. All patients 
had deposits of IgG and C3 at the basement membrane zone 
demonstrated by routine direct immunofluorescence. The 
specimens were obtained one year previously and had been 
frozen and stored at -70°C. They were thawed and in­
cubated in 1M sodium chloride solution as described above. 
Direct IgG and C3 immunofluorescence of the separated 
biopsies was performed using the standard technique. The 
ultrastructural level of split was confirmed by im­
munofluorescence mapping using monoclonal antibodies 
against type IV and type VII collagen.
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2.3.3 Sodium Dodecyl Sulfate Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and Western Immuno- 
blotting Studies 
This study included seven of the 27 pemphigoid sera 
initially examined on split skin. All samples gave an 
epidermal staining pattern. An epidermolysis bullosa ac­
quisita serum which produced a dermal pattern of staining 
was also tested. All sera had a titre equal to or greater 
than 1:160 when tested on salt-split skin. Normal human 
serum from healthy individuals was used as a control.
In addition, sera from patients with other dermatoses 
also served as controls. This group included two patients 
with psoriasis, two with generalized eczema, five with 
pemphigus vulgaris and two with pemphigus foliaceus. All 
pemphigus sera contained circulating intercellular an­
tibodies at titres greater than 1:160.
Epidermal extraction. The epidermal extract was 
prepared using normal human skin obtained from surgical 
specimens of breast. The skin was cut into small pieces 
0.5 x 0.5cm or strips 5 x 0.5cm and incubated in a fresh 
solution of 1M sodium chloride at 4°C for 72-96 hours. 
The solution also included ImM of phenyl methyl sulfonyl 
fluoride (PMSF) and 2mM of ethylenediaminetetra acetic 
acid (EDTA). The reactivity of separated skin was tested 
by indirect immunofluorescence using epidermolysis bullosa 
acquisita and bullous pemphigoid sera. After dermal 
epidermal separation the bullous pemphigoid antigen was
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extracted from the epidermis following the procedure of 
Stanley et al.142. Approximately 25cm2 of epidermis was 
added to 2ml of extraction buffer composed of 62.5;W]ris 
.{idpH 6.8, 2% w/v SDS, 2mM PMSF, lOmM EDTA and 
0.3M mercaptoethanol, and incubated at room temperature 
for one hour. The epidermis was then homogenized using a 
motor-driven homogenizer for 60 seconds (4 x 15s) at room
temperature. The homogenate was then centrifuged at 13500
(qsoo * 3)
rpntffor 20 min. The supernatant was collected, divided 
into aliquots and stored at -70°C until use.
Dermal extraction. Dermal extracts were prepared 
using a modification of the method described by Woodly et 
al.146. The dermis was extracted for one hour at room 
temperature with 12.5mM tris HC1, pH 6.8, containing 8M 
urea, 2%(w/v) SDS, 0. 3M mercaptoethanol, ImM PMSF and 2mM
EDTA. The preparation was then vortexed for 15 min. at
(RSoox9)
room temperature and then centrifuged at 13500 rpmrfor 20 
min. The supernatant was collected and stored at -70°C 
until it was used for electrophoresis.
Protein content estimation. The protein concentra­
tion in epidermal and dermal extracts was estimated by 
Lowry's assay176.
Reagents: Reagent A, 2% Na£03 in 0.1M NaOH
Reagent B, 0.5% CuSO4.5H20 in sodium 
citrate
Reagent C, alkaline copper solution - mix 
50ml of solution A with 1ml of reagent B
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Reagent D, prepared by adding equal volumes 
of Folin's solution and distilled water.
Preparation:
0.1ml of epidermal or dermal extract sample, diluted 
1:50, and 0.1ml 1M NaOH were placed in test tubes. Dis­
tilled water was added to a final volume of 1ml.
Tubes containing 0, 0.02, 0.04, 0.06, 0.08 and 0.1ml 
of bovine serum albumin (lmg/ml) were run in parallel to 
provide a standard curve. Two ml. of reagent C were added 
to all samples and standards. The tubes were vortexed for 
a few seconds and left at room temperature for 10 min. 
Finally 0.2ml of reagent D was added rapidly and the tubes 
briefly mixed on a vortex mixer, then left at room tem­
perature for 30 min. r ‘AbWlwmcje^ were fHcASMh^ d.
. at 550nm.
SDS-PAGE of epidermal and dermal extracts. This was 
performed according to the method of Laemmli177. The com­
position of the running and stacking gels is indicated in 
Table 1.
Gels were cast in a cassette consisting of two glass 
plates (160 x 180 x 3mm) kept apart with 2mm spacers and 
held together by two clamps.
The running gel (125 x 145 x 2mm) was poured, over­
laid with distilled water and allowed to polymerize for 
approximately 30 min. After removing the overlay solu­
tion, the stacking gel (35 x 145 x 2mm) was cast onto the
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surface of the resolving gel. A clean Teflon comb was im­
mediately inserted into the stacking gel solution. The 
gel was allowed to polymerize at room temperature.
Samples of epidermal and dermal proteins were 
prepared for electrophoresis by incubating in sample 
buffer at 100°C for 3 min. The composition of sample 
buffer is shown in Table 2.
Standard protein markers were also run for calibra­
tion. A mixture of high molecular weight standards was 
purchased from Sigma. The mixture contained the standards 
- Myosin (205KD), B-Galactosidase (IloKD), Fhosphorlase B 
(97K£>) and Bovine Albumin (66KD). It was prepared in the 
appropriate sample buffer and boiled before loading on 
gels.
When polymerization of the stacking gel was complete 
(approximately 30 min.), the Teflon comb was removed and 
up to 75ug of epidermal or dermal proteins were loaded per 
well.
The whole cassette was then mounted in the 
electrophoresis apparatus. Electrophoresis was performed 
at 50mA for 4-5 hours. The electrophoresis was stopped 
when the dye front had travelled at least 100mm into the 
resolving gel.
The gel running buffer, which was added to both upper 
and lower reservoirs, contained 0.192M glycine, 0.1% (w/v) 
SDS in 0.25MT*ris HCl (pH 8.3).
73
Table 2
COMPOSITION OF SAMPLE BUFFER
Component Volume
0.5  Aft Tris HC1, pH 6.8 1.25 ml
Disti l led water 4 ml
Glycerol 2 ml
10% ( w / v )  SDS 2 ml
2-Mercaptoethanol 0 .5  ml
0.05% ( w / v )  Bromophenol 0 .25  ml
blue
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Western blotting. Immediately after electrophoresis, 
proteins from SDS-PAGE gels were transferred to nitrocel­
lulose sheets following the method of Towbin178. Transfer 
was carried out at room temperature using a BioRad trans­
blot cell. The transfer (Towbin's) buffer contained 25mM 
Tris HC1, 192mM glycine and 20% (V/v) methanol at pH 8.3.
Transfer was performed at 80mA for approximately 18 
hours.
Gels were then transferred to a tray containing 
Coomas5ie blue to monitor the disappearance of proteins 
from gels.
Staining with CoomasyLe blue. Coomassie blue is a 
staining reagent used in the procedure of SDS-PAGE and 
Western blotting to visualize protein bands on SDS gels 
and to establish the efficiency of transfer of proteins 
from gels to nitrocellulose filters.
The gel was immersed in the staining solution and 
left at room temperature for 3 hours. The stain was then 
removed and the gel de stained over a period of 4-6 hours 
in 5%f(v/v) and 7.5% (v/v) acetic acid.
Staining with Ponceau S . Proteins may be stained 
directly on the nitrocellulose membrane with Ponceau S 
stain to establish that the electrophoretic transfer of 
proteins has taken place and to determine the location of 
molecular weight markers. The staining procedure was per­
formed immediately after the nitrocellulose sheet was 
removed from the blotting apparatus. It was then trans­
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ferred to a tray containing a solution of Ponceau S 
(Sigma) and incubated at room temperature for 10 min. with 
gentle agitation. It was then briefly washed in distilled 
water to visualize lanes and protein bands.
The molecular weight marker lanes were cut off before 
proceeding to the immunostaining stage.
Immunostaininq. The nitrocellulose sheet from the 
Western blot was incubated for one hour at room tempera­
ture in 5% (w/v) non-fat dried milk to block free protein 
binding sites and then washed briefly with phosphate buf­
fered saline.
The nitrocellulose filter was cut lengthwise into 
0.5cm strips corresponding to each sample application lane 
of the acrylamide gel.
The strips were placed in a tray and each incubated 
with l-2ml of patient's or control serum diluted 1:5 with 
0.05% Tween 20 in phosphate buffered saline pH 7.4. The 
incubation was at 37°C for two hours with gentle agita­
tion.
The nitrocellulose strips were then washed with phos­
phate buffered saline-Tween 20 3 times for 5-10min. Each 
strip was then incubated for one hour at 37°C with 1:200 
dilution of a peroxidase conjugated goat antihuman IgG 
(SAPU) in washing buffer.
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After 3 washes with phosphate buffered saline-Tween 
20 the strips were developed at room temperature using 
4-chloronaphthol. Colour development was complete in 20- 
30 min.
2.4 THE SPECIFICITY AND SENSITIVITY OF ENDOMYSIAL 
ANTIBODIES
Serum samples were collected from twenty patients 
with dermatitis herpetiformis. Direct immunofluorescence 
was performed to detect tissue bound IgA antibodies. Five 
patients had been on a gluten-free diet for at least six 
months. The remaining fifteen patients were on a normal 
diet. A control group consisting of 20 patients with pem­
phigus and 20 patients with bullous pemphigoid was in­
cluded. The serum samples were stored at -70°C until 
processing. The presence of endomysial antibodies was 
sought by standard indirect immunofluorescence. Testing 
was performed on 5um cryostat sections of monkey 
oesophagus. The sections were incubated with patients' 
sera starting at 1:2.5 dilution. A positive control serum 
was included in each experiment. After serum treatment 
the sections were washed in phosphate buffered saline and 
incubated with fluorescein conjugated goat antihuman IgA. 
The protein concentration of the conjugate was 8.8mg/ml
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and the Molar fluorescein:protein ratio was 3.1. The 
reagent was used at a dilution of 1:20 in phosphate buf­
fered saline.
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3. RESULTS
3.1 THE REACTIVITY OF BULLOUS PEMPHIGOID AND PEMPHIGUS 
ANTIBODIES ON DIFFERENT SUBSTRATES
Normal human skin has been regarded by some authors 
as an inferior substrate for the titration of circulating 
anti-basement membrane zone and anti-intercellular an­
tibodies in pemphigoid and pemphigus173. However, this 
view has not taken into account the differences in the 
distribution of bullous pemphigoid and pemphigus antigens 
at various areas of the body.
3.1.1 Variations in the Distribution of Bullous 
Pemphigoid and Pemphigus Antigens in Normal Skin
To study the expression of the bullous pemphigoid an­
tigen at different body sites a panel of nine sera 
(samples nos. 1-9) from patients with bullous pemphigoid 
was reacted with three skin specimens from the face, trunk 
and limb. The results showed variations in the maximum 
dilution of bullous pemphigoid sera giving positive reac­
tions when tested against skin from different regions of 
the body. The titre of bullous pemphigoid antibodies
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ranged from 0-160. Eight of the nine samples examined had 
antibodies to bullous pemphigoid antigen in normal skin 
when tested on sections from the three skin specimens. 
One of the nine sera failed to demonstrate bullous pem­
phigoid antigen in trunk tissue (Table 3).
The greatest expression of bullous pemphigoid an­
tigen, as estimated from the end point titre of bullous 
pemphigoid antibody, was with skin from the face and limb. 
In contrast, high concentrations of bullous pemphigoid an­
tibodies were required to detect the antigen in trunk 
tissue, indicating that only small amounts were present.
These studies were repeated using another panel of 
high titre bullous pemphigoid sera (samples nos. 10-18).
The results of testing the additional nine sera 
(Table 3) showed that the greatest expression of bullous 
pemphigoid antigen was also with skin obtained from the 
face and limb. The antibody level in these samples ranged 
between 160-640 when tested against facial skin. Slightly 
lower titres were observed with sections from limb skin. 
Most sera showed a titre above 1:80. Titres of the same 
sera ranged from 1:10 to 1:160 when skin from the trunk 
was used as a substrate. In most instances low dilutions 
were required to demonstrate bullous pemphigoid antigen 
with the majority of reactions at or below 1:40.
Statistical evaluation showed a significant dif­
ference between the geometric mean of all end point titres 
obtained on facial skin and trunk skin. Similarly, a
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Table 3
THE EXPRESSION OF BULLOUS PEMPHIGOID ANTIGEN 
IN SKIN OBTAINED FROM VARIOUS LOCATIONS
Serum No. Facial Trunk Limb
Skin Skin Skin
1 1:80 1:20 1:40
2 1:80 0 1:40
3 1:80 1:40 1:40
4 1:80 1:10 1:40
5 1:40 1:20 1:40
6 1:80 1:40 1:80
7 1:160 1:160 1:160
8 1; 80 1:20 1:80
9 1:80 1:40 1:80
10 1:320 1:20 1:160
11 1:160 1:10 1:80
12 1:640 1:40 1:80
13 1:160 1:40 1:160
14 1:640 1:40 1:640
15 1:160 1:40 1:640
16 1:320 1:160 1:320
17 1:160 1:20 1:160
18 1:160 1:10 1:40
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significant difference was detected between the geometric 
mean of titres on limb skin and trunk skin (P<0.05, 
Fisher's exact test). There was no significant difference 
between titres on facial and limb skin (Figure 5). These 
results showed that variations between tissue reactivity 
may reflect differences in antigen expression at different 
sites on the body.
Pemphigus vulgaris. Studies to determine whether the 
regional differences in antigen expression is a phenomenon 
specific to bullous pemphigoid antigen or involve the pem­
phigus vulgaris antigen were also performed. The expres­
sion of this antigen was also estimated by indirect im­
munofluorescence using skin specimens from the face, trunk 
and limb. Each specimen was reacted with serial dilutions 
of twelve pemphigus vulgaris sera (Table 4). The expres­
sion of the antigen in different body regions was es­
timated from the end point titre obtained when a serum 
sample was tested against sections from a particular 
anatomic area.
In contrast to bullous pemphigoid, the expression of 
pemphigus antigen in normal skin from three different 
areas of the body was similar. The difference was limited 
to one dilution. Figure 6 shows a comparison between the 
geometric mean of titres on specimens from the different 
body regions. There was no significant difference between 
the mean of end point titres obtained on different sites. 
There was some correlation between the patterns of antigen
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Table 4
QUANTITATIVE EXPRESSION OF PEMPHIGUS VULGARIS ANTIGEN 
IN SKIN OBTAINED FROM DIFFERENT SITES
Serum No. Facial Trunk Limb
Skin Skin Skin
1 1:160 1:80 1:80
2 1:640 1:640 1:320
3 1:80 1:80 1:80
4 1:80 1:80 1:80
5 1:320 1:320 1:160
6 1:160 1:160 1:160
7 1:320 1:320 1:320
8 1:80 1:80 1:160
9 1:160 1:160 1:320
10 1:160 1:160 1:160
11 1:80 1:40 1:80
12 1:80 1:80 1:40
83
G
eo
m
et
ri
c 
me
an
 
of 
en
d 
po
in
t 
ti
tr
es
200 -
150
100
Face LimbTrunk
Figure 6. Geometric means of all pem phigus vulgaris  
sera  end point t itres  on d ifferent skin specim ens.
expression in pemphigoid and pemphigus. Marked concentra­
tions of both antigens were found in facial and limb skin. 
Conversely, the expression of pemphigus vulgaris antigen 
was high in trunk tissue which showed much less expression 
of the bullous pemphigoid antigen.
The results therefore indicate a difference in the 
distribution between bullous pemphigoid and pemphigus vul­
garis antigens with the latter being more uniformly ex­
pressed over the body.
3.1.2 The Sensitivity of Normal Skin, Primate Oesophagus 
and Guinea Pig Lip for the Determination of Circul­
ating Antibodies 
Studies were performed on 21 sera from patients with 
bullous pemphigoid and 15 sera from pemphigus vulgaris 
patients. Indirect immunofluorescence testing was carried 
out using three epithelial substrates - monkey oesophagus, 
guinea pig lip and normal human skin. Tissue from the 
face was selected for its strong expression of both pem­
phigoid and pemphigus antigens.
All samples were tested simultaneously on all sub­
strates to exclude variations in technique which may in­
fluence the assessment of reactions and antibody titre 
levels. Some sera showed comparable reactivity on all 
three antigenic substrates; however, differences in titre 
were encountered with many of the samples tested.
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Bullous pemphigoid. The results of the affinity of 
bullous pemphigoid antibodies for the different antigenic 
substrates are summarized in Table 5. In spite of the 
differences in reactivity, all sera yielded a positive 
reaction on sections from the three epithelial sources. 
Antibody titres obtained with facial skin were generally 
lower than those obtained using animal substrates. In the 
21 sera studied, antibody levels ranged between 1:40 and 
1:160 when tested against normal skin and between 1:40 and 
1:640 when monkey oesophagus and guinea pig lip were used 
as substrates.
The pattern of reactivity of bullous pemphigoid sera 
studied is illustrated in Figure 7. Seventeen (81%) of 
the 21 assays performed with monkey oesophagus were posi­
tive in titres equal to or greater than 1:160 compared to 
13 (62%) when guinea pig lip was used as a substrate and 9 
(43%) of 21 with normal skin. None of the sera tested 
reacted more strongly on facial skin than on the animal 
substrates. Two samples gave identical results on all 
three substrates. Conversely, the end point titre on 
monkey oesophagus exceeded that on normal skin by one to 
two dilutions in 15 samples and by three dilutions in one 
case.
Analysis of the binding of bullous pemphigoid an­
tibodies to each of the two animal substrates showed that 
antibody titres were identical in 8 of the 21 samples 
tested. Four sera displayed higher titres on guinea pig
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Table 5
THE REACTIVITY OF BULLOUS PEMPHIGOID SERA 
ON DIFFERENT SUBSTRATES
Serum
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20 
21
Facial
Skin
1:40
1:40
1:80
1:80
1:40
1:40
1:160
1:40
1:160
1:80
1:80
1:40
1:80
1:80
1:160
1:160
1:160
1:160
1:160
1:160
1:160
Monkey
O esophagus
80
160
160
160
80
160
160
80
320
160
160
40
160
640
160
160
640
160
160
320
320
Guinea Pig  
Lip
1:40
1:80
1:80
1:80
1:40
1:40
1:160
1:80
1:320
1:160
1:160
1:40
1:160
1:160
1:320
1:320
1:640
1:640
1:320
1:160
1:160
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Facial skin Monkeyoesoph agus Guinea p ig  lip
640 - • • • •
320 - • • • • • • •
160
• • • •
• • • • 
• • •
80 • D O • • • •
40 • • • • •
Figure  7. Comparison of  bullous pemphigoid ant ibodies  in 21 
sera  reacted with facial sk in ,  monkey oes o p h a g u s  and guinea  
p ig  lip.
lip whereas 8 sera yielded higher end point titres on 
monkey oesophagus. The titre difference ranged between 
one and two doubling dilutions. Figure 8, A-C, il­
lustrates the characteristic staining of bullous pem­
phigoid antibodies on different substrates.
Pemphigus vulgaris. Serum samples from 15 patients 
with pemphigus vulgaris were concurrently tested on normal 
human skin, monkey oesophagus and guinea pig lip to deter­
mine the most sensitive substrate for the detection of in­
tercellular antibodies by indirect immunofluorescence.
The study showed variations in antibody levels be­
tween human skin and animal tissue (Table 6). The stain­
ing reactions observed with monkey oesophagus and guinea 
pig lip were similar. On both substrates the antibodies 
produced a fine sharp linear fluorescence. However, the 
intercellular staining on human skin sections was more 
diffuse and, in some cases, more difficult to interpret.
The titre of intercellular antibodies ranged from 
1:40 to 1:640 when tested against normal skin and 1:40 to 
1:1280 when guinea pig lip and 1:40 to 1:2560 when monkey 
oesophagus was used as a substrate (Figure 9). The 
majority of sera displayed lower titres when reacted with 
sections of normal skin. Five (33%) of 15 assays per­
formed with facial skin were positive in titres equal to 
or greater than 160 compared to 11 (73%) when guinea pig 
lip and 13 (87%) when monkey oesophagus were used in the 
indirect immunofluorescence assay. None of the 15 sera
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Figure 8. Basement membrane zone sta in ing  by bullous  
pemphigoid antibodies on d ifferent epithelial s u b s tr a te s .
A. Monkey oesop h agus
Figure 8 (cont inued) .  B. Guinea pig lip
Figure 8 (cont inued) .  C. Human skin.
12
3
4
5
6
7
8
9
10
11
12
13
14
15
Table 6
THE REACTIVITY OF PEMPHIGUS SERA 
ON DIFFERENT SUBSTRATES
Facial Monkey Guinea Pig
Skin Oesophagus Lip
1:40 1 80 1 80
1:40 1 40 1 80
1:40 1 160 1 80
1:320 1 320 1 320
1:80 1 320 1 320
1:40 1 320 1 160
1:80 1 320 1 320
1:640 1 2560 1 1280
1:80 1 160 1 320
1:160 1 1280 1 640
1:80 1 160 1 40
1:80 1 160 1 160
1:160 1 320 1 160
1:160 1 320 1 320
1:80 1 160 1 160
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Facial skin Monkeyoesophagus Guinea p ig  lip
2560 - •
1280 - • •
640 • •
320 •
160 •  •  • •  •  •  •
80 •  •  •  •  •  • • •  •  •
40 •  •  •  • • •
F igure  9.  The reac t iv i ty  of  pemphigus  sera with facial sk in ,  
monkey oesophagus  and guinea p ig  lip.
tested gave a higher antibody titre on normal skin than on 
monkey oesophagus or guinea pig lip. One sample yielded 
identical results on normal skin and the animal sub­
strates. In the remaining 14 sera the end point titre on 
either monkey oesophagus or guinea pig lip exceeded that 
on normal skin sections by up to three doubling dilutions.
The intercellular antibody titres were identical on 
sections from both animal substrates in 7 of the 15 sera 
examined.
Six samples gave a higher titre on monkey oesophagus 
than on guinea pig lip by one or two doubling dilutions, 
whereas two samples were more reactive with guinea pig lip 
by one dilution.
Figure 10, A-C, illustrates the characteristic stain­
ing pattern of pemphigus antibodies on various substrates.
3.2 THE DISTRIBUTION OF TISSUE BOUND AND CIRCULATING IgG 
SUBCLASSES IN PEMPHIGOID AND PEMPHIGUS
3.2.1 IgG Subclasses in Bullous Pemphigoid
Skin subclass distribution. A summary of the sub­
class distribution of anti-basement membrane zone an­
tibodies in perilesional skin biopsies from patients with 
pemphigoid is shown in Table 7.
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Figure 10. Intercellu lar s ta in ing  by pem phigus vu lgar is  
antibodies on d ifferent epithelial s u b s tr a te s .
A. Monkey oeso p h a g u s .
Figure 10 (continued) .  B. Guinea pig lip.
Figure 10 (continued) .  C. Human skin
Table 7
IgG SUBCLASSES OF TISSUE BOUND ANTIBODIES 
IN BULLOUS PEMPHIGOID
F luorescence IgG I&G1 I£G3 IgG4
N egative 0 7 14 2 1
Positive 0 3 3 6 0
Stron g  Positive 17 2 0 9 16
Total Positive 17 10 3 15 16
P ercent Positive 100 59 18 88 94
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Deposits of IgG were present in all 17 cases studied, 
15 of which contained IgG4, 10 IgGi, and 3 IgG3. In only 
two cases was IgG4 autoantibody not detected. However, 
both cases were positive for IgGi, and in one of the two 
cases IgG3 was also demonstrated (Figure 11, A-C).
In 5 (29%) of 17 biopsies IgG4 was the only IgG sub­
class detected, whereas IgGi was the only subclass ob­
served in one (6%) of the 17 biopsy specimens. C3 deposi­
tion was noted in all cases but one. It was positive only 
for IgG4.
Serum subclass distribution. The results of the dis­
tribution of circulating IgG subclasses in the serum of 
patients with bullous pemphigoid are summarized in Table 
8. Indirect immunofluorescence examination showed IgG 
pemphigoid antibodies in all 25 serum samples tested. 
IgG4 was present in 24 of 25 cases, IgGi in 14 and IgG3 in 
4 cases. IgG4 was the only subclass detected in 11 (44%) 
of the total samples examined. Furthermore, in the 
majority of cases IgG4 produced a more intense fluore­
scence than other IgG subclasses (Figure 12, A and B). 
Controls of skin and serum were negative for all sub­
classes .
Complement immunofluorescence. Complement fixing an­
tibodies were detected in 15 (60%) out of the 25 bullous 
pemphigoid sera (Figure 13). To determine the relation­
ship between complement fixing ability and the distribu-
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Figure 11. Direct immunofluorescence sta in ing  for IgG s u b ­
c la sse s  in the skin lesion of a patient with bullous pemphigoid.
A. Positive s ta in in g  for IgG^.
Figure II (co n t in u ed ) .  B. Faint sta in ing  for IgG
Figure 11 (c o n t in u e d ) .  C. Intense sta in ing  for IgG
Table 8
IgG SUBCLASSES OF CIRCULATING ANTIBODIES 
IN BULLOUS PEMPHIGOID
Fluorescence IgG I&Gi J£G3 i g c 4
N egative 0 11 21 1
Positive 12 4 9
Strong  Positive 25 2 0 15
Total Positive 25 14 4 24
Percent Positive 100 56 16 96
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Figure 12. Indirect immunofluorescence of bullous pemphigoid  
patient's  serum stained  for IgG su b c la s se s .
A. Positive sta in ing  for IgG^.
Figure 12 (cont inued) .  B. Intense staining for IgG^.
Figure 13. Positive indirect complement im m unofluorescence  
sta in in g  of human skin with bullous pemphigoid serum.
tion of IgG subclasses, cases were grouped based on their 
ability to fix complement and the presence of one or both 
complement fixing subclasses, IgGx and IgG3 (Table 9).
In 15 sera with complement fixing antibodies, 11 
showed IgGx as well as IgG4. In addition, 3 were positive 
for IgG3. The remaining 4 samples contained only IgG4.
In the 10 sera without complement binding antibodies 
IgG4 was the only subclass observed in 7 sera; however, 
one or both complement fixing IgG subclasses were 
demonstrable in the remaining 3 samples.
3.2.2 IgG Subclasses in Pemphigus Vulgaris
Skin subclass distribution. The results of the 
direct immunofluorescence studies to determine the tissue 
distribution of IgG subclasses of intercellular antibodies 
are shown in Table 10. The most prominent finding on ex­
amination of skin lesions of 9 patients with pemphigus 
vulgaris was the demonstration of intense deposits of IgG4 
in the intercellular areas of all cases studied. Deposits 
of IgGi were detected in three patients (Figure 14, A and 
B ). IgG3 was not observed in any of the specimens tested. 
The third component of complement was present in 7 of 9 
biopsies. In the two cases lacking C3 deposits, IgG4 was 
the only detectable subclass.
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Table 9
RELATIONSHIP BETWEEN COMPLEMENT FIXING 
BASEMENT MEMBRANE ZONE ANTIBODIES AND IgG SUBCLASSES 
WITH COMPLEMENT ACTIVATING ABILITY
No. of Sera IgG^, IgG  ^ IgG  ^ Complement
F ixing  A ntibodies
11
4
3
7
94
Table 10
IgG SUBCLASSES OF TISSUE BOUND ANTIBODIES IN PEMPHIGUS
F luorescence IgG I&G.1 IgG3 ^3
N egative 0 7 9 0 2
P osit ive 0 3 0 1 0
S tron g  Positive 9 0 0 8 7
Total Positive 9 3 0 9 7
P ercen t Positive 100 33 0 100 78
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Figure 14. Direct immunofluorescence sta in ing  for IgG s u b ­
c la sse s  in the perilesional skin of a patient with pem phigus  
v u lg a r i s .
A. Positive sta in ing  for IgG^.
Figure 14 (continued) .  B. Strong intercellular staining of IgG^.
__
__
__
Serum subclass distribution. The results of in­
direct immunofluorescence studies to determine serum sub­
class distribution of circulating intercellular antibodies 
in patients with pemphigus are shown in Table 11.
IgG subclass analysis revealed IgG4 in all samples 
tested. IgGi was the next most frequently detected sub­
class, being present in 8 sera (Figure 15, A and B). IgG4
resulted in a stronger intercellular staining in most
samples. It was the only subclass found in 9 (53%) sera.
IgG3 was not detected.
Complement immunofluorescence. The relationship be­
tween the presence of complement fixing antibodies and the 
distribution of IgG subclasses is summarized in Table 12.
Pemphigus antibodies capable of binding complement 
were detected in 7 (41%) sera (Figure 16). In contrast to 
the bullous pemphigoid study, where the result did not 
show a correlation between the complement fixing an­
tibodies and the IgG subclass distribution, the complement 
activating capability of intercellular antibodies appeared 
to be compatible with the distribution of IgG subclasses 
in terms of their complement fixing ability.
All the sera with complement fixing antibodies were 
positive for IgGx as well as IgG4, whereas the non­
complement fixing samples contained only IgG4. Only one 
serum sample showed a negative indirect complement im­
munofluorescence reaction in spite of the presence of IgGx 
in addition to IgG4.
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Table 11
IgG SUBCLASSES OF CIRCULATING INTERCELLULAR ANTIBODIES
IN PEMPHIGUS
F luorescence IgG I&Gi l£G3
N egative 0 10 17 0
Positive 0 5 0 9
Stron g  Positive 17 3 0 8
Total Positive 17 8 0 17
Percent Positive 100 47 0 100
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Figure 15. Indirect im m unofluorescence of bullous pemphigoid  
p atien t’s serum sta ined  for IgG s u b c la sse s .
A. Positive sta in ing  for IgG^.
Figure 15 (continued) .  B. Intense intercellular staining for IgG^.
Table 12
RELATIONSHIP BETWEEN COMPLEMENT FIXING INTERCELLULAR 
ANTIBODIES AND IgG SUBCLASSES  
WITH COMPLEMENT ACTIVATING ABILITY
No. o f  Sera IgG  ^ IgG  ^ Complement
F ixing Antibodies
7 + +
9 -  +
1 + +
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Figure 16. Positive ind irect complement im m unofluorescence  
sta in ing  of human skin with pem phigus vu lgar is  serum.
w.
 I
3.3 ANTIGEN SPECIFICITIES OF ANTI-BASEMENT MEMBRANE ZONE 
ANTIBODIES
3.3.1 Localization of Type IV and Type VII Collagen on 
Intact and* . ..-Separated Skin
Intact and frozen skin specimens of separated skin 
from three individuals were examined by indirect im­
munofluorescence using antibodies to type IV collagen and 
type VII collagen. Both antibodies produced a bright 
linear band of fluorescence at the dermal epidermal junc­
tion of intact skin (Figure 17, A and B). Anti-type IV 
collagen antibody also produced staining around dermal 
blood vessels.
clxVtW <cl-C
Ont: -separated skin the antibody against type IV
collagen resulted in a thin, sharp, continuous fluorescent 
band on the dermal side of the separation (Figure 18). 
Staining around dermal blood vessels was also noted. No 
staining was observed on the epidermal side.
Antibody to type VII collagen produced a broad, in­
tense linear staining band. The fluorescence was confined 
to the dermal edge of the split. There was no staining of 
the appendages or dermal vessels (Figure 19).
These results confirm that the separation was occur­
ring at the level of the lamina lucida.
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Figure 17. Linear deposition  of (A) anti ty p e  IV collagen antibody and 
(B ) with anti ty p e  VII collagen antibody at the basement membrane zone  
of normal intact human sk in .
Figure 18. Sodium ch lor ide-separated  skin show ­
in g  f luorescence  on the dermal side of the split 
with anti ty p e  IV collagen antibody.
Figure 19. Sodium ch lor id e-sep arated  skin show ­
ing  f luorescence  on the dermal side of the split  
with anti ty p e  VII collagen antibody.
3.3.2 Indirect Immunofluorescence of Bullous Pemphigoid
and Epidermolysis Bullosa Acquisita Antibodies on 
Split-Skin
Each of the test sera was examined at a titre of 1:10
on cryostat sections of separated skin obtained from one
specimen. Two patterns of binding were noted. Staining 
was either of the epidermis (roof of split) or dermis 
(floor of split). A mixed (combined) staining pattern of 
the epidermis and dermis has not been seen in any of the 
cases tested.
All 27 bullous pemphigoid sera demonstrated an
epidermal staining pattern (Figure 20). None of the sera
produced a dermal pattern.
The epidermolysis bullosa acquisita serum produced 
fluorescence along the dermal side of separation (figure 
21). All control sera were negative on split-skin.
To determine the reproducibility of the staining pat­
terns, the epidermolysis bullosa acquisita and 12 bullous 
pemphigoid sera were tested on separated skin sections ob­
tained from two other specimens. The staining pattern was 
identical on all specimens.
To study the sensitivity of sodium chloride-separated 
skin as a substrate for detecting anti-basement membrane 
zone antibodies, the epidermolysis bullosa acquisita and 8 
bullous pemphigoid sera were titrated in doubling dilu­
tions and simultaneously tested on intact and separated 
skin. The results are shown in Table 13. Two of the bu-
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Figure 20. Sodium ch lor id e-sep ara ted  skin with 
bullous pemphigoid serum, show ing linear fluor­
escen ce  on the epidermal s id e .
Figure 21. Sodium ch lor id e-sep arated  skin with 
ep iderm olysis  bullosa acquisita  serum , showing  
dermal pattern  of f lu orescen ce .
Table 13
INDIRECT IMMUNOFLUORESCENCE USING 
BULLOUS PEMPHIGOID AND EPIDERMOLYSIS BULLOSA ACQUISITA  
SERA ON INTACT AND SPLIT SKIN
D isease  Serum N o. Intact Skin Split Skin
Bullous pem phigoid 1 i - 80 1:160
2 * :320 1: 640
3 / : 4 0  1:160
4 1: 640 ' : 640
5 »: 160 1 : 320
6 I: 160 l :  320
7 l 1 160 1: 320
8 l : 160 I1 160
Epiderm olysis
bullosa acqu is ita  1 I 1 160 11 320
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llous pemphigoid sera demonstrated equal titres on both 
substrates while the epidermolysis bullosa acquisita serum 
and the remainder of the bullous pemphigoid sera showed 
titres on split skin that were 1-2 dilutions greater on 
split skin than on intact skin.
cVortJ-e.
3.3.3 Immunofluorescence Studies off' . -Separated 
Biopsy Specimens
In addition to performing IgG and C3 direct im­
munofluorescence studies to determine the pattern of 
fluorescence on sodium chloride-separated specimens, sec­
tions from each biopsy were simultaneously reacted with 
monoclonal antibodies against type IV collagen and type 
VII collagen. The antibodies produced staining along the 
dermal edge of the split in all cases (Figures 22 and 23). 
This finding indicated that the ultrastructural level of 
separation was occurring at the level of the lamina 
lucida. Separation beneath the lamina densa would have 
resulted in an epidermal pattern of fluorescence.
Table 14 shows the result of testing^, . -separated 
biopsy specimens from seven patients with bullous pem­
phigoid. Attempts to separate a specimen from an epider­
molysis bullosa acquisita patient were unsuccessful. 
Direct IgG and C3 immunofluorescence showed staining on 
the epidermal side of the separation in six patients
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Figure 22. Sodium ch lor id e-sep arated  pemphigoid b iopsy  
specimen sta in ing  the dermal s ide of the split with anti 
ty p e  IV antibody .
Figure 23. Sodium ch lor id e-sep ara ted  bullous pemphigoid  
b iop sy  specimen sta in ing  the dermal side of the split with 
anti ty p e  VII antibody .
Table 14
DIRECT IMMUNOFLUORESCENCE OF 
BULLOUS PEMPHIGOID BIOPSIES SEPARATED BY SODIUM CHLORIDE
Patient No. Antibody F luorescence Pattern
—  E C D
IgG +
C3
IgG +
C3
IgG +
C3
IgG +
C3
IgG +
C3
IgG +
C3
IgG +
Cn +
E = epidermal
C = combined, epidermal and dermal 
D = dermal
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(Figure 24). In one patient the deposits were observed on 
both the epidermal and dermal sides of the split (Figure 
25).
3.3.4 SDS-PAGE and Western Immunoblotting
Ponceau S staining. Staining with this reagent was 
performed on blots to visualize protein bands and thus 
confirm that electrophoretic transfer of proteins has 
taken place. Figure 26 shows a nitrocellulose sheet 
stained with Ponceau S and indicates the total protein 
transferred in each lane in addition to the simultaneously 
run molecular weight standards.
Protein content estimation. Lowry's assay was used 
to determine the protein content in epidermal and dermal 
extracts. The total protein in the epidermal extract was 
approximately 3.75mg/ml and the dermal extract contained 
3.Omg/ml.
Western immunoblotting patterns. The skin antigens 
defined by one epidermolysis bullosa acquisita and seven 
bullous pemphigoid serum samples were investigated by 
Western immunoblotting. The pattern of protein bands 
demonstrated by different sera is shown in Table 15. Five 
of the seven samples tested had antibodies to specific an­
tigens that could be visualized in immunoblots. Four of 
the five positive sera recognized a protein with a
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Figure 24. Direct im m unofluorescence of a bullous pemphigoid  
biopsy  specimen separated  through  the lamina lucida . Linear 
d ep os its  of IgG are p resen t  along the epidermal side of the sp lit .
Figure 25. Direct im m unofluorescence of separated  bullous  
pemphigoid b iopsy  specimen showing an epidermal-dermal 
sta in in g  p attern .
205 KD
116 KD-  
97 KD
66 KD -
1 2 3 4 5 6  7 8 9
Figure 26. A nitrocellu lose sheet stained with 
Ponceau S. Lane 1 shows the molecular w eight  
m arkers. Lanes 2-5 and 7-9 show the epidermal 
and dermal ex tr a c ts  r e sp ec t iv e ly .
Table 15
ANTIGENS RECOGNIZED BY 
ANTI-BASEMENT MEMBRANE ZONE ANTIBODIES 
IN WESTERN IMMUNOBLOTTING
D isease  Serum No. T itre Molecular
B ullous pemphigoid
Weight (KD)
1 O 
tO
 
1—
i 
/
» -
2 i :  320 -
3 l:  160 220
4 1: 640 220
5 V.' 320 220
6 160 180
7 <: 640 220
Epiderm olysis  
bullosa acquisita 1 1:640
molecular weight of approximately 220 Kd. The remaining 
positive sample reacted to a 180 Kd protein and a faint 
band was also observed at 205 Kd. Figure 27 shows ex­
amples of two pemphigoid and two control sera. The 
proteins recognized in this assay were extracted from the 
epidermis. They were not detected in the dermal extract. 
Two bullous pemphigoid sera and the epidermolysis bullosa 
acquisita serum did not react with any protein in either 
the dermal or epidermal extracts. Bands staining below 66 
Kd were considered non specific because they were seen 
with some bullous pemphigoid as well as control sera. All 
controls did not detect any major antigen in either 
epidermal or dermal extracts.
3.4 ENDOMYSIAL ANTIBODIES IN BULLOUS DISEASES
The diagnosis of dermatitis herpetiformis was con­
firmed by the demonstration of granular papillary IgA 
deposits in normal appearing skin (Figure 28).
The specific indirect immunofluorescence pattern of 
the IgA anti-endomysial antibodies on the smooth muscle of 
monkey oesophagus is illustrated in Figures 29 and 30. 
The staining reaction appears as a network of thin lines 
in the connective tissue surrounding individual muscle 
fibres. Figure 31 shows a negative reaction for en-
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Figure 27. Immunoblot of epidermal extrac t  with 
bullous pemphigoid sera reacting  with 220 KD on 
lane 1 or a 180 KD on lane 2. A non specific  
reaction  is  seen  with normal human serum on lane 
3. A n ega tive  reaction on lane 4 with serum from 
a pem phigus p atien t .  C oncurrently  e lectroph or-  
esed  standard prote ins  are in lane A.
Figure 28. Direct im m unofluorescence of dermatitis h erp eti­
formis show ing granular IgA deposits  at the dermal papillae.
Figure 29. Low magnification of monkey oesophagus section  
treated  with a 1: 2 . 5  dilution of a posit ive  serum for endo-  
mysium antibod ies .
Figure 30. Higher magnification of oesop h agus  section  show ­
in g  re t icu lin -lik e  pattern  in the smooth muscle layer adjacent  
to epithelium .
Figure 31. Monkey oesoph agus  section  treated  
with pem phigus serum and FITC conjugated IgA.  
Note n ega tive  reaction .
domysial antibodies in a 1:2.5 dilution of a control serum 
from a patient with pemphigus. In contrast to endomysial 
antibodies, anti-smooth muscle antibodies which are com­
monly found at low titres react only to the sarcoplasm 
producing a homogenous fluorescence of myofibrils (Figure 
32).
The immunofluorescence findings obtained with sera 
from dermatitis herpetiformis patients and control sera 
from patients with bullous pemphigoid and pemphigus are 
summarized in Table 16.
Circulating endomysium antibodies were detected in 
60% of the dermatitis herpetiformis cases in titres that 
ranged from 1:2.5 to 1:160 (Table 17). However, a higher 
frequency of the antibodies was observed in patients on a 
normal, gluten-containing diet. The endomysium antibodies 
were demonstrated in 11 (73%) of 15 patients who were on a 
normal diet. Conversely, the antibodies occurred in only 
one (20%) of the five patients adhering to a gluten-free 
diet.
The endomysium antibodies could not be detected in 
any of the 40 control sera from bullous pemphigoid and 
pemphigus patients.
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Figure 32. Indirect im m unofluorescence of anti-sm ooth muscle 
antibodies of the IgA c la ss .  Note the homogenous f luorescence  
of the smooth muscle sarcoplasm.
Table 16
FREQUENCY OF IgA CLASS ANTI-ENDOMYSIAL ANTIBODIES 
IN DERMATITIS HERPETIFORMIS,
BULLOUS PEMPHIGOID AND PEMPHIGUS
No. o f  No. with
Samples Positive Percent
T ested  Titre
Dermatitis 20 12 60
herpetiform is (total)
Dermatitis
herpetiform is 15 11 73
(normal d iet)
Dermatitis
herpetiform is 5 1 20
(g lu te n - fr e e  d iet)
Bullous pemphigoid 20 0 0
Pem phigus 20 0 0
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Diet
Normal
Gluten-
Table 17
ANTI-ENDOMYSIAL ANTIBODY TITRES 
IN DERMATITIS HERPETIFORMIS PATIENTS 
ON NORMAL OR GLUTEN-FREE DIET
Anti-Endom ysial A ntibody Titre  
N eg . 2 .5  5 10 20 40 80 160
4 1 1 2 4 1 1 1
-free 4 1
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4. DISCUSSION
4.1 SELECTION OF EPITHELIAL TISSUE FOR INDIRECT IMMUNO­
FLUORESCENCE STAINING OF BULLOUS PEMPHIGOID AND 
PEMPHIGUS ANTIBODIES
Indirect immunofluorescence is used to detect cir­
culating anti-basement membrane zone and intercellular an­
tibodies (referred to as antiepithelial antibodies) which 
can be identified by their distinct staining patterns on 
various antigenic substrates.
Failure to demonstrate the serum autoantibodies in 
some patients with bullous pemphigoid or pemphigus vul­
garis is not the result of species specificity of cir­
culating antibodies. Species specificity studies have 
shown that basement membrane and intercellular antibodies 
are not species specific and react with human skin and 
tissue from different mammals46. However, the intercel­
lular antibodies of pemphigus are organ specific and react 
only with squamous epithelium46. Normal human skin, which 
contains both bullous pemphigoid and pemphigus antigens, 
should be the ideal substrate to test for serum pemphigoid 
and pemphigus antibodies. However, it remains controver-
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sial which substrate is superior for the demonstration of 
these autoantibodies because of conflicting data obtained 
by different investigators.
Although normal human skin is the natural substrate 
for the antiepithelial antibodies to react with, several 
studies have suggested that primate tissue is the ideal 
substrate for the detection of these antibodies46*173. In 
addition, other reports indicated that human skin is not a 
sensitive enough substrate to use in indirect im­
munofluorescence assays61 •62•179 . However, this conclu­
sion may be inaccurate in light of the reported 
regional4*180 and individual181 variations in the expres­
sion of bullous pemphigoid and pemphigus vulgaris an­
tigens .
In the present study the expression of both bullous 
pemphigoid and pemphigus vulgaris antigens was inves­
tigated. Subsequently, sera from patients with these con­
ditions were simultaneously assayed on standard animal 
substrates in addition to normal human skin with strong 
antigen expression. The findings of this investigation 
suggest that the bullous pemphigoid antigen is not 
uniformly expressed over the body but rather shows varia­
tions between different sites. The expression of this an­
tigen estimated by reacting sera containing bullous pem­
phigoid antibodies with specimens of normal skin from 
face, trunk and flexural lower limb showed a high con­
centration of bullous pemphigoid antigen in the face.
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Skin from the limb also showed strong antigen expression. 
However, much lesser amounts were present in the skin ob­
tained from the trunk. In contrast to bullous pemphigoid 
antigen, the degree of variation in the expression of pem­
phigus vulgaris antigen was minimal. The results of this 
study showed that the antigen was more uniformly dis­
tributed over the body. The expression of antigen was 
similar in the areas of the face, trunk and limb. When 
bullous pemphigoid and pemphigus vulgaris antigen dis­
tribution studies were repeated it became evident that the 
expression of an antigen was similar in skin specimens ob­
tained from the same region in different individuals but 
may differ in skin obtained from different sites. These 
observations indicate that variations in antigen expres­
sion cannot be attributed entirely to differences in an­
tigen concentration between individuals. In contrast to 
the findings of a previous investigation4, the results of 
antigen expression in this study did not correlate well 
with the distribution of lesions in bullous pemphigoid. 
Although the incidence of facial blisters is low in pem­
phigoid, high concentrations of antigen were found in skin 
biopsy specimens obtained from that area. This dis­
crepancy in the results may be due to variations in the 
specificity of anti-basement membrane zone antibodies in 
different sera. In addition, it must be stressed that 
little is known about the different factors involved in 
determining the distribution of lesions in various blis­
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tering disorders. Thus the involvement of factors other 
than antigen expression in the localization of lesions in 
bullous pemphigoid and pemphigus vulgaris cannot be ruled 
out.
Choice of substrate.
The variability in the expression of bullous pem­
phigoid and pemphigus vulgaris antigens must be considered 
when normal human skin is used as a substrate in indirect 
immunofluorescence assays.
The diagnostic significance of immunofluorescence 
tests for antiepithelial antibodies of bullous pemphigoid 
and pemphigus underlines the importance of selecting a 
highly reactive substrate for serum antibody determina­
tions in these disorders. In this study the sensitivity 
of normal human skin was compared with two other 
epithelial substrates commonly used in indirect im­
munofluorescence testing. The results showed that the 
titres of circulating antibodies may vary depending on the 
type of epithelial substrate used in the immunofluores­
cence assay. The investigation involved testing for cir­
culating antiepithelial antibodies in the sera of 21 
patients with bullous pemphigoid and 15 patients with pem­
phigus vulgaris against three antigenic substrates - nor­
mal skin from the face, monkey oesophagus and guinea pig 
lip. The sensitivity of the substrates was evaluated by 
the concurrent testing of each serum sample on all three 
epithelial sources. The most sensitive substrate for the
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detection of both bullous pemphigoid and pemphigus vul­
garis antibodies was monkey oesophagus. The highest 
titres were most frequently observed when this substrate 
was used. This finding is in accordance with previous 
reports173*182 . The study also demonstrated the useful­
ness and reliability of guinea pig lip for serum antibody 
estimation in bullous pemphigoid and pemphigus vulgaris. 
Many of the serum samples examined produced equal titres 
on guinea pig lip and monkey oesophagus. This is in con­
trast to the findings in other studies73*103 which sug­
gested that guinea pig lip is inferior to other animal 
substrates and normal human skin for the detection and 
titration of bullous pemphigoid and pemphigus antibodies.
Although it has been suggested that normal skin, ob­
tained from an appropriate site, is as sensitive or even 
superior to monkey oesophagus for the detection of an­
tiepithelial antibodies184, the findings of the present 
study showed normal skin to yield lower basement membrane 
zone and intercellular antibody titres compared to monkey 
oesophagus despite using tissue from an area rich in both 
bullous pemphigoid and pemphigus vulgaris antigens. 
However, the titre difference was mostly confined to one 
or two doubling dilutions. A difference of three dilu­
tions was only observed in one case of bullous pemphigoid 
and two cases of pemphigus vulgaris.
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Site differences.
Differences in the expression of bullous pemphigoid 
and pemphigus antigens have been described in the litera­
ture. Table 18 indicates areas with the greatest antigen 
expression reported in different studies.
Bullous pemphigoid. Using three bullous pemphigoid 
sera, Goldberg et al.4 determined the end point titre 
variations in 46 different specimens of normal human skin 
and found that there were marked differences in the con­
centration of bullous pemphigoid antigen at various sites. 
They observed that the highest amounts of antigen were in 
skin obtained from the flexor surfaces; flexor arm, 
flexor thigh and popliteal fossa. The lowest concentra­
tion of bullous pemphigoid antigen was in the scalp, face 
and extensor surfaces of the arm. Skin from trunk, knee 
and extensors of thighs had intermediate amounts of an­
tigen. The expression of bullous pemphigoid antigen from 
the same site in different individuals was comparable. 
Interestingly, the highest concentration of antigen was in 
areas commonly involved in the disease (flexural 
surfaces), whereas the lowest was in areas (head and ex­
tensor arm) which are rarely involved. This apparent cor­
relation between the expression of antigen and the loca­
tion of lesions in bullous pemphigoid suggests that the 
concentration of bullous pemphigoid antigen may play a
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Table 18
BODY SITES WITH THE GREATEST EXPRESSION OF 
BULLOUS PEMPHIGOID AND PEMPHIGUS VULGARIS ANTIGENS
Date S tu d y  Group Bullous Pemphigoid Pemphigus V ulgaris
1984 G oldberg et 
a l . (4 )
F lexor arm, flexor  
th igh  and popliteal  
fossa
1986 S ison  Fonacier
and B y s tr y n (1 8 0 )
A xilla, sca lp , fa ce ,  
buccal mucosa
1988 Hamm and
Wozniak(185)
Plantar s ite s ,  
sacral region
1991 Ioannides et 
a l . (186)
Buccal mucosa, sca lp ,  
face
1992 Alkarawi Face and limb Face, tru n k , limb
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role in the distribution of lesions in this disease4. 
Hamn and Wozniak185 also reported regional variations in 
the expression of bullous pemphigoid antigen in normal 
skin, as estimated by end point titres of antibody in sera 
of two patients with bullous pemphigoid. The study con­
firmed that the amount of bullous pemphigoid antigen 
varies markedly at different sites on the body. They 
found that the highest antibody titres were obtained in 
assays using skin from the plantar region, whereas the 
lowest titres were observed when skin from flexural areas 
was used as a substrate. In addition, bullous pemphigoid 
antigen expression in relation to age was also inves­
tigated. Studies of skin samples from cadavers of dif­
ferent age groups showed that the highest end point titres 
were found in the oldest individuals examined and the 
lowest in the youngest.
Differences in antibody titres of bullous pemphigoid 
sera on different biopsy specimens were first described by 
Zhu and Bystryn181. They studied 16 serum samples against 
five skin specimens from different individuals. Their ob­
servation suggested that the expression of bullous pem­
phigoid antigen is not an all or none phenomenon but that 
it differs between individuals.
Pemphigus. Studies have also been carried out to 
determine the concentration of pemphigus vulgaris antigen 
in various body regions. Sison Fonacier and Bystryn180 
studied three sera with pemphigus vulgaris antibodies
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against 46 skin specimens obtained from different in­
dividuals. They noted variations in pemphigus vulgaris 
antigen expression depending on the site from which the 
biopsy specimen was obtained. They found that antigen 
concentration was greatest on scalp, face, axilla, buccal 
mucosa and neck. It was lowest on skin from lower back 
and groin. There was an intermediate expression of pem­
phigus vulgaris antigen in other areas: chest, abdomen, 
upper back and legs. Similar observations were made by 
Ionnides et al.186. They found that the greatest expres­
sion of antigen determined from the highest antibody 
titres of two pemphigus vulgaris sera was in the buccal 
mucosa, scalp and face. These studies, therefore, 
demonstrate that the pemphigus vulgaris antigen is 
strongly expressed in sites frequently affected by pem­
phigus lesions whereas antigen expression is poor in areas 
that are usually spared.
Substrates.
Differences in the reactivity of antiepithelial an­
tibodies on various substrates have also been reported. 
Discrepancy in the results obtained in different studies 
led to controversy regarding the most suitable tissue for 
the detection and titration of these antibodies.
Bullous pemphigoid. Table 19 indicates the sub­
strates used in different investigations. Beutner et 
al.45 studied the use of guinea pig lip and human skin for 
the demonstration of basement membrane zone antibodies in
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Table 19
Date
1967
1969
1969
1972
1977
1985
1986 
1992
EPITHELIAL SUBSTRATES USED FOR THE 
DETECTION OF BULLOUS PEMPHIGOID ANTIBODIES
S tu d y  Group
B eu tn er et 
al. (45)
Wick and  
B eu tn er(1 8 7 )
Katz et a l .(6 4 )
C horzelsk i and  
B eu tn er(6 1 )
Gligora et 
al. (189)
G oldberg et  
al. (184)
B y str y n  and  
S ab olin sk i(62)
Alkarawi
S u b stra tes T ested
Guinea p ig  lip , 
human skin
Guinea p ig  and 
monkey lip
Normal human sk in  
and rabbit oeso ­
ph agus
M onkey, rabbit 
and guinea p ig  
lip
Human tonsil and  
m onkey oesophagus
Normal s k in , 
m onkey and guinea  
p ig  oesophagus
Normal sk in , 
m onkey and guinea  
p ig  oesophagus
Normal sk in , 
m onkey oesophagus  
and guinea p ig  lip
Recommended S u b stra te  
Guinea p ig  lip
Guinea p ig  lip
Human sk in
M onkey lip mucosa
Human ton sil
Normal sk in  (flex u ra l  
s ite )
Guinea p ig  oesop h agu s
Monkey oesop h agu s
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bullous pemphigoid. They considered guinea pig lip more 
sensitive than human skin. The authors suggested that the 
low titres obtained on human skin sections were due to im­
munoglobulin staining of the dermis which obscured base­
ment membrane zone fluorescence. Conversely, such dermal 
staining was not observed on guinea pig lip sections. In 
another report Wick and Beutner187 studied two bullous 
pemphigoid sera using monkey and guinea pig lip and 
mucosa. They confirmed the value of guinea pig lip as a 
substrate for the detection of bullous pemphigoid an­
tibodies. In contrast, other studies have suggested that 
tissue of primate origin is the most reliable for the 
demonstration of these antibodies46*173. Chorzelski et 
al.61 evaluated the reactivity of three bullous pemphigoid 
sera by indirect immunofluorescence on monkey, rabbit and 
guinea pig lip tissue. They found that only one serum 
showed a positive reaction on all three substrates whereas 
the other two sera reacted with monkey tissue but failed 
to react with any of the rabbit and guinea pig tissue. 
Other authors have observed that human skin is a reliable 
substrate in indirect immunofluorescence assays. Muller 
et al.188 found that normal human skin was as sensitive as 
guinea pig oesophagus for antibody estimation in bullous 
pemphigoid. Katz et al.64 compared the affinity of human 
skin and rabbit oesophagus for anti-basement membrane zone 
antibodies and found that two bullous pemphigoid sera 
yielded a positive reaction only when human skin was used
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as a substrate. In a study comparing human skin with 
monkey and guinea pig oesophagus, bullous pemphigoid an- 
tibodies were detected on human skin in 10% of sera that 
failed to react with animal substrates181. Studies by 
Goldberg et al.184 also suggested that human skin taken 
from an appropriate site may be the best substrate for 
demonstrating bullous pemphigoid antibodies. They ex­
amined the reactivity of three bullous pemphigoid sera on 
36 skin specimens obtained from different sites and showed 
that the highest titres were observed with skin from areas 
of the body commonly involved with bullous pemphigoid such 
as flexor arm, flexor thigh and popliteal fossa. An 
analysis comparing serum titres obtained with flexural 
skin, monkey oesophagus and guinea pig oesophagus showed 
normal skin to give titres that were equal or even higher 
than those noted with monkey or guinea pig oesophagus184. 
The sensitivity of the same substrates for indirect im­
munofluorescence assay of bullous pemphigoid antibodies 
was evaluated by Bystryn and Sabolinski62. Normal human 
skin was obtained from different locations on the body. 
The study included 56 sera containing anti-basement 
membrane zone antibodies. Similar results between the 
three substrates were found in 45% of the samples. Varia­
tions in reactivity on different substrates was seen in 10 
(18%) of cases. More importantly, more than one-third of 
sera failed to react with one substrate which indicated 
that the nature of the epithelial substrate has a sig­
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nificant effect on the result of indirect immunofluores­
cence. Although one serum reacted only to human skin, ap­
proximately one-third of the samples failed to react 
against sections of normal skin. This finding is in con­
trast to the result obtained by Goldberg et al.184. 
However, normal skin used in the study of Bystryn and 
Sabolinski62 was randomly collected and not chosen from a 
flexural area. Guinea pig oesophagus was slightly more 
sensitive than monkey oesophagus. Fifty-four sera reacted 
with the former compared to 51 with the latter substrate. 
However, the sensitivity of the indirect immunofluores­
cence assay was maximally increased when both substrates 
were used which raised the proportion of positive sera to 
55 out of the 56 samples studied.
Other authors have recommended substrates other than 
human skin and animal tissue. Gligora189 studied five 
cases of bullous pemphigoid and found human tonsil more 
sensitive than primate oesophagus.
Pemphigus. As in bullous pemphigoid, various inves­
tigators have advocated the use of different antigenic 
substrates for demonstrating intercellular antibodies in 
pemphigus vulgaris (Table 20). In the original im­
munofluorescence studies of Beutner and Jordon41 and Beut- 
ner et al.42, monkey oesophagus and monkey lip were used 
as substrates to detect pemphigus antibodies. In 1967 
Beutner et al.45 indicated that guinea pig lip and normal 
skin are suitable substrates for these studies. A study
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Table 20
EPITHELIAL SUBSTRATES USED FOR THE 
DETECTION OF PEMPHIGUS VULGARIS ANTIBODIES
D ate S tu d y  Group
1969 C horzelsk i and
B eu tn er(1 8 3 )
1969 Katz et a l .(6 4 )
1978 Weismann et  
a l. (76)
1979 Judd and
M escon(191)
1981 Feibeiman et  
a l . (182)
1982 A costa and  
Ivan y i(73 )
1986 B y str y n  and  
S ab olin sk i(62)
1987 K ransy et 
a l . (190)
1987 Sabolinsk i et
a l . (192)
1992 Alkarawi
S u b stra tes  T ested
M onkey, rab b it, 
guinea p ig  lip and 
normal sk in
Normal sk in , rabbit 
oesop h agus
Normal human sk in , 
guinea p ig  o eso ­
p h agu s
Human fo resk in , 
guinea p ig  o eso ­
p h a g u s , rabbit 
oeso p h a g u s, m onkey  
oesop h agus and lip
Monkey and gu inea  
p ig  oesop h agus
Human sk in  and  
to n s i l , monkey 
oesop h agus and  
l ip , gu inea p ig  
oesop h agus and lip 
and rabbit lip
Normal sk in , m onkey  
oesop h agus and  
guinea p ig  oesop h agu s
Normal sk in; monkey, 
guinea p ig , rabbit 
and dog oesop h agus
Monkey and gu inea  
p ig  oesop h agus
Normal skin , m onkey  
oesop h agus and  
guinea p ig  lip
Recommended S u b stra te  
Monkey lip m ucosa
Normal sk in  
Normal sk in
Monkey o esop h agu s and 
lip
Monkey oesop h agu s  
Human ton sil and sk in
Monkey oesop h agu s
Monkey oesop h agu s
Monkey oesop h agu s  
Monkey oesop h agu s
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by Chorzelski and Beutner183 later demonstrated that con­
siderable disparity may occur with the use of different 
epithelial substrates in indirect immunofluorescence. 
They reported two cases of pemphigus vulgaris in which 
serum testing yielded negative results with human skin, 
monkey epidermis, rabbit and guinea pig lip tissue whereas 
high titres were observed when monkey oral mucosa was 
used. In contrast, others suggested that normal human 
skin is a more reliable tissue than mammalian epithelia. 
Katz et al.64 found that human skin was a more sensitive 
substrate than rabbit oesophagus and Weissman' et al.76 
stated that human skin is a superior substrate compared to 
guinea pig oesophagus.
The conflicting indirect immunofluorescence results 
obtained with different epithelial tissue has prompted 
research to compare the sensitivity of commonly used sub­
strates and determine the most reactive with pemphigus 
vulgaris antibodies. Feibeiman et al.182 studied the sub­
ject of substrate sensitivity by comparing serum titres 
from 16 patients with active pemphigus using monkey and 
guinea pig oesophagi. Five of the patients who had shown 
a positive antibody titre against monkey oesophagus failed 
to demonstrate activity when guinea pig oesophagus was 
used. In addition, antibody titres were consistently 
lower on guinea pig oesophagus. In another study Acosta 
and Ivanyi73 confirmed the effect of antigenic substrate 
on the results of immunofluorescence examination. The
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authors compared the sensitivity of different epithelial 
sources including human skin, human tonsil, monkey 
oesophagus and lip, guinea pig oesophagus and lip and rab­
bit lip. Sera from five patients with active pemphigus 
were used to test the reactivity of substrates. The 
highest antibody levels were demonstrated when human 
tissue was used. Although skin and tonsil yielded similar 
results in terms of antibody titre, greater epidermal and 
dermal background fluorescence was noted with skin com­
pared to tonsil. Monkey oesophagus and lip produced the 
best results compared to other animal substrates. The 
least useful tissues were guinea pig lip and rabbit lip. 
The high reactivity of pemphigus antibodies with human 
tonsil has been reported by others189. A group of 75 sera 
with pemphigus antibodies were tested on human skin, 
monkey and guinea pig oesophagi62. Similar results be­
tween the three substrates were found in 59% of the 
samples. Eight sera (11%) showed variable titres on dif­
ferent substrates. However, the most striking finding was 
the failure of about one-third of the samples to react 
with any of the substrates. The most reactive tissue was 
monkey oesophagus with only one serum failing to react to 
it. Fifty-three (71%) samples were positive on guinea pig 
oesophagus. The reactivity of human skin was slightly 
lower than that of guinea pig oesophagus. The low sen­
sitivity of normal skin was probably the result of using 
specimens with weak antigen expression. The combined use
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of monkey oesophagus and guinea pig oesophagus was found 
to increase the sensitivity of indirect immunofluorescence 
to 100% in pemphigus. Kransy et al.190 compared the reac­
tivity of 111 sera from 11 patients with pemphigus on five 
substrates. Samples were examined on normal human breast 
skin, monkey oesophagus, guinea pig oesophagus, rabbit 
oesophagus and dog oesophagus. Many of the sera tested 
showed variable reactivity on different substrates. The 
highest frequency of positive sera was obtained using 
monkey oesophagus. Pemphigus antibodies were detected in 
104 (94%) of the sera tested when this substrate was used. 
Sera from three patients failed to react to guinea pig 
oesophagus, human skin and dog oesophagus. Samples from 
three other patients yielded a negative reaction on human 
skin. The study showed that sera which were consistently 
negative for pemphigus antibodies on monkey oesophagus 
were also non reactive on sections from other substrates. 
In a similar study Judd and Mescon191 tested 56 pemphigus 
sera on human foreskin, guinea pig oesophagus, rabbit 
oesophagus, monkey oesophagus and monkey lip mucosa. 
There was no significant difference in the frequency of 
positive results on rabbit, guinea pig oesophagus or human 
skin. Primate tissues were considered better substrates 
because of a high rank correlation coefficient. 
Sabolinski et al.192 studied 50 sera from patients with 
various forms of pemphigus on monkey oesophagus and guinea 
pig oesophagus and confirmed the conclusion of other in­
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vestigators that the choice of substrate has a con­
siderable influence on the result of immunofluorescence 
tests for pemphigus antibodies. Eight of the 50 samples 
tested failed to react against either monkey oesophagus or 
guinea pig oesophagus. The authors confirmed previous 
observations62 that optimal results are obtained when both 
substrates are used concomitantly. In addition, 
Sabolinski et al.192 investigated whether the reactivity 
of antibodies with monkey oesophagus or guinea pig 
oesophagus is related to the clinical form of pemphigus. 
They showed that pemphigus vulgaris sera can be differen­
tiated from pemphigus foliaceus sera by variations in 
reactivity on the substrates. Pemphigus vulgaris an­
tibodies produced higher titre and brighter fluorescence 
on monkey oesophagus whereas sera from pemphigus foliaceus 
and Brazilian pemphigus foliaceus patients gave more in­
tense reactions on guinea pig oesophagus.
Finally, it is important to emphasize that although 
the results of the present study are in accordance with 
previous reports in that antibody titres do vary on dif­
ferent antigenic substrates, false negative results were 
not observed, i.e. none of the sera tested failed to react 
against any of the substrates. Thus, the diagnosis would 
still have been established regardless of the tissue used 
in the immunofluorescence assay. This investigation con­
firmed that while monkey oesophagus is the most sensitive 
substrate for detecting bullous pemphigoid and pemphigus
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vulgaris antibodies, guinea pig lip and human skin may be 
used as reliable alternative tissue for routine im­
munofluorescence testing if primate oesophagus is not 
available.
4.2 RESTRICTED DISTRIBUTION OF IgG SUBCLASSES IN BULLOUS 
PEMPHIGOID AND PEMPHIGUS VULGARIS
Bullous Pemphigoid
In the present study 17 skin biopsy specimens and 25 
serum samples from patients with active bullous pemphigoid 
were tested. Eighty-eight percent of skin specimens con­
tained IgG4 antibody while IgGx was present in 59% of 
cases. IgG4 was the only subclass present in five 
specimens. IgG3 was the rarest subclass. The third com­
ponent of complement was observed in 16 (94%) out of 17 
biopsies. Serum studies also demonstrated that IgG4 was 
the predominant circulating subclass. Only one serum 
sample was negative for IgG4 antibody. The ability of 
bullous pemphigoid antibodies to fix complement in vitro 
was also determined in this study using indirect comple­
ment immunofluorescence. Complement fixing antibodies 
were detected in 15 (60%) of the 25 cases examined.
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Complement fixing IgG subclasses were present in three 
sera yet they did not fix complement. In addition, some 
of the complement fixing sera contained only IgG4.
The demonstration of a predominant IgG4 response in 
the skin and serum of bullous pemphigoid patients is in 
accordance with the results obtained in previous studies.
The distribution of IgG subclasses in various inves­
tigations is indicated in Table 21.
Subtyping of anti-basement membrane zone antibodies 
was first reported in 1973193. The authors established 
that bullous pemphigoid antibodies are heterogenous. They 
examined serum antibodies from six patients. In three of 
the six sera tested IgG4 was the only IgG subclass ob­
served whereas all IgG subclasses were demonstrated in the 
remaining sera. In a more recent study by Bird et al.108, 
the nature of IgG subclass distribution of the antibody in 
bullous pemphigoid was examined using monoclonal an­
tibodies specific for each of the four subclasses. The 
study included 24 patients with active disease. The 
results showed IgG4 in 23, IgGx in 18, IgG3 in 8 and only 
three patients were weakly positive for IgG2. The non­
complement fixing subclass, IgG4, was the only antibody 
observed in two biopsies which were negative for comple­
ment. Circulating IgG antibodies were detected in 20 
serum samples. Serum subclass distribution of anti-
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-basement membrane zone antibodies demonstrated the 
presence of IgG4 in all 20 sera whereas IgGx was detected 
in 16 samples. Unlike the study of Sams and Schur, IgG2 
and IgG3 were not observed in any of the sera examined. 
The predominance of IgG4 in the serum and tissue of bul­
lous pemphigoid patients was confirmed in another study by 
Kelly et al.109 of a group of 12 patients. All skin 
biopsies showed IgG4. IgGx was present in 8 cases while 
IgG2 and IgG3 were demonstrated in one and three patients 
respectively. Serum subclass analysis revealed IgG4 in 
all samples. IgGx was demonstrated in 8 sera whereas IgG3 
was only found in the sera of two patients. IgG2 was not 
detected. The IgG subclass distribution reported by 
Brooks et al.194 also showed that lgG4 was the most fre­
quently detected subclass in serum, it being demonstrated 
in all 9 cases studied. IgGi was found in 33%, IgG2 in 
44% and IgG3 in 22% of cases. Yamada et al.195 examined 
the sera of 29 patients with bullous pemphigoid. They 
confirmed the heterogenous distribution of IgG subclasses 
in serum. IgG4 was the predominant anti-basement membrane 
zone antibody in 29 patients. IgGi was detected in 15 
cases. Like Brooks et al.194, the authors found IgG2 a 
relatively frequently detected subclass in serum, being 
observed in 16 cases. Eight samples showed IgG3 activity. 
Flotte and Baird196 evaluated the heterogeneity of IgG 
response in bullous pemphigoid by direct and indirect im­
munofluorescence using anti-human mouse monoclonal an-
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tibodies against IgG subclasses. The results showed 
predominance of IgG4 subclass in circulating and tissue 
bound antibodies. Hadi et al.197 studied 50 patients with 
pemphigoid. IgG4 was present in most patients with cir­
culating antibodies. IgGi was the next most reactive an­
tibody. Sequential serum studies over a period of several 
years showed two groups of patients. One group consisted 
of patients with high IgG4 titre which tended to persist 
for long periods in spite of clinical improvement and dis­
continuation of treatment. The second group included 
patients presenting with low antibody titres that even­
tually became undetectable within a few months. The 
authors also found that serum IgG4 concentration was sig­
nificantly raised compared to normal controls. Elevated 
levels of serum IgG4 were associated with high titres of 
basement membrane zone antibodies. A correlation between 
total serum IgG4 and bullous pemphigoid antibody titres 
was also noted by others100.
In contrast to the result obtained in this study, 
Yamada et al.195 detected more frequent binding of comple­
ment by bullous pemphigoid antibodies in vitro. They ob­
served complement fixing antibodies in 72% of their 
patients. Furthermore, analysis of the relationship be­
tween IgG subclasses distribution and their capability of 
complement fixation showed that in addition to IgG4 at 
least one of the IgG subclasses which are capable of ac­
tivating complement was also observed in all complement
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fixing sera. On the other hand, the non-complement fixing 
sera were only positive for IgG4. Thus the results were 
in accordance with the complement activating characteris­
tics of IgG subclasses. Conversely, the distribution of 
IgG subclasses in bullous pemphigoid sera examined in this 
study did not correlate with their complement activating 
capacity. Although the cause for this discrepancy is not 
clear, it is possible that complement activation, which 
requires at least two closely spaced IgG molecules to bind 
antigen198, did not occur because only few antigenic sites 
were available. The demonstration that sera containing 
only IgG4 do activate complement has also been reported by 
Kelly et al.109. They detected complement fixing an­
tibodies in 9 out of 12 patients including serum from one 
patient in whom only IgG4 was present. Unlike other in­
vestigators, Brooks et al.194 detected complement fixing 
antibodies in only 3 (33%) of 9 pemphigoid sera. The 
authors did not indicate whether the result correlated 
with the IgG subclass findings.
The predominance of IgG4 antibody in the sera and 
skin of pemphigoid patients is a surprising finding be­
cause it does not correlate with its distribution in nor­
mal serum which is 3-4% of total IgG114. In contrast, 
IgGi, which represents 64-70%114, was consistently present 
in lower quantities.
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Although immunoglobulin responses may be seen in all 
four subclasses, a restricted subclass response is more 
commonly observed in certain disorders including autoim­
mune conditions. It has been shown that IgG4 was the 
predominant subclass in the autoimmune blistering disor­
ders pemphigus107 and epidermolysis bullosa acquisita199. 
High IgG4 anti-thyroglobulin titres in patients with 
autoimmune thyroiditis have been reported200. Antibodies 
to factor VIII are primarily IgG4201. This subclass has 
also been recognized as the major IgG antibody against a 
variety of antigens such as grass pollen allergens106 and 
certain food antigens202 .
The cause of the prominent production of IgG4 in bul­
lous pemphigoid has not been established. It is possible 
that it represents an acquired phenomenon related to the 
nature of the antigen. Conversely, this restricted sub­
class response may be the result of specific genetic 
factors114. It has been speculated that continued an­
tigenic stimulation affects the normal distribution of IgG 
subclasses and leads to an IgG4 restricted response203. 
However, sequential studies of IgGx and IgG4 in bullous 
pemphigoid serum did not reveal any major change in the 
pattern of IgG subclasses197.
In addition to being present in low concentration in 
normal serum, IgG4 is unique compared with other IgG sub­
classes because it does not activate complement by the 
classical pathway90. It is also doubtful whether IgG4 has
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the capacity to activate complement via the alternative 
pathway204. Thus, the prominent lgG4 response was also an 
unexpected finding since almost all patients tested in 
this study demonstrated C3 deposits in the basement 
membrane zone. Furthermore, five of the 16 cases with 
complement deposits had an IgG4 restricted response. 
Similar findings were observed by Kelly et al.109. They 
reported that IgG4 was the only subclass detected in the 
perilesional skin of two bullous pemphigoid patients 
despite the presence of tissue fixed C3 in all 12 cases 
studied. Conversely, others108*195 have shown that pem­
phigoid cases with complement deposits were always as­
sociated with one of the IgG subclasses which are charac­
terized by their ability to activate complement.
Involvement of the complement system in the 
pathogenesis of bullous pemphigoid has been suggested. 
However, the precise role that complement plays in the 
development of the disease has not been fully determined.
It has been shown that circulating anti-basement 
membrane zone antibodies in some patients lack the 
capacity to activate complement. Sams and Schur193 
demonstrated that non-complement fixing sera were composed 
only of IgG4 whereas sera containing complement fixing an­
tibodies were found in the subclasses Glf G3 and G4.
Roberts et al.205 showed a correlation between the 
distribution of IgG subclasses in in vitro complement 
studies and the histologic picture in two distinct types
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of glomerular pathology in systemic lupus erythematosus. 
IgGi and IgG3, which have the greatest capacity to fix 
complement, were the dominant IgG subclasses in prolifera­
tive glomerulonephritis. In vitro complement studies were 
positive in all cases. Conversely, the poor complement 
fixing subclasses, IgG2 and IgG4, were detected in 
membranous glomerulonephritis. Antibodies in this form 
generally failed to fix complement in vitro. The authors 
suggested that the difference in the biological property 
of complement fixation of these antibodies provides an ex­
planation for the inflammatory histologic picture of the 
proliferative form and the contrasting bland morphology of 
membranous glomerulonephritis.
In support of a pathogenic role for complement in 
bullous pemphigoid is the detection of C3 in a linear pat­
tern at the basement membrane zone in all patients with 
active disease*. Immunoelectron microscopy studies show 
C3 deposits localized in the lamina lucida which cor­
respond to the ultrastructural site of the blister in 
pemphigoid206 . This is in addition to the finding of 
other components of the classical and alternate pathways 
at the dermal epidermal junction207. Dahl208 demonstrated 
deposition of membrane attack complex (C5-Cq) in 
perilesional skin which established that complement ac­
tivation proceeds to the terminal stage. Furthermore, in 
vitro studies209 have shown that bullous pemphigoid an­
tibodies are capable of activating complement via the
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classical and alternate pathways. Local activation of 
complement is demonstrated by the depressed levels of to­
tal haemolytic complement and individual components in 
blister fluid complement210. Gammon et al.211 described 
an in vitro model for bullous pemphigoid which 
demonstrated a functional interaction between bullous pem­
phigoid antibodies, complement and peripheral blood 
leukocytes. The leukocyte attachment method involved the 
incubation of cryostat sections of normal human skin with 
complement fixing bullous pemphigoid antibodies, viable 
leukocytes and fresh normal human serum as a complement 
source. Subsequently, leukocytes migrated and attached to 
the basement membrane zone. In addition, prolonged in­
cubation of the activated leukocytes was associated with 
focal areas of basement membrane zone separation as seen 
in early lesions of bullous pemphigoid. The importance of 
serum complement in the process of leukocyte attachment 
and dermal epidermal separation was shown by the sig­
nificant reduction of leukocyte attachment and dermal 
epidermal separation when the complement source was 
omitted. In a study by Naito et al.212, human skin ex­
plants were cultured with sera, IgG fractions and blister 
fluid from patients with bullous pemphigoid. Dermal 
epidermal separation occurred with blister fluid. The 
significance of complement in this experiment was 
demonstrated by the lack of dermal epidermal separation 
when complement inactivated by heat or anti-serum to
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complement was used. In another report Naito et al.213 
demonstrated dermal epidermal separation in vivo by in­
jecting concentrated bullous pemphigoid serum or IgG frac­
tion from pemphigoid patients into the skin of guinea 
pigs. The development of blisters was completely in­
hibited when bullous pemphigoid IgG was injected into C3 
inactivated guinea pigs. However, dermal epidermal 
separation was noted in some C4-deficient animals. The 
results suggested that the alternative pathway may par­
ticipate in the formation of bullous pemphigoid blisters.
Sams and Gammon214 proposed that the process of 
blister formation in bullous pemphigoid is initiated by 
the binding of complement-activating IgG antibodies to the 
bullous pemphigoid antigen with subsequent activation of 
complement and the production of many inflammatory 
mediators including the generation of the anaphylotoxins 
C3a and C5a. As a result, mast cells degranulate and 
release histamine and chemotactic factors such as 
eosinophil chemotactic factor of anaphylaxis and 
neutrophil chemotactic factor which lead to the recruit­
ment and activation of eosinophils and neutrophils. The 
inflammatory cells adhere to the basement membrane zone 
and liberate proteolytic enzymes that cause dermal/epider­
mal separation.
The role of mast cells in bullous pemphigoid has been 
evaluated by sequential histologic examination. Wintraub 
et al.215 presented a morphologic evidence for the release
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of mast cell products and showed that the cells are in­
volved in the initial stages of blister formation in bul­
lous pemphigoid. This was based on histological examina­
tion of lesions obtained at different clinical stages. 
Early erythematous lesions showed hypogranulated mast 
cells in the papillary dermis whereas more advanced le­
sions were associated with more extensive mast cell 
hypogranulation. The events that cause mast cells to 
degranulate are unclear. IgE antibodies after binding 
with antigen can trigger mast cell degranulation. Al­
though deposits of IgE have been detected in the basement 
membrane zone of patients with pemphigoid, this occurs 
only occasionally, which suggests that IgE is unlikely to 
be a major mediator of mast cell activation. It is pos­
sible that complement anaphylotoxins cause the degranula­
tion of mast cells. However, in view of some doubts over 
the role of complement216, the existence of non-complement 
fixing sera193 and the frequent detection of IgG4 subclass 
in this study and previous investigations, it is conceiv­
able that the inflammatory response in bullous pemphigoid 
may occur through other mechanisms.
IgG4 is an antibody which does not have the capacity 
to activate complement but has been shown to have 
homocytotropic properties for mast cells102. Thus, the 
interaction of IgG4 antibodies with mast cells in the 
skin108 may represent an alternative or additional
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mechanism of tissue injury leading to mast cell degranula­
tion, inflammation and blister formation in bullous pem­
phigoid.
Pemphigus Vulgaris
In this study 9 skin biopsy specimens and 17 serum 
samples from patients with active pemphigus were examined. 
All skin and sera had IgG. The predominant IgG subclass 
in both skin and serum was IgG4, which was detected in 
100% of cases. Seven (78%) of the biopsies studied had 
IgG4 as the only subclass present. C3 component of 
complement was detected in all skin specimens. IgG4 was 
the only subclass observed in 10 (59%) of the 17 sera 
tested. The complement fixing capability of intercellular 
antibodies in the 17 sera was determined by indirect 
complement immunofluorescence. The results of the in 
vitro complement test appeared to correlate well with the 
distribution of IgG subclasses. All seven sera containing 
complement fixing antibodies were also positive for IgGi 
which is characterized by a strong capacity to activate 
complement.
The frequency of IgG subclasses reported by different 
investigators is shown in Table 22. The IgG subclass dis­
tribution in pemphigus serum was first determined by Sams 
and Schur193 using stepwise immunoglobulin elution from 
diethylaminoethyl cellulose columns and immunofluorescence 
methods. The IgG subclasses were localized using
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monospecific antisera to IgG and the different subclasses. 
The results showed that serum IgG from three patients was 
composed of all four subclasses. This is in contrast to 
the results obtained in this study where IgG2 and IgG3 
were absent from all skin and sera tested. The distribu­
tion of IgG subclasses was determined by Jones et al.107 
in a study of 10 pemphigus sera using monoclonal an­
tibodies against human IgG subclasses. They found that 
the IgG antibody response was composed mainly of the IgGi 
and IgGA subclasses. IgG4-specific autoantibodies were 
demonstrated in all 10 sera with antibody levels up to 
1:320. IgGx antibodies were found in 9 serum samples but 
at lower titres. IgG3 was detected in the serum of one 
patient only after isolation of IgG using ion exchange 
chromatography. IgG2 was not detected in any sample. The 
predominance of IgG* in the sera of pemphigus patients was 
confirmed by Yamada et al.195. In a study of 27 patients 
with various types of active pemphigus the intercellular 
antibody activity was detected in all four IgG subclasses. 
IgG* was detected in the sera of all patients. IgGi was 
present in 7 sera whereas IgG2 and IgG3 were observed in 6 
and 5 cases respectively. In another report Kelly et 
al.109 analysed the pattern of IgG subclasses in the serum 
and skin of 10 pemphigus vulgaris patients. IgG* was ob­
served in all 10 biopsies examined. IgGx and IgG3 were 
positive in 9 and 3 cases respectively whereas IgG2 was 
not detected in any of the cases studied. IgG* and IgGi
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subclasses were also the predominant intercellular an­
tibodies in serum. IgG2 and IgG3 were rarely detected. A 
heterogenous distribution of IgG subclasses in the sera of 
patients with pemphigus vulgaris was reported by Brooks et 
al.194. In contrast to other studies, IgGx was the most 
commonly detected subclass whereas IgG4 was the least en­
countered antibody. Examination of 15 patients showed 
that IgGi was found in 11, IgG2 in 9, IgG3 in 7 and IgG4 
in only 5 patients. David et al.217 compared the dis­
tribution of IgG subclasses in the perilesional skin of 
two groups of pemphigus vulgaris patients. The first in­
cluded 13 patients with active disease and the other group 
consisted of 14 patients in remission. IgGx was detected 
in all patients with active pemphigus while IgG4 was 
present in 11 of the 13 biopsy specimens studied. IgG2 
and IgG3 were seen in 7 and 10 cases respectively. IgG4 
was the predominant subclass in patients who were in 
clinical remission, being observed in 11 of 14 patients. 
Complement was found in 11 patients in the first group but 
detected less frequently among patients in remission. 
Analysis of the results showed that the frequency of IgGi, 
IgG3 and C3 among patients in remission decreased sig­
nificantly compared with active disease. It was concluded 
that C3 and IgG3 are possible indicators of a state of 
remission whereas IgGx may be considered a marker of dis­
ease activity.
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Studies of IgG subclasses in endemic pemphigus 
foliaceus showed results which were generally similar to 
those in other types of pemphigus. IgG* is the 
predominant antibody in the skin and serum of patients 
with this disorder. The next most reactive antibody is 
IgGj. The remaining IgG subclasses are detected only oc- 
casionally in both circulating and tissue bound 
antibodies123.
Several investigators have studied the complement 
binding capability of IgG subclasses in pemphigus. Yamada 
et al.195 found complement fixing antibodies in only 6 of 
27 pemphigus sera. Three samples contained one of the 
complement fixing IgG subclasses (G^G^) as well as IgG*. 
Conversely, the result of the remaining three sera was not 
in accordance with the complement fixing characteristics 
of IgG subclasses because the three samples were only 
positive for IgG*. Furthermore, in the 21 sera which did 
not contain complement fixing antibodies only IgG* was 
present in 13 samples, whereas in the remaining 8 sera 
subclasses with complement fixing ability were detected in 
addition to IgG*. This finding is similar to that 
reported in the study of Sams and Schur193 where three 
sera from patients with active pemphigus failed to fix 
complement in spite of the presence of the complement 
fixing subclasses G1# G2 and G3. Brooks et al.194 studied 
the complement binding activity in their patients and 
found that two-thirds (10 out of 15) of the pemphigus sera
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tested bound complement in vitro. This appeared to corre­
late with the frequency of IgGi (11 out of 15) which is an 
efficient complement fixer. The authors, however, did not 
point out the distribution of IgG subclasses in the sera 
with complement fixing antibodies.
It has been proposed that pemphigus antibodies have 
an important role in the pathogenesis of the disease. The 
suggestion that intercellular antibodies are involved in 
the development of pemphigus lesions has been based on 
different clinical and laboratory observations. These an­
tibodies are deposited in the skin of all patients67. 
They are also present in the sera of most patients and the 
titre tends to correlate with disease activity70. Removal 
of pemphigus antibodies induces a state of remission218. 
Neonates of mothers with pemphigus may have the disease 
too. It gradually improves with the disappearance of the 
placentally transferred maternal pemphigus antibodies219. 
In addition, there are in vitro studies which suggest that 
circulating pemphigus vulgaris antibodies may be 
pathogenic. Michel and Ko220 showed that serum antibodies 
can cause acantholysis. When serum is incubated in vitro 
with normal skin organ cultures, antibody binds to the 
epidermal intercellular areas in the tissue explant. This 
was associated with suprabasal acantholysis. Schiltz and 
Michel221 used explants of normal skin in organ culture 
and identified IgG fraction from pemphigus serum as the 
element responsible for acantholysis. Further studies222
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demonstrated that pemphigus antibodies cause epidermal 
cell detachment when added to monolayers of epidermal 
cells in culture. Farb et al.222 also showed that pem­
phigus antibodies elicited the release of proteases from 
epidermal cells in culture. In a more recent study 
Hashimoto et al.223 suggested that plasminogen activator 
is the protease secreted by epidermal cells treated with 
pemphigus IgG. Furthermore, the authors found that acan­
tholysis does not occur if protease inhibitors are added 
to the cell cultures. It was therefore concluded that 
acantholysis in pemphigus may be mediated by the plas­
minogen plasmin system. The involvement of intercellular 
antibodies in the pathogenesis of pemphigus is also sup­
ported by in vivo studies. The disease has been induced 
in neonatal mice by the injection of IgG fractions of 
serum from patients with pemphigus224. Using the neonatal 
mouse model, Anhalt et al.225 found that the addition of 
dexamethasone can significantly reduce the release of pem­
phigus IgG induced plasminogen activator by epidermal 
cells. Treatment with dexamethasone, however, did not in­
hibit the development of blisters.
It is not clear whether activation of complement sys­
tem is necessary for the induction of pemphigus. In addi­
tion to C3, other complement components have been iden­
tified in pemphigus skin including Clq and C4226*227 . 
Properdin has also been observed in some cases, which sug­
gests a degree of complement activation by the alternative
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pathway226 . The involvement of the complement system is 
supported by the presence of low total haemolytic comple­
ment in pemphigus blister fluid compared to serum 
levels220 . Activation of complement is also suggested by 
the reduced levels of the early classical pathway com­
ponents Clf Cq and C4229 .
Although intercellular antibody activity has been ob­
served in IgG subclasses that are usually associated with 
complement fixation, the initial attempts of Jordon et 
al.230 to demonstrate that pemphigus antibodies are 
capable of fixing complement were unsuccessful. However, 
subsequent in vitro complement studies by Nishikawa et 
al.231 demonstrated that some pemphigus antibodies will 
fix complement to human skin. Although there are indica­
tions that complement may have a role in the pathogenesis 
of pemphigus, in vitro studies have demonstrated that 
acantholysis can be induced by pemphigus sera devoid of 
complement221. A study by Anhalt et al. 224 provided fur­
ther evidence that complement activation is not a prereq­
uisite for blister formation. The authors showed that 
F(ab)2 fragments of human pemphigus antibodies do produce 
pemphigus lesions in the neonatal mouse model despite the 
lack of the complement fixing Fc portion. In addition, 
when pemphigus vulgaris antibodies were injected into nor­
mal and genetically deficient C5 neonatal mice extensive 
blistering was observed in all animals. Acantholysis was 
also noted in controls and mice pretreated with cobra
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venom factor to deplete C3 when large doses of pemphigus 
vulgaris IgG were used. However, a significant decrease 
in disease activity was noted when lower doses of antibody 
were administered. The result suggested that, under cer­
tain conditions, complement activation may have an 
amplifying role in the development of pemphigus lesions.
The predominance of IgG4 subclass in the serum and 
skin in pemphigus vulgaris led to the suggestion that it 
may contribute to the pathogenesis of this disorder232 . 
This IgG subclass has been implicated as an aetiological 
factor in the pathogenesis of allergic disorders. High 
concentrations of IgG4 have been observed in atopic 
dermatitis120*233 and asthma121. In addition, various al­
lergens may be associated with elevated levels of 
IgG4 106-202 . It has been suggested that IgG4 can sen­
sitize leukocytes for the release of histamine and thus 
play a role in hypersensitivity reactions. On the other 
hand, a b l o c k i n g  eff e c t  of I g G 4 has been 
proposed105-106»234 . This occurs by the binding of IgG4 
and allergen complexes on effector cells, thus interfering 
with the mechanisms which lead to histamine release. A 
protective role for IgG4 has also been suggested in the 
case of immunotherapy. Aalberse et al. 203 found that the 
initial response to the honey bee venom phospholipase A is 
predominantly of the IgGx subclass whereas repeated ex­
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posure to the antigen was associated with a change in the 
antibody distribution with antibody activity being 
predominantly of the IgG4 subclass.
In their study of pemphigus vulgaris patients, David 
et al. speculated that IgG4, which was the most common 
subclass in patients in remission, may act as a blocking 
antibody to other IgG subclasses. However, a blocking or 
protective function of IgG4 in pemphigus has not been 
proved. In fact, there is in vivo evidence supporting a 
pathogenic role for IgG4 antibodies in one type of pem­
phigus, endemic pemphigus foliaceus. The pathogenicity of 
this subclass was established when passive transfer of 
IgG4 from patients to a neonatal mouse model was as­
sociated with a reproduction of the clinical histological 
and immunological features of the human disease123. It 
therefore seems likely that IgG4 antibodies may also con­
tribute to the development of tissue injury in pemphigus 
vulgaris.
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4.3 IMMUNOFLUORESCENCE AND WESTERN IMMUNOBLOTTING 
STUDIES OF ANTI-BASEMENT MEMBRANE ZONE ANTIBODIES
The differentiation between bullous pemphigoid and 
other bullous diseases may be more difficult than previ­
ously believed, particularly in patients with epider­
molysis bullosa acquisita. Although the specificity of 
circulating anti-basement membrane zone antibodies in each 
of the two disorders has been shown to be distinct, an 
overlap between the clinical histologic and routine im­
munofluorescence features are similar and can cause 
problems.
Studies of patients with epidermolysis bullosa ac­
quisita diagnosed on the basis of specific criteria28-124 
showed that this disorder may be confused with other blis­
tering diseases, especially bullous pemphigoid. Gammon et 
al .29 reported a patient with generalized bullous eruption 
indistinguishable from bullous pemphigoid but with im- 
munoelectron microscopy features of acquired epidermolysis 
bullosa. Classical features of epidermolysis bullosa ac­
quisita eventually developed. In another report Gammon et 
al .235 described cases in which clinical manifestations of 
bullous pemphigoid or, less commonly, cicatricial pem­
phigoid were observed on presentation or during the course 
of the illness whereas immunoelectron microscopy and im- 
munoblotting results were consistent with a diagnosis of 
epidermolysis bullosa acquisita. These observations
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provide evidence that the dependence on clinical and im- 
munopathologic features to distinguish between bullous 
pemphigoid and epidermolysis bullosa acquisita may lead to 
incorrect diagnoses. The establishment of a definite 
diagnosis is of particular importance in view of the dif­
ferences in the natural history and response to therapy 
between the two disorders. Epidermolysis bullosa ac­
quisita typically runs a chronic and protracted course 
with only limited response to treatment. In contrast to 
bullous pemphigoid, which is relatively easy to control by 
corticosteroids, epidermolysis bullosa acquisita usually 
requires higher initial doses and longer maintenance of 
corticosteroids in addition to immunosuppressive or 
cytotoxic agents143.
In the present study basement membrane zone antigens 
were localized using sodium chloride-separated skin as a 
substrate. The investigation included one epidermolysis 
bullosa acquisita and 27 bullous pemphigoid sera. All 
pemphigoid sera produced an epidermal fluorescence pattern 
whereas the epidermolysis bullosa acquisita serum stained 
the dermal aspect of the split. In addition, testing for 
type IV and type VII collagen showed that they were local­
ized on the floor of separated skin. It was noted that 
the incubation time required to separate the skin was ap­
proximately 96 hours at 4°C whereas a duration of only 48 
hours at room temperature was necessary before separation
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was achieved. This may have been due to continued 
p r o t e a s e  a c t i v i t y  allowed for by the higher 
temperature236 .
The same technique was also used to separate 
perilesional skin biopsies obtained from bullous pem­
phigoid patients. Seven specimens were stained by FITC 
conjugated IgG and C3. Immunoreactants were detected on 
the epidermal side of the split in six specimens whereas a 
split biopsy specimen from one patient showed IgG and C3 
staining on both the epidermal and dermal sides of the 
separation. Western immunoblotting was also performed 
utilizing circulating anti-basement membrane zone an­
tibodies from the sera of patients with bullous pemphigoid 
and epidermolysis bullosa acquisita. Five of 7 pemphigoid 
sera which stained the epidermal aspect of separated skin 
reacted by immunoblotting. An epidermolysis bullosa ac­
quisita serum did not react with any band. Four bullous 
pemphigoid sera recognized a 220 KG> protein whereas one 
serum showed reactivity with a 180 KQ antigen.
Adult human skin may be separated at the dermal 
epidermal junction by different methods including cold 
sodium chloride, cold trypsinization, induction of a suc­
tion blister and phosphate buffered saline. Various base­
ment membrane components were localized by indirect im­
munofluorescence on skin separated by these techniques. 
Laminin and type IV collagen, which are localized in the 
lamina lucida and lamina densa respectively, are usually
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detected along the dermal edge and around dermal blood 
vessels. Bullous pemphigoid antibodies reacted against 
split skin consistently produced staining of the roof of 
the split regardless of the separation method used237. In 
addition, it has been suggested that the ultrastructural 
binding sites of circulating anti-basement membrane zone 
antibodies of other bullous disorders can be determined by 
indirect immunofluorescence using sodium chloride 
separated skin as a substrate238.
Treatment of normal skin with 1M sodium chloride 
causes separation of the basement membrane through the 
lamina lucida237. Thus, all the antigenic compounds 
within or beneath the lamina densa are localized on the 
dermal side of the separated skin. Consequently, binding 
of bullous pemphigoid anti-lamina lucida antibodies (as 
determined by immunoelectron microscopy) would be expected 
to occur on the epidermal side of the split whereas 
epidermolysis bullosa acquisita sera, which contain anti­
sublamina densa antibodies, would react with the dermal 
aspect of the separation. Based on these data, Gammon et 
a l .238 confirmed and extended previous observations by 
using skin, separated by sodium chloride at 4°C, to local­
ize the bullous pemphigoid and epidermolysis bullosa ac­
quisita antigens. Antibodies from a reference bullous 
pemphigoid serum reacted with the epidermal aspect of the 
split whereas an epidermolysis bullosa acquisita reference 
serum produced a staining pattern restricted to the dermal
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side of the split. The authors also used this method to 
detect anti-basement membrane zone antibodies in the sera 
of patients suspected of having bullous pemphigoid on the 
basis of clinical, histological and routine immunofluores­
cence features. Six of 51 sera showed binding on the der­
mal side of the split and immunoelectron microscopy 
studies revealed that these samples contained anti­
sublamina densa antibodies which are different from the 
anti-lamina lucida antibodies of bullous pemphigoid. One 
case of epidermolysis bullosa acquisita showed an epider­
mal staining pattern and proved to have lamina lucida 
deposits. A combined epidermal dermal pattern, exhibited 
by 9 sera, was associated with lamina lucida antibodies.
Gammon et al. therefore proposed that a significant 
proportion of patients thought to have bullous pemphigoid 
have epidermolysis bullosa acquisita. Furthermore, they 
indicated that a bullous pemphigoid-like presentation of 
acquired epidermolysis bullosa may be seen in up to 50% of 
patients235*230. The same authors determined the 
ultrastructural binding site of 34 additional patients 
thought to have bullous pemphigoid using indirect im­
munofluorescence and split-skin. The results showed that 
5 sera produced a dermal fluorescence pattern consistent 
with a diagnosis of epidermolysis bullosa acquisita which 
was subsequently confirmed by indirect immunoelectron
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microscopy. Thus they suggested that about 10% of 
patients originally diagnosed as bullous pemphigoid may 
actually have epidermolysis bullosa acquisita230.
Logan et al. 239 evaluated the use of indirect im­
munofluorescence with the split-skin technique as an al­
ternative method to immunoelectron microscopy for deter­
mining the site of immune deposits. In contrast to the 
findings of Gammon et al., they suggested that patients 
with dermal staining pattern on sodium chloride separated 
skin do not invariably have epidermolysis bullosa ac­
quisita. The authors examined a group of 228 sera from 
cases previously diagnosed as bullous pemphigoid. Nine 
samples showed a linear pattern of fluorescence along the 
dermal edge of the separation. The remaining sera 
produced an epidermal or a combined pattern. When the 
nine sera were tested by indirect immunoelectron micros­
copy only three sera showed immune deposits within or 
beneath the lamina densa. The immune reactants in the 
other six samples were observed within or above the lamina 
lucida. Thus there was no compatibility between the im­
munofluorescence reaction pattern and immunoelectron 
microscopy findings in these cases. In addition, clinical 
details available from six of the nine cases were not con­
sistent with a diagnosis of epidermolysis bullosa ac­
quisita. The authors concluded that the split skin tech­
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nique was unhelpful in identifying cases of epidermolysis 
bullosa acquisita incorrectly diagnosed as bullous pem­
phigoid.
In another study Kelly et al .236 examined 20 bullous 
pemphigoid sera on sodium chloride-separated skin. The 
majority of samples produced an epidermal or combined pat­
tern. The dermal pattern was observed in three cases. 
Although immune deposits were not localized by im­
munoelectron microscopy, the authors felt that the clini­
cal features of the three cases were not suggestive of 
epidermolysis bullosa acquisita.
Conversely, others240-241 have confirmed that in­
direct immunofluorescence with split-skin is a useful 
method to distinguish between anti-bullous pemphigoid and 
anti-epidermolysis bullosa acquisita antibodies. Zhu et 
al .240 presented data supporting the findings of Gammon et 
al238 that patients showing a dermal staining pattern may 
have epidermolysis bullosa acquisita. However, they sug­
gested that the proportion of patients with basement 
membrane antibodies who may have acquired epidermolysis 
bullosa rather than bullous pemphigoid is smaller than 
that previously reported. The authors examined 100 serum 
samples with anti-basement membrane zone antibodies on 
split skin. Three sera which were obtained from patients 
clinically diagnosed as bullous pemphigoid or cicatricial 
pemphigoid demonstrated fluorescence on the dermal side of 
the split. Two of these sera reacted with the epider­
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molysis bullosa acquisita antigen on Western immunoblot- 
ting assay. In another report, Fine et al .241 observed a 
dermal pattern when sera from patients diagnosed as 
epidermolysis bullosa acquisita were tested on split skin. 
Direct immunoelectron microscopy of perilesional skin 
showed immunoreactants to be associated with the lamina 
densa and sublamina densa areas, thus confirming the diag­
nosis of epidermolysis bullosa acquisita.
McCuaig et al. 242 suggested that the split skin tech­
nique may also be a useful diagnostic procedure in 
children with bullous disorders. They reported a rare 
childhood case of epidermolysis bullosa acquisita that was 
originally diagnosed as hereditary epidermolysis bullosa. 
The correct diagnosis was suggested by indirect im­
munofluorescence using split-skin and was subsequently 
confirmed by specialized techniques. It is therefore 
recommended that this procedure be part of the immunologic 
evaluation of children with mechanobullous skin disease.
In addition to the value of sodium chloride separated 
skin in the differentiation between anti-lamina lucida and 
anti-sublamina densa antibodies, the substrate appears to 
increase the sensitivity of indirect immunofluorescence 
for the detection of anti-basement membrane zone 
antibodies236-238*241 . The improvement in the sensitivity 
of split skin may be due to exposure of antigenic sites 
during the separation process. Low background fluores­
cence, possibly due to the removal of dermal gam­
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maglobulins, may have contributed to the increased ability 
to detect these antibodies238. A similar observation was 
noted in the present study. Higher antibody titres were 
obtained with separated skin compared to normal intact 
skin.
The results of various investigations have 
demonstrated that the split-skin technique is a useful 
diagnostic procedure in bullous disorders. In addition, 
the method is relatively simple and can be performed at 
any immunofluorescence laboratory which is in contrast to 
the technically difficult and time-consuming im­
munoelectron microscopy and immunochemical methods. 
However, the split skin technique is only applicable in 
cases associated with circulating anti-basement membrane 
zone antibodies. This has led some authors239 to suggest 
immunofluorescence mapping as an alternative method in 
patients lacking serum antibodies. The method involves 
localization of the ultrastructural level of skin cleavage 
by mapping basement membrane antigenic determinants. 
Electron microscopy studies have shown that blister forma­
tion in epidermolysis bullosa acquisita occurs beneath the 
lamina densa124-143: thus this structure remains in the
roof of the blister. In contrast, skin cleavage in bul­
lous pemphigoid develops within the lamina lucida55, which 
leaves the lamina densa in the floor of the blister. 
These levels may be determined by the use of antibodies 
against normal antigenic components of the basement
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membrane such as laminin and type IV collagen. The 
blister level can be established by evaluating whether the 
roof or the floor is stained by the antibodies. In bul­
lous pemphigoid the labelling pattern for both laminin and 
type IV collagen is on the floor of the blister whereas in 
epidermolysis bullosa acquisita the staining is noted on 
the roof of the blister243 . However, others suggested 
that this method may give inaccurate results in some case 
of epidermolysis bullosa acquisita. Fine et al .241 
studied 1 0 patients with this disorder in whom the diag­
nosis was confirmed by direct immunoelectron microscopy. 
However, most skin specimens examined showed an 
intralamina lucida, rather than sublamina densa blister. 
Consequently, immunomapping showed the immune deposits on 
the floor of the blister. The authors concluded that 
routine electron microscopy and immunomapping studies of 
patients' blistered skin are not reliable diagnostic 
methods in epidermolysis bullosa acquisita.
In cases where circulating antibodies are absent, 
direct immunofluorescence on sodium chloride separated 
skin biopsies has been shown to be a useful technique in 
delineating cases of bullous pemphigoid from epidermolysis 
bullosa acquisita. The method involves separating 
patients' perilesional skin using 1M sodium chloride. The 
separated skin is then used as a substrate for standard 
direct immunofluorescence to identify the level of an­
tibody deposition. Gammon et al .244 showed that in bul­
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lous pemphigoid the immune reactants are found on the 
epidermal side or both sides of the split whereas in 
epidermolysis bullosa acquisita the immune deposits are 
associated with the dermal aspect of the separation. 
Wuepper245 tested stored frozen biopsies by the direct im­
munofluorescence separation method and confirmed the use­
fulness of the procedure in differentiating between anti­
lamina lucida and anti-sublamina densa antibodies. These 
results indicate that the technique is reliable for diag­
nosing epidermolysis bullosa acquisita and distinguishing 
it from bullous pemphigoid without requiring the presence 
of circulating antibodies. It must be stressed, however, 
that when this method is used accurate results can be ob­
tained only if it is established that separation has taken 
place through the lamina lucida. Gammon et al .244 em­
phasized that this must be confirmed by immunofluorescence 
mapping because of the possibility of an atypical split 
occurring with tissue from patients with epidermolysis 
bullosa acquisita which could lead to inaccurate localiza­
tion of the immune deposits.
In addition to the split skin techniques described 
above, a reliable differentiation between bullous pem­
phigoid and epidermolysis bullosa acquisita can be 
achieved by Western immunoblotting. In recent years many 
investigations have been performed to explore the charac­
teristics of the normal antigenic components reactive with 
anti-lamina lucida and anti-sublamina densa antibodies.
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In bullous pemphigoid circulating anti-basement 
membrane zone antibodies recognize a specific non- 
collagenous glycoprotein in epidermal extracts which are 
separated by SDS-PAGE and then electrophoretically trans­
ferred to nitrocellulose paper142. The antigen is not 
reactive with normal sera or with antibodies from patients 
with other bullous disorders, which indicates that Western 
immunoblotting is a useful method for confirming the diag­
nosis of bullous pemphigoid.
The use of Western immunoblotting to investigate the 
bullous pemphigoid antigen was originally described by 
Stanley et al.142. Their results showed that a single 
220-240 KI> bullous pemphigoid antigen was regularly 
detected in all immunoblotting studies. However, other 
authors in subsequent studies presented evidence of bul­
lous pemphigoid antigen heterogeneity at the molecular 
level. Labib et al .246 used Western immunoblotting, with 
epidermal extracts prepared from heat separated epidermis, 
to determine the proteins reactive with anti-basement 
membrane zone antibodies from 28 patients with bullous 
pemphigoid. Proteins with different molecular weights 
(240 m ,  200 KQ, 180 Kf>, 97 KD and 77 K&) were observed 
but two particular bands were most often detected by the 
sera tested. The 240 KOantigen and the 180 KQ antigen 
reacted with 43% and 29% of the samples respectively. The 
authors suggested that the smaller molecular weight 
proteins detected in their study do not represent
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proteolytic degradation products of larger antigens be­
cause, although they were uncommonly observed, they 
produced intense staining reactions. In addition, they 
attributed their ability to detect the 180 K D  antigen, 
which was not previously reported to the use in all ex­
periments of a panel of protease inhibitors during the 
preparation of epidermal extracts.
Heterogeneity of the bullous pemphigoid antigen was 
first suggested by Zhu and Bystryn181 on the basis of 
variations in antigen expression, as determined by in­
direct immunofluorescence between skin specimens obtained 
from different individuals. Analysis of the reactivity 
patterns indicated that there are two groups of bullous 
pemphigoid antigen. The first is a major antigen reactive 
with antibodies present in the majority of patients with 
bullous pemphigoid. The other group consists of antigens 
which are expressed in some individuals. Antibodies reac­
tive with these 'minor' antigens are only present in a 
proportion of bullous pemphigoid patients. The same 
group247 used Western immunoblotting to confirm that bul­
lous pemphigoid antibodies are heterogenous. In a study 
of 38 patients they demonstrated that approximately 90% of 
patients had antibodies to a major bullous pemphigoid an­
tigen with a molecular weight of 230 KD. Antigens with 
molecular weights of 200 KD and 180 Kd were detected in up 
to 75% of patients whereas 11% of sera contained an­
tibodies that reacted solely to a 160 KC>protein. This
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molecular heterogeneity was also observed by other inves­
tigators. Bernard et al .248 reported the detection of 
various antigens by 30 bullous pemphigoid sera. The most 
commonly detected antigens were the 2 2 0  KOprotein and a 
165 K6  protein. Bands with a molecular weight of 190 K£> 
and 97 KD were also detected by some antibodies. Inter­
estingly, the study included sera which were negative by 
indirect immunofluorescence on standard substrates and 
sodium chloride separated skin but produced a positive 
result by immunoblotting. Fourteen of 29 of these sera 
contained antibodies that recognized the 2 2 0 KD and/or the 
165 KD antigen. In contrast, some sera which contain bul­
lous pemphigoid antibodies, demonstrable by indirect im­
munofluorescence, may not be detected by the immunoblot­
ting procedure. Such sera represented 10% of the total 
samples assayed by Zhu et al. 240 . It has previously been 
suggested that there is rough correlation between the in­
direct immunofluorescence titre of bullous pemphigoid sera 
and their reactivity by the immunoblotting assay246 . 
However, low serum antibody titre was excluded by Zhu as a 
cause of negative immunoblotting because, as noted in the 
present study, antibody levels in the sera that failed to 
stain any bands were comparable to those in other samples 
which recognized specific bullous pemphigoid antigens. 
Zhu et al. also ruled out the possibility of degradation 
or loss of antigen during the extraction process since 
other simultaneously tested sera resulted in positive im-
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munoblots. Conversely, other studies249 have suggested 
that the denaturing of bullous pemphigoid antigen 
(necessary for SDS-PAGE) may lead to complete or partial 
loss of reactivity with some sera. Mueller et a l .249 
could not demonstrate antigen heterogeneity but confirmed 
that the 230 KD antigen is a frequently detected protein 
by Western immunoblotting. The authors investigated 
whether the antibodies reacting with the 230 K D  antigen 
are identical to the bullous pemphigoid antibodies that 
are detected by indirect immunofluorescence. They af­
finity purified the IgG bullous pemphigoid antibodies on 
the 230 KD band and then used these antibodies for im­
munofluorescence which showed linear binding along the 
basement membrane zone.
Immunoprecipitation methods were shown by Mueller et 
al. to be more sensitive than immunoblotting to identify 
the 230 KD antigen. In addition, they noted that some 
sera precipitated a 166 KD antigen. The authors suggested 
that it may be a degradation product of the 230 KP antigen 
and that it may be identical to the 180 K O  antigen 
described by Labib et al.246. However, none of the sera 
tested recognized either a 166 KD or a 180 K D  band by im­
munoblotting. Mueller et al. used PMSF and EDTA as 
protease inhibitors during the epidermal extract prepara­
tion which may not have been sufficient to prevent 
proteolysis. In contrast, Labib et al. used additional
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inhibitors to different groups of proteases which may ac­
count for their ability to detect the 180 K& and the 
smaller molecular weight proteins.
It has been proposed that the 160-165 K D  band 
detected in some studies corresponds to the 180 KD antigen 
and that the disparity in molecular weight determination 
may have been the result of differences in the extraction 
procedure or the standard markers used240. However, Zhu 
et al. 247*250 regarded the 160 K<t> band to be distinct from 
the 180 KD and 230 Ko antigens because all have been 
detected on the same immunoblot and sera reactive mainly 
with the 160 K b  antigen did not recognize the 180 K.. 
protein sera while antibodies directed against the 180 K* 
antigen did not react to the 160 KD antigen. In addition, 
they suggested that the 180 Kb protein may be a breakdown 
product of a larger molecule since it was not regularly 
detected in different extracts. To study the effect of 
proteolysis on the different antigens, Zhu et al .247*250 
prepared blots using epidermal extracts with or without 
the addition of protease inhibitors. The results showed 
that despite the absence of protease inhibitors the ex­
pression of the 230 Kb antigen was not affected, which in­
dicated that the 160 KDprotein is not a breakdown product 
of the major 230 KDantigen. However, proteolysis caused 
the degradation of the 160 Kb antigen to a 140 Kb frag­
ment .
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To determine the relationship of different antigens 
detected by Western immunoblotting, Mayer et al .251 af­
finity purified the bullous pemphigoid antibodies on the 
different antigens. The eluted antibodies were subse­
quently used in immunoblotting assays. The antibodies af­
finity purified from the 240 KD and the 160 Kfc> band 
stained the corresponding antigens on nitrocellulose blots 
with no cross reactivity. Although this result confirmed 
that the 160 K a n t i g e n  is not a degradation product of 
the 230 KD antigen, it remains possible that it is a 
proteolytic fragment of a 180 KD antigen251. In a similar 
study Robledo et al. 252 detected the 230 KD and a 180 KD 
antigen by Western immunoblotting and re-examined eluted 
IgG antibodies from these bands. Binding of affinity 
purified antibodies to the corresponding antigens occurred 
without cross reactivity. Their result provided evidence 
that the two antigens are distinct and that the 180 KD an­
tigen is not a breakdown product of the 220-240 KD an­
tigens .
As in bullous pemphigoid, Western immunoblotting has 
been wsed to investigate the antigen reactive with sub­
lamina densa antibodies from patients with epidermolysis 
bullosa acquisita. The target antigen has been identified 
as a polypeptide consisting of two components with 
molecular weights of 290 Kfc. and 145 KD146. The antigen is 
a specific type of collagen that is associated with 
anchoring fibrils129. Circulating anti-basement membrane
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antibodies from patients with blistering disorders includ­
ing bullous pemphigoid, dermatitis herpetiformis, herpes 
gestationis and pemphigus do not recognize this 
antigen146*240 .
In the present study a high titre epidermolysis bul­
losa acquisita serum, with dermal staining pattern on 
split skin, was tested by Western immunoblotting but 
showed no specific bands. The failure of some epider­
molysis bullosa acquisita antibodies to react with antigen 
on immunoblots has been reported240*253 . In a study by 
Stanley et a l .253 of 5 epidermolysis bullosa acquisita 
sera the 290 KD antigen was identified by 4 samples 
whereas one serum did not stain any bands. Conversely, by 
immunoprecipitation, which does not involve denaturing of 
proteins, the 290 KE> antigen was precipitated by all 5 
sera. The authors suggested that some epidermolysis bul­
losa acquisita sera contain antibodies which do not bind 
denatured antigen on immunoblots.
Although sera from some patients with bullous pem­
phigoid stain both the epidermis and dermis of split skin, 
studies have demonstrated that they do not contain an­
tibodies against the epidermolysis bullosa antigen240*254.
The results of different reports and the present 
study have shown that bullous pemphigoid sera always 
produce an epidermal or combined staining pattern when 
tested on split skin regardless of their antigenic 
specificity as determined by Western immunoblotting. In
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addition, it has been confirmed that antibodies from 
patients with epidermolysis bullosa acquisita consistently 
bind to the dermal side of sodium chloride separated skin. 
Sera with such a staining pattern regularly recognize the 
290 KOand 145 KfE> antigen.
These observations therefore indicate good correla­
tion between the indirect immunofluorescence with split 
skin and Western immunoblotting findings and support the 
value of these techniques in establishing the correct 
diagnosis in bullous pemphigoid and acquired epidermolysis 
bullosa.
4.4 ANTI-ENDOMYSIAL ANTIBODIES IN DERMATITIS HERPETI­
FORMIS
Circulating IgA class antibodies to the lining of 
smooth muscle fibrils can be detected by indirect im­
munofluorescence using smooth muscle-containing substrate 
such as monkey oesophagus. The diagnostic significance of 
these antibodies was determined in the present study by 
testing 2 0 patients with dermatitis herpetiformis, 2 0 with 
pemphigus and 20 with bullous pemphigoid. The overall 
sensitivity of the anti-endomysial antibodies for the 
diagnosis of dermatitis herpetiformis was 60%. However, a 
higher frequency was observed in patients on a non­
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restricted diet with normal gluten intake. The antibodies 
were detected in 11 (73%) of 15 patients who were on a 
normal diet. Conversely, the endomysial antibodies oc­
curred in only one (2 0 %) of the five patients following a 
gluten-free diet. The antibodies could not be detected in 
any of the control sera from patients with pemphigus or 
bullous pemphigoid.
The anti-endomysial antibodies were first described 
in 1983 by Chorzelski et al.172. Table 23 indicates the 
incidence of these antibodies in various studies. The an­
tibodies, which are found in dermatitis herpetiformis and 
coeliac disease, are directed against the endomysium of 
smooth muscle fibres and are predominantly of the IgA 
class although IgG antibodies may be seen in low titres. 
The target of these antibodies appears to be the reticular 
component associated with the endomysium of smooth muscle. 
The antibodies, however, do not react with reticular 
fibrils of other organs172. Chorzelski et al. 255 per­
formed indirect immunofluorescence tests on oesophagi of 
selected species to determine the most suitable for the 
reactivity of anti-endomysial antibodies. The antibodies 
did not react with the endomysium of the smooth muscle of 
mouse and rat and negative or low antibody levels were 
seen with oesophagus of cattle, calf, goat and guinea pig. 
The highest titres were obtained when monkey oesophagus 
was used as a substrate. These studies confirmed that the 
smooth muscle of monkey oesophagus is the most appropriate
169
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tissue for this serologic test. However, differences in 
the distribution of the endomysium antigen at various 
levels of the oesophagus between the pharynx and the 
stomach have been reported256 . The variability in the ex­
pression of this antigen is a consequence of the anatomic 
distribution of smooth and skeletal muscle between the up­
per and the lower oesophagus. The reactivity of sera con­
taining anti-endomysial antibodies with monkey oesophagus 
would depend on the use of sections obtained from an ap­
propriate site. Kumar et al .256 studied the distribution 
of the endomysium antigen throughout the entire length of 
the oesophagus using serum from a patient with dermatitis 
herpetiformis. The immunofluorescence results showed that 
the antigen was completely absent in the upper oesophagus 
whereas sections obtained from the middle part of the 
oesophagus showed positive and negative muscle fibres. In 
contrast, the greatest amount of antigen was observed in 
the lower oesophagus.
The frequencies of IgA anti-endomysial antibodies in 
the original report of Chorzelski et al .172 were 6 8 % and 
60% in dermatitis herpetiformis and coeliac disease 
respectively. The same group255 confirmed these observa­
tions in a subsequent report and showed that the an­
tibodies are not detectable in other skin disorders in­
cluding pemphigus and bullous pemphigoid. Of particular 
interest was the finding of negative results with sera ob­
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tained from patients with linear IgA bullous dermatosis 
which emphasized that this disorder is distinct from der­
matitis herpetiformis.
On the initial studies on endomysial antibodies some 
false positive results were reported after testing sera 
from patients with gut diseases other than coeliac dis­
ease, such as malabsorption syndrome and milk-sensitive 
enteropathy. However, follow-up and re-examination of 
these cases showed that circulating anti-endomysial an­
tibodies were only detected in patients subsequently 
proved to have coeliac disease255*257. Further studies of 
patients with other enteropathies including ulcerative 
colitis and Crohn's disease confirmed that the endomysial 
antibodies are specific of gluten enteropathy257.
Chorzelski et al .255 reported an association between 
the presence as well as the titre of anti-endomysial an­
tibodies and the severity of intestinal pathology. they 
demonstrated a correlation between these antibodies and 
the extent of mucosal damage in the gut. Almost all 
patients with jejeunal mucosal atrophy of grades III and 
IV had the endomysium antibodies.
Despite the fact that dermatitis herpetiformis is as­
sociated with a milder degree of gluten-sensitive en­
teropathy than coeliac disease258, the endomysial an­
tibodies were detected in a higher proportion in the 
former disease172*255. Subsequent studies, however, 
showed that the endomysial antibodies were found in 1 0 0 %
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of coeliac disease patients when they are tested prior to 
the institution of gluten-free diet which is an essential 
part of the management in this disorder259 . The effect of 
gluten-free diet on endomysial antibodies in dermatitis 
herpetiformis has also been studied. Muerer et al. 260 in­
vestigated six seropositive patients with a pathologically 
confirmed enteropathy. Treatment of this group of 
patients with gluten-free diet was associated with the 
progressive decline then the disappearance of endomysial 
antibodies within 4-11 months. In contrast, the antibody 
titres are not affected by the treatment with dapsone or 
sulfapyridine without dietary therapy260*261 . A similar 
effect of gluten-free diet on the levels of endomysium an­
tibodies in childhood cases of dermatitis herpetiformis 
has also been described. Chorzelski et al. 262 studied 32 
patients with this diagnosis who had been following a 
gluten-free diet and showed that the presence of en­
domysium antibodies is related to the duration and 
adherence to the diet. The antibodies were detected in 
one patient before treatment but were absent after one 
month of dietary therapy. The endomysial antibodies 
remained detectable in children treated for less than one 
year, and in the majority of patients not strictly adher­
ing to the gluten-free diet. These findings were also 
confirmed and extended by other investigators. In a study 
of 29 dermatitis herpetiformis patients Reunala et al .263 
showed that endomysial antibodies correlate with the
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severity of jejeunal atrophy. The mucosal damage was 
graded as subtotal villous atrophy, partial villous 
atrophy or slight changes-normal mucosa. The anti- 
endomysial antibodies were detected in all patients with 
subtotal villous atrophy and in the majority of patients 
with partial villous atrophy. Conversely, the lowest fre­
quency and antibody levels were found in patients with 
slight changes or normal mucosa. Based on this observa­
tion, it is possible that seronegative patients on normal 
diet found in the present study and previous 
investigations257*2 5 9 •264 might have had only minimal or 
no jejeunal mucosal atrophy. Reunala et al .263 placed 
some patients on a gluten-free diet and performed sequen­
tial antibody titre estimations. The treatment was as­
sociated with a decline in the endomysial antibody levels 
in patients who adhered to the gluten-free diet for a few 
months. In contrast, there was no fall in antibody titres 
in a group of patients on a normal diet. Furthermore, one 
initially seronegative patients developed endomysial an­
tibodies while continuing on normal gluten-containing 
diet, which may have caused some damage to the jejeunal 
mucosa.
Leonard et al .265 further investigated the associa­
tion between gluten-sensitive enteropathy and endomysial 
antibodies. They studied 12 dermatitis herpetiformis 
patients who were controlled by strict gluten-free diet 
and challenged with gluten. Prior to challenge, jejeunal
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biopsies showed essentially normal mucosa and serologic 
tests for endomysial antibodies were negative in all 
patients. The ingestion of gluten was followed by the ap­
pearance of antibodies and deterioration of intestinal 
mucosa (graded on a scale of I-IV) in a proportion of 
patients. In six cases the rise of endomysial antibody 
titre correlated with a deterioration of gluten en­
teropathy. In one patient who showed changes in gut his- 
topathology but did not become seropositive, the mucosal 
damage was only of grade I-II. Importantly, the study in­
cluded evidence of the reappearance and rise of endomysial 
antibodies occurring prior to the development of 
pathological changes of mucosa.
The effect of gluten challenge on endomysial an­
tibodies and the morphology of the intestinal mucosa was 
also determined by Chorzelski et al. 266 . They studied two 
dermatitis herpetiformis patients with normal jejeunal 
mucosa and negative serology for endomysial antibodies. 
Aggressive gluten challenge for 3-5 months was associated 
with the appearance of endomysial antibodies. In addi­
tion, pathological examination of jejeunal mucosa in one 
patient showed changes of grade III. Treatment with 
gluten-free diet led to the decline of endomysial an­
tibodies to undetectable levels and the return of gut mor­
phology to grade II.
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The high degree of sensitivity and specificity of 
circulating anti-endomysial antibodies in patients with 
dermatitis herpetiformis has led to the suggestion that 
they may have a pathogenic significance257 . To examine 
whether the antibodies are of a pathogenic nature, in 
vitro studies were performed to determine if the en­
domysial antibodies are capable of reacting with their 
homologous antigen in explants of normal gut mucosa. In­
direct immunofluorescence studies of endomysial antibodies 
on sections of normal monkey gut mucosa explant cultured 
in human serum showed a positive reaction. However, no 
reaction was observed by direct immunofluorescence using 
sections from the normal gut explants which indicated that 
the endomysial antibodies cannot react with their 
homologous antigen in viable explants. In contrast, posi­
tive direct immunofluorescence reactions were obtained 
with pemphigus and bullous pemphigoid antibodies under 
comparable conditions257.
Despite these data, the detectibility of endomysial 
antibodies after gluten challenge and their appearance 
prior to the deterioration of gut pathology suggests that 
they may be pathogenic antibodies.
In addition to IgA anti-endomysial antibodies, other 
antibodies including anti-gliadin and anti-reticulin an­
tibodies have been reported in patients with dermatitis 
herpetiformis. Anti-gliadin antibodies of the IgG class 
have been detected in the majority of patients267.
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However, these antibodies lack disease specificity as they 
have been demonstrated in normal individuals and patients 
with other bullous diseases267-268 . Conversely, IgA class 
anti-gliadin antibodies are more disease specific but oc­
cur in only a small proportion of dermatitis herpetiformis 
patients267-269 . Anti-reticulin antibodies may also be of 
the IgG or IgA class. IgG anti-reticulin antibodies occur 
in 20% of patients and, like IgG gliadin antibodies, are 
not specific for dermatitis herpetiformis270. In con­
trast, anti-reticulin antibodies of the IgA class are 
specific for dermatitis herpetiformis and coeliac 
disease271. Hallstrom271 studied the occurrence of IgA 
reticulin and endomysial antibodies in patients with der­
matitis herpetiformis. They found the frequencies of both 
antibodies to be similar. In another report Kumar et 
al.272 compared the incidence of these antibodies in 45 
dermatitis herpetiformis patients and in a control group 
of normal individuals and patients with pemphigus and bul­
lous pemphigoid. The endomysial antibodies were detected 
in about two-thirds of dermatitis herpetiformis patients 
on normal diet but in none of the patients on 5-ta^%*ifdiet 
or the control group. IgG anti-reticulin antibodies were 
observed in one-third of dermatitis herpetiformis patients 
and were also detected in the control group including 
healthy individuals.
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In contrast, anti-reticulin antibodies of the IgA 
class were disease specific but occurred only in 25% of 
dermatitis herpetiformis patients. Furthermore, these an­
tibodies were not detected in any of the sera that were 
negative for the endomysial antibodies. These results 
provide evidence of the diagnostic importance of im­
munofluorescence tests for endomysial antibodies. The en­
domysial antibody test has been used in evaluating 
suspected cases of dermatitis herpetiformis with equivocal 
histologic and direct immunofluorescence findings. 
Studies have suggested that patients positive for IgA en­
domysial antibodies but with negative direct im­
munofluorescence for IgA deposits may eventually prove to 
have dermatitis herpetiformis261*273 . Accetto et al.261 
reported three such cases with atypical clinical features. 
The initial biopsy specimens yielded negative or non­
diagnostic histologic and direct immunofluorescence fea­
tures. However, serologic studies showed high titres of 
endomysial antibodies. Immunofluorescence studies of sub­
sequent skin biopsies demonstrated IgA deposits in all 
patients.
In summary, the results of the present study and pre­
vious investigations indicate the high degree of 
specificity and sensitivity of the endomysial antibodies 
for the diagnosis of dermatitis herpetiformis and em­
phasize the value of this serologic test in the study of 
patients with bullous disorders. The availability of the
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test is of particular importance in confirming the clini­
cal diagnosis of dermatitis herpetiformis cases where the 
investigations may be negative or non-specific. In addi­
tion, the demonstration of endomysial antibodies is a use­
ful screening test to determine the presence of associated 
gluten enteropathy. The absence of the antibodies in 
patients following a gluten-free diet indicates that the 
endomysial antibody assay is a helpful, minimally invasive 
method to monitor the compliance of patients to dietary 
therapy and decrease the need for repeated intestinal 
biopsies.
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5. CONCLUSIONS
The present study has demonstrated quantitative dif­
ferences in the expression of bullous pemphigoid antigen 
on normal skin that appear to be related to the body site 
from which a particular skin specimen is obtained. There 
was only partial correlation between antigen expression 
and the distribution of lesions in bullous pemphigoid. 
Conversely, the amount of pemphigus vulgaris antigen was 
generally similar in the areas tested. These findings in­
dicate that the distribution of lesions in these disorders 
is not entirely dependent on the concentration of antigen 
in a particular area.
Indirect immunofluorescence testing of 36 serum 
samples from patients with pemphigoid and pemphigus 
produced positive staining reactions on three different 
epithelial substrates but showed variable antibody levels. 
These results indicated that the choice of epithelial 
source may influence antibody titres. This, however, does 
not represent a major problem in evaluating the indirect 
immunofluorescence test because the variations related to 
the type of substrate used do not affect the detectability 
of pemphigoid and pemphigus antibodies.
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Examination of the distribution of IgG subclasses in 
the skin and serum of bullous pemphigoid patients showed a 
predominance of the non-complement fixing IgG4. Studies 
of the capability of serum antibodies to fix complement 
revealed non-complement fixing sera and the results were 
not in agreement with the complement binding characteris­
tics of IgG subclasses. These findings argue against a 
primary role for complement in the induction of bullous 
pemphigoid and since IgG4 has homocytotropic properties 
for mast cells then this favours the view that it may play 
a role in mast cell degranulation with subsequent inflam­
mation and blister formation.
IgG4 was also the prevalent IgG subclass in the skin 
and serum of patients with pemphigus vulgaris. Although 
there is no evidence that IgG4 is pathogenic in this dis­
order, the clinical and immunological reproduction of en­
demic pemphigus foliaceus in neonatal mice injected with 
IgG4 antibodies obtained from patients affected with this 
form of pemphigus suggests that the subclass may also be 
involved in the pathogenesis of pemphigus vulgaris.
It was concluded from the immunofluorescence testing 
of sera containing anti-basement membrane zone antibodies 
on 1M sodium chloride-separated skin that bullous pem­
phigoid and epidermolysis bullosa acquisita antibodies 
produce two different staining patterns on this substrate. 
Furthermore, it was demonstrated that the same technique 
can be applied to patients' skin to determine the site of
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in vivo bound immune deposits, which is particularly use­
ful in patients with no detectable circulating antibodies. 
In view of the clinical, histologic and immunopathologic 
overlap between bullous pemphigoid and epidermolysis bul­
losa acquisita, the definite diagnosis of some cases could 
previously be determined only by immunoelectron microscopy 
or immunochemical methods. However, the development of 
the split skin technique now provides a relatively simple 
yet efficient method that can be used to reach a certain 
diagnosis without the need to resort to other sophisti­
cated laboratory techniques.
Western immunoblotting studies of pemphigoid sera 
showed that circulating anti-basement membrane zone an­
tibodies react with specific protein bands on immunoblots 
and demonstrated heterogeneity of the bullous pemphigoid 
antigen at the molecular level.
The present study confirmed that endomysial an­
tibodies are frequently detected in dermatitis herpetifor­
mis patients on a non-restricted diet but are absent in 
the majority of patients following a gluten-free diet. 
The antibodies were also not detectable in the sera of 
patients with other bullous disorders. These results in­
dicate that the demonstration of anti-endomysial an­
tibodies is of considerable value in the diagnosis of der­
matitis herpetiformis and the assessment of patients with 
bullous diseases with clinical and histologic features 
that may simulate those of dermatitis herpetiformis. In
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addition, the endomysial antibody test is a simple and 
useful method to verify patients' adherence to a gluten- 
free diet and decrease the requirement for repeated intes­
tinal biopsies.
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